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CHAPTER 1 
Introduction 
Parts of this chapter were published in Ned Tijdschr Geneeskd 1983; 127:2193-98. 
ThJM van Ditzhuijsen', AM van Loon2, and SH Yap1. 
Div. of Gastrointestinal and Liver Disease, Dept. of Medicine1 ; Dept. of Medical Microbiology2, 
St. Radboud University Hospital, Nijmegen, the Netherlands. 

CHAPTER 1 
Introduction 
1.1 Historical perspective 
About 2000 years ago, Hippocrates described 'epidemic icterus' as an acute onset 
of illness associated with fever, chills, weakness, headache and yellow urine (1). 
This might have been the first description of type A hepatitis. In the eighth centu­
ry, Pope Zacharias suggested that at least some forms of jaundice were infectious 
(1). In subsequent centuries, the idea of an infectious nature of jaundice gradually 
gained acceptance, although in the beginning of this century hepatitis was still 
widely regarded as a catarrhal jaundice due to the occlusion of bile ducts by 
mucous plugs. Originally, hepatitis was thought to be transmitted either orally or 
by the airborne route. However, this concept was changed with the observation 
of the first classical transmission of hepatitis В at Bremen in 1883, when large-
scale vaccination of shipyard workers with a smallpox vaccine resulted in an epi­
demic of hepatitis (2). In 1939, the pathology of epidemic catarrhal jaundice was 
described by Findlay et al., who suggested viral infection as the cause of infective 
hepatitis (3). Epidemiological evidence accumulated since that date has implica­
ted at least two infectious agents, an epidemic form called type A, and a serum-
transmitted form called type В (4). The discovery of the so-called Australia anti­
gen, by Blumberg et al. (5, 6), initially in serum of an Australian aborigine, later 
in sera of patients with Down's syndrome, leukemia and hemodialysis patients, 
and the detection, by Prince in 1968 (7), of serum hepatitis-associated antigen, 
which turned out to be identical to the Australia antigen, provided the key ele­
ments of our knowledge of hepatitis В virus (HBV) infection. 
The milestones of HBV research since then include: 
- The demonstration of small spherical particles as well as long filamentous 
structures in serum of carriers of the virus by Bayer et al. in 1968 (8) using elec­
tron microscopy. 
- The discovery of double-layered structures, which later turned out to repres­
ent the complete virus (Dane particle) by Dane in 1970 (9). 
- The detection of a new antigen/antibody system, HBeAg /anti-HBe, by Mag-
nius et al. in 1972 (10). 
- Association of a subpopulation of cores with D N A polymerase (Kaplan, 1973) 
(И)· 
- The demonstration of circular double-stranded DNA in cores of DNA parti­
cles by Robinson in 1974 (12). 
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- The close relationship between hepatitis В virus infection and hepatocellular 
carcinoma established in the early seventies (13). 
- The introduction of vaccination against HBV (14). 
- The advances in molecular biology of the viral genome (15). 
1.2 The hepatitis В virus 
1.2.1 Structure 
Hepatitis В virus (HBV) together with ground squirrel hepatitis virus (GSHV), 
woodchuck hepatitis virus (WHV) and duck hepatitis В virus (DHBV) are mem­
bers of a unique class of so-called hepadna viruses: hepatotrophic DNA viruses. 
These hepadna viruses contain a circular DNA molecule that is partially double-
stranded (16). 
HBV can induce hepatitis only in humans and infect certain non-human primates 
(chimpanzee and gibbon) (16). Under the electron microscope, HBV shows up as 
a double-shelled spherical particle, 42 nm in diameter. These particles, represent­
ing complete virions, can be identified in serum as well as in hepatocytes. The 
hexagonal inner core of these particles, about 27 nm in diameter, contains some 
of the viral antigens (hepatitis В core antigen, HBcAg, molecular weight 18,000 -
19,000 daltons), hepatitis В e antigen, HBeAg, molecular weight 24,000 daltons), 
the circular partial double-stranded DNA (12) and DNA polymerase (molecular 
weight 90,000 daltons) (17). 
The outer, 7-nm thick, envelope of the HBV particle contains the hepatitis В 
virus surface antigen (HBsAg) (molecular weight 24,000 daltons). This envelope 
is ultrastructurally and antigenically identical to smaller particles found in serum 
either as spherical forms or as tubular filaments, representing aggregates of 
HBsAg. Unlike the double-shelled particles (complete virions), these (non-infec­
tious) particles, with an average diameter of 22 nm, circulate in large excess. 
HBcAg and HBeAg are almost always present in serum in association with the 
complete HBV particle. All three antigens can induce a specific antibody response. 
1.2.2 Hepatitis В virus genome 
The HBV genome has an unusual and characteristic structure (18,19): (fig 1.1). 
It consists of a small circular, double-stranded DNA molecule with a single-
stranded region of variable length. The long, complete minus or L(-) DNA 
strand is approximately 3,200 nucleotides long, while the short or S(-l-) strand is 
of variable length, 50-75% of the length of the long strand (20). A polypeptide is 
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covalently attached to the 5' end of the long strand and probably functions as a 
primer for synthesis of the viral minus strand (21). The 3' terminus of the plus 
strand is complexed with a DNA polymerase that can elongate this 3' terminus, 
using the complete minus strand as a template, to make fully double-stranded 
DNA molecules (17). The double structure of the genome is maintained by base 
pairing of the 5' ends of both strands (22). 
There is a profound difference in the coding capacity of L and S strands: L strand 
transcripts contain four large coding regions, which partialy overlap so that HBV 
uses unusual strategies to increase its repertoire of functional proteins. S (+) 
strand transcripts have no conserved open reading frames of considerable length 
(23). The L(-) strand transcript therefore seems to carry all, or virtually all, of the 
protein coding capacity of the virus. The four open reading frames, termed C, P, 
S and X, are approximately the same in size and occupy the same relative genomic 
position in all mammalian hepadna viruses (18). 
The Ρ region (see fig. 1.1), spanning more than 75% of the virus genome and 
overlapping all the other three, codes for the viral DNA polymerase which 
possesses reverse transcriptase activity (24). 
The S region, coding for the protein of the viral envelope, is divided into the S-
gene, pre-Sl region and pre-S2 region. The S-gene codes for the major envelope 
protein, HBsAg, a 24,000 dalton protein which exists in both glycosylated 
(GP27) and non-glycosylated (P24) forms. Besides this HBsAg two other pro­
teins, designated large surface protein and middle surface protein, have been 
identified in serum of HBV-infected individuals. Large surface protein exists in 
glycosylated (GP42) and non-glycosylated (P39) forms, containing pre-Sl and 
pre-S2 regions, whereas the middle surface protein is found only as glycosylated 
(GP33, GP36) forms, containing merely the pre-S2 region (19). The size of the 
pre-Sl region, containing the major HBsAg-transcriptional signals, varies 
slightly according to the virus, suggesting that the polypeptide sequence specified 
by this D N A sequence is less critical of viral assembly than that specified by pre-
S2- and S-regions (18). 
The С gene, whose sequence is most highly conserved in the hepadna viruses 
(18), specifies the major viral core protein and the polypeptide with HBeAg spe­
cificity (25). It is preceded by a pre-C region, encoding for largely hydrophobic 
amino acids. This precore region seems to be involved in targeting core proteins 
to cytoplasmatic membranes and in facilitating secretion of cryptic forms of e 
antigen (26). 
The X region codes for a polypeptide of 145 to 154 amino acids, which peptide is 
associated with the core particles. The function of this polypeptide, which can be 
found in the liver and in serum of some infected patients (27), is still unknown. 
In humans, two major HBV-specific poly(A-l-) RNAs can be characterized. Both 
are L(-) strand transcripts and are referred to as 2.1 and 3.5 kb RNA. The 2.1 kb 
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Figure 1.1: Structure and genetic organization of the H BV genome. The broad arrows surroun-
ding the genome represent the four Urge open reading frames of the L (-) strand transcript. The 
number of amino acids encoded by the coding sequences are mdicaed. The two thin arrows repre-
sent the two major HBVmRNAs. (From Tiollais P., et al., Hepatology 1987, 7. 61-3, supplement, 
with permission). 
RNA transcript is the messenger for the middle protein and S-gene specified 
polypeptides, whereas the 3.5-kb transcript is messenger for core protein and 
DNA polymerase synthesis (18). The 3.5-kb transcript is also the template for 
viral DNA synthesis (pre-genomic RNA). Synthesis of these RNA trancripts is 
controlled by direct repeat sequences present in the HBV genome, 11 base pairs 
long, called DR1 and DR2 (28). 
1.2.3 Hepadna virus replication 
The mechanisms of viral entry into the hepatocyte are still obscure. However, 
advances in molecular biology have allowed some insight into the mechanism of 
viral replication. 
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According to the model proposed by Summers and Mason (29), replication of 
HBV is thought to take place as represented in figure 1.2: following virus entry 
into the liver cell, the viral genome is transported to the nucleus of the hepatocyte 
and converted to 3,200 bp covalently closed, circular viral DNA (cccDNA) (a). 
This cccDNA functions as a template for transcription (b) with generation of 
messenger RNAs, coding for viral proteins, and of a long RNA transcript: the 
pregenomic viral RNA (full-length plus strand RNA). Long RNA transcript, 
newly synthesized viral DNA polymerase and primer protein are packed with 
HBcAg and form core particles (c). Pregenomic RNA is then reverse transcribed 
into minus strand DNA (d). After completion of the minus DNA strand, viral 
mRNA's—' 
( ribosomes) 
viral proteins 
* primer protein 
© DNA polymerase 
-nucleus 
cccDNA 
-^ H R N A 
"Pre-genome 
immature core (pregenomic RNA ) 
long(-) DNA strand 
long(-) DNAstrandand 
short (*)DNAstrand 
"cytoplasm" 
Figure 1 2: Proposed mechanisms of hepatitis В virus replication in hepatocytes. (Modification 
from Summers], et al., réf. 29). 
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DNA plus strand is synthesized, utilizing the minus strand DNA as a template 
and probably a fragment of the pregenomic RNA as a primer (e). Finally, core 
particles are coated with HBsAg and cell membrane lipid-containing envelopes. 
Completion of the plus strand is not an absolute requirement for coating and 
release from the cell, as extracellular virions may contain incomplete plus strands 
and even DNA-RNA hybrids (30). 
1.3 Hepatocellular necrosis in hepatitis В virus infection 
Clinical observations and laboratory studies suggest that hepatitis В virus is not 
directly cytopathic (31), and that liver cell damage is probably due to host's 
immune response to viral and/or auto-antigens expressed on the membrane of 
infected cells. Some investigations suggest that 'focal' necrosis in liver histology 
represents T-cell lysis of liver cells containing replicating virus, whereas 'piece­
meal necrosis' is a result of an autoimmune response (32,33). The major clinical 
observations supporting this immunologic mechanism of hepatocellular necrosis, 
are the close association between liver cell necrosis and mononuclear inflamma­
tory cells, and the finding of normal liver histology in asymptomatic HBsAg car­
riers, despite the presence of HBV in the hepatocyte (34). Furthermore, several 
lines of evidence indicate the major role of cell-mediated immune mechanisms in 
both persistence of the chronic HBsAg carrier state and hepatocellular necrosis: 
1. The high prevalence of chronic HBsAg carrier state in subjects with defects in 
cellular immunity (35). 
2. The occurrence of massive hepatocellular necrosis after restoration of cellular 
immunocompetence, i.e. after discontinuation of cytotoxic or immunosup­
pressive therapy (36,37). 
3. The observation that stimulation of cellular immune response, rather than that 
of humoral response, resulted in liver cell necrosis (37, 38). 
4. The fact that the inflammatory cell infiltrate in liver tissue of patients with 
acute or chronic type В hepatitis consists largely of T-lymphocytes, predomi­
nantly of the suppressor/cytotoxic cell types (39-41). 
HBcAg, rather than HBsAg, displayed on the hepatocyte plasma membrane, 
seems to be the target for the attack of cytotoxic T-cells (42) (fig. 1.3). However, 
it has also been suggested that in some cases viral infection initiates an autoim­
mune response to liver cell membranes, and that this process can continue after 
cessation of viral replication (32). In the latter cases, such as in anti-HBe positive 
patients, the inflammatory reaction may respond to treatment with a low dose of 
prednisolone (43). 
Among the factors regulating the immune réponse, interferons and the HLA-
system play a prominent role in presenting viral antigens to the cytotoxic T-cell 
(44). 
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CYTOTOXIC 
T-cell 
B-cell 
anti-HBc 
(HEPATOCYTE) 
HLA antigen 
HBc-Ag 
Figure 1.3: Interactive mechanisms involved in immune mediated hepatocellular injury. 
1.4 Epidemiology of hepatitis В infection 
The distribution of hepatitis В virus is worldwide. However, marked differences 
exist in the prevalence of the infection, as a result of a mix of behavioral, environ­
mental, and host factors (45). In the early sixties up to the late seventies, a drama­
tic increase in HBV infection was noted in the US as well as in parts of Europe 
and in Australia (46). HBsAg carrier rates vary from country to country, and are 
in general low (<1%) in countries with high standards of living such as the US, 
Canada, Australia and some parts of Europe (46). Intermediate carrier rates are 
found in the Soviet Union, Eastern Europe, and parts of Asia and Africa (fig. 
1.4). However, in individual countries, major differences can also be observed 
between ethnic groups (47, 48). In highly endemic areas, peak rates of HBsAg 
carrier state can usually be found in children, in contrast to low-prevalence areas, 
where peakrates are found in young adults. In adults the probability of becoming 
chronic HBsAg carriers after acute type В hepatitis varies between five and ten 
per cent (49); this risk is considerably higher in infants, patients on immunosup­
pressive therapy, as well as in subjects with Down's syndrome (50). Although an 
inverse relationship exists between inoculum size and incubation period (51), no 
such relation has been found between inoculum size and the likelihood of 
becoming chronic HBsAg carrier (52). 
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Figure 1.4 Hepatitis В surface antigen (HBsAg) prevalence m the world. (From Szmuness W, et 
al. Viral Hepatitis - 1978, with permission). 
Traditionally, hepatitis В has been recognized as a hazard of parenteral exposure 
to infected blood; however, the infection may be transmitted via several modes: 
in the endemic areas, the major mode of transmission is by vertical spread from 
the infected mother to her child at the time of birth (53). This risk of maternal 
transmission is highest in case the mother harbors the e-antigen in serum, when 
80-90% of neonates will become HBsAg positive carriers (54,55). Data from 
Japan indicate that maternal transmission may account for 30-50% of all HBsAg 
carriers (56). Other groups at risk of acquiring HBV infection include: intrave­
nous drug abusers, certain health care workers, patients requiring repeated trans­
fusions of blood products, male homosexuals, promiscuous heterosexuals and 
household contacts of HBsAg-positive carriers (57). In male homosexuals, the 
clinical response to infection seems different (58), which has been attributed to an 
altered cell-mediated immunity (59). However, it has also been suggested that the 
high rate of acute hepatitis represents the major factor contributing to the high 
prevalence of markers of HBV infection in this group (60). 
In view of the high prevalence of HBV infection in certain areas, even in the 
absence of well documented contacts with infective blood, other routes of trans­
ió 
mission are also suggested. Viral antigens have been detected in blood and saliva 
of some insects; yet, there is no evidence that insects, such as mosquitos or bed­
bugs, play a role in the transmission of HBV (61). 
In humans, HBV can be detected in most body fluids and excretions (62-73) 
(table 1.1). In general, the concentrations of viral DNA in such fluids and secre­
tions were low (64, 66). Although the extent and precise mechanisms of spread 
via these routes is largely unknown, close contacts (kissing, sexual intercourse) 
seem to be of epidemiologic significance (74, 75). 
Table 1.1 Hepatitis В virus in body fluids and excretions 
HBsAg Dane particles/hepatitis В 
virus D N A 
urine 
saliva 
seminal fluid 
vaginal secretions 
CSF 
breast milk 
feces 
(references in parentheses) 
1.5 Acute and chronic type В hepatitis 
Exposure to HBV may result in very different clinical conditions (fig. 1.5). 
In typical self-limiting acute type В hepatitis, the following serologic markers 
appear sequentially in serum: HBsAg, HBeAg, anti-HBc and anti-HBs (76) (fig. 
1.6). Other serum markers, such as DNA polymerase and hepatitis В virus 
DNA, are not yet available for routine clinical use on a large scale. 
HBsAg: The duration of HBs surface antigenemia in patients with uneventful 
acute HBV infection may range from five days to five months (77,78). In patients 
who recover from acute type В hepatitis, a significant decrease in HBsAg titer 
can usually be observed within the first three weeks of clinical onset (79). 
(62,63) (64,65,66) 
(62,67) (64,65,68) 
(67) (64,69) 
(70) 
(71) 
(72,73) 
(62) 
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exposure to HBV 
no clinical 
manifestations 
chronic 
hepatitis 
cirrhosis 
acute hepatitis 
fulminant 
hepatitis 'healthy 
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Ì 
hepatoma 
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Ftgure 1.3: Clinical manifestations and courses of disease after exposure to hepatitis В virus. 
HBeAg: This antigen, one of the major markers of viral replication, is present in 
serum of almost all patients with acute type В hepatitis and disappears prior to 
the loss of HBsAg during early convalescence. A few days to weeks after the dis­
appearance of HBeAg from serum, anti-HBe can be detected in serum (80). The 
appearance of anti-HBe indicates a reduction in infectivity and in activity of the 
inflammatory liver disease (32). However, these antibodies seem to play no role 
in virus neutralization, as both viral DNA (81) and Dane particles (82) can occa­
sionally be detected in serum of HBsAg/anti-HBe-positive carriers. 
anti-HBc: IgM class anti-HBc antibodies at high titers (>1:1,000) are present in 
the early phase of infection. They can be detected in the first six weeks when 
HBsAg is present (83). Detection of IgM-class anti-HBc is a useful method for 
diagnosing acute type В hepatitis, especially in 5 to 10% of patients with acute 
type В hepatitis, in whom HBsAg is negative during the acute phase (84,85). 
Appearance of IgM-class anti-HBc is soon followed by IgG-class anti-HBc anti­
bodies, which may persist lifelong (45). 
anti-HBs: The period between loss of HBsAg (and HBeAg) from serum and the 
appearance of anti-HBs is designated as the 'window phase'. This phase, persis­
ting for two to 16 weeks, usually ends during the late convalescent phase. Appea­
rance of anti-HBs indicates recovery from and immunity to HBV infection (86). 
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3 4 5 6 
MONTHS AFTER EXPOSURE 
24 
Figure 1.6: Serologic profile m acute self-limiting type В hepatitis (according to HoofnagleJH, et 
al.. Virus And The Liver - /979, with permission). 
The two major unfavorable clinical conditions of acute type В hepatitis are a) 
fulminant hepatitis and b) long-term persistence of viral replication and the 
development of chronic hepatitis. 
a) Fulminant viral hepatitis, characterized by progression of signs and symp­
toms of liver failure, is found in less than 1% of patients with acute type В 
hepatitis (87). Risk factors for a fulminant course of viral hepatitis include: 
old age, female sex, pregnancy, simultaneous infection, and immunosup­
pressive therapy (88). Overall mortality of acute viral hepatitis is approxima­
tely 0.1 to 0.2% (88). However, fulminant type В hepatitis has a lethal out­
come in more than 80% of cases (89,90). The relatively low level of factor V, 
detectable HBsAg, and the absence of elevation of serum alpha-fetoprotein 
concentrations are signs of a poor prognosis (91). 
b) In adults, the risk of a chronic HBsAg carrier state following primary infec­
tion with hepatitis В virus is approximately 5-10% (92,93). However, recent 
studies from Greece indicated a considerably lower risk (0.2%). It was 
suggested that the high prevalence of HBsAg in Greece, and in other areas 
with a relatively high prevalence of HBV infection, is mainly due to perinatal 
and childhood infection (94). A representative course of serologic markers of 
chronic type В hepatitis is shown in fig. 1.7. 
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Figure 1.7- Serologic course during chronic type В hepatitis (according to Hoofnagle JH, et al., 
Progress In Liver Disease, Vol. VII - 1982, with permission) 
The annual spontaneous seroconversion, i.e. loss of HBeAg and develop­
ment of anti-HBe, is reported to occur in 5-25% of patients in the course of 
chronic type В hepatitis (95-97). Clearance rates seem to be higher in men 
than in women (95). In about half of the cases, seroconversion is preceded by 
acute exacerbation of liver disease with elevation of serum aminotransferase 
values (98, 99). 
Elevation of serum alpha-fetoprotein levels (>100 ng/ml) during exacerba­
tions seems to have a predictive value for HBeAg clearance (95). In addition, 
sex, age, duration of HBsAg carrier state, and extent of hepatic damage are 
important determinants for HBeAg clearance (95, 99). However, sponta­
neous reversion from HBeAg-negative to HBeAg-positive status, accompa­
nied by biochemical deterioration, may occur as well (99). 
In both acute and chronic type В hepatitis, co-occurrence of HBsAg and anti-
HBs is a well-documented phenomenon. This serologic finding is present in 10 to 
40% of chronic HBsAg carriers (100). The clinical significance of this phenome­
non in such carriers still remains to be elucidated (100-103). 
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1.6 The chronic HBsAg carrier 
Chronic carrier state of HBsAg has been defined as the presence of HBsAg in 
serum for more than six months. It is estimated that worldwide more than two-
hundred million subjects - 5% of the earth's population - are chronic carriers of 
HBsAg, with marked geographic variations (104). Approximately 5-10% of 
patients with clinically manifest acute type В hepatitis would become chronic 
carriers (93,105). Factors that seem to favor the development of the chronic car­
rier state include: a) infection at a young age (106-108), b) male sex (109), с) a 
mild anicteric illness (110), d) a small viral inoculum (51) and e) possible impair­
ment of cell-mediated immune responsiveness at the time of infection, such as in 
patients with Down's syndrome, chronic renal failure, or leukemia, and during 
corticosteroid therapy (111). However, in asymptomatic carriers no clear defect 
in cell-mediated immunity has been found (112, 113). 
The chronic carrier state of HBsAg may be accompanied by normal or abnormal 
biochemical findings (liver enzymes). 
Asymptomatic HBsAg carriers with normal serum aminotransferases are consi­
dered to represent 'healthy carriers'. Liver biopsy in these carriers usually reveals 
hardly any evidence of active hepatitis and only minor nonspecific changes (as 
portal inflammatory cellularity, ground glass cells, and variable degrees of portal 
fibrosis) are found (114). The prognosis of these 'healthy carriers', who are 
usually anti-HBe positive (115-117), seems to be favorable (118, 119), although 
there have been reports of progression to chronic hepatitis and cirrhosis (120-
122); in a large prospective study (123) mortality among HBsAg carriers with 
initially normal liver function tests was found to be 44.5 times higher than in 
non-carriers. Most importantly, however, these asymptomatic carriers are at risk 
of developing hepatocellular carcinoma (124). 
In HBsAg carriers with abnormal liver parameters, a broad spectrum of histolo­
gic abnormalities may be present ranging from chronic lobular hepatitis with a 
favorable prognosis (125), via chronic persistent hepatitis with only occasional 
progression to chronic active hepatitis or liver cirrhosis (126), to chronic active 
hepatitis and cirrhosis. Chronic active hepatitis shows a significant death rate due 
to liver failure and hepatocellular carcinoma with a five-year survival of 72-86% 
(127, 128). The degree of liver damage cannot be predicted from serum amino­
transferase values, HBsAg titer or HBeAg/anti-HBe status (126). 
Most hepatitis В virus carriers remain HBsAg-positive for many years: only 
1-8% per year lose the HBsAg with seroconversion to anti-HBs (129,130), 
whereas up to 25% per year of the persistent HBsAg carriers lose HBeAg and 
develop anti-HBe (96, 97). The factors promoting this seroconversion are still 
unknown. Two phases of the chronic HBsAg carrier state can be recognized: a) 
an early replicative phase and b) a late non-replicative phase (131). During the 
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early phase of the chronic HBsAg carrier state, there is active viral replication 
(lasting three to ten years). In the later phase, viral replication ceases and serocon­
version to anti-HBe occurs. The level of HBV replication does not correlate with 
the severity of chronic liver disease (126,132,133). Clearance of HBeAg is often 
preceded by abrupt elevation of serum aminotransferases (134-136). Unfortuna­
tely, a significant percentage of carriers will have developed liver cirrhosis by that 
time and will be at risk of the development of hepatocellular carcinoma (137). In 
general, seroconversion to anti-HBe is accompanied by cessation of active viral 
replication (138) with normalization of aminotransferase values and regression of 
histologic abnormalities. In case symptoms and biochemical data of chronic liver 
disease persist after seroconversion there are several possibilities: 1. although 
seroconversion and improvement in clinical and biochemical findings coincide in 
most patients, improvement may be delayed in some (139); 2. in a considerable 
number of carriers, especially from Mediterranean countries and from the Far 
East, viral replication continues after seroconversion (138); 3. reactivation of 
viral replication, especially during the first year after seroconversion (139-141). 4. 
the course of chronic HBsAg carrier state may be modified by concurrent infec­
tion with other hepatotrophic viral agents, such as non A-non В hepatitis viruses 
and the delta agent, or by drug or alcohol-induced liver damage. 
1.7 IgM anti-HBc 
a. Acute type В hepatitis 
A transitory rise of specific IgM-class antibodies to viral antigens is a well-known 
phenomenon in the early phase of viral infections, including HBV infection. 
Methods for detection of this class of antibodies have been developed, such as 
sucrose gradient centrifugation (142, 143), indirect immunofluor-escence (144), 
radio-immunoassays (145-148), enzyme linked immunosorbent assays (149-152) 
or enzyme linked fluorescence assay (ELFA) (153). In the acute phase of type В 
hepatitis, IgM-class anti-HBc is almost always present in serum (154), usually at 
a high titer (144, 155), with a peak in the fourth to fifth week after the onset of 
symptoms (155). The detection of IgM anti-HBc is of particular importance for 
diagnosis of acute type В hepatitis under the following circumstances: 
1. Five to ten per cent of patients with acute type В hepatitis have already 
become HBsAg-negative by the time of examination (107, 156), especially in 
fulminant hepatitis B, a condition in which massive necrosis of liver cells 
occurs, leading to an undetectable HBsAg serum level, with or without anti-
HBs (157, 158). In these conditions IgM anti-HBc determination is particu­
larly important for diagnosis of acute type В hepatitis. 
2. Superinfection of HBsAg carriers with other viruses may lead to acute hepati-
16 
tis that cannot be clinically distinguished from acute type В hepatitis. In cases 
of acute type В hepatitis, high titers of IgM anti-HBc could be detected (159). 
However, there are several exceptions: a) in some cases of acute type В hepati­
tis, IgM anti-HBc may appear as late as four weeks after the onset of acute 
hepatitis (146, 159, 160); b) in symptomatic patients, HBsAg determination 
could be more sensitive in the first two weeks than IgM anti-HBc measure­
ment (161); and c) IgM-class anti-HBc could not be detected in neonates 
before the age of nine months (162). 
b. Chronic type В hepatitis 
Chronic liver disease in association with type В hepatitis 
Data on the prevalence of IgM-class anti-HBc in patients with HBV-related 
chronic liver disease have been conflicting (147, 148, 150, 154, 163-166). Most 
authors agree that, for a limited interval, IgM-class anti-HBc titers are mode­
rately elevated. However, a sharp decrease of the titer has been noted between 
the first and the second year after the acute phase (167). 
The 'healthy' H'BsAg-positive carrier 
In these carriers, a high prevalence of IgM anti-HBc has been reported (150,151, 
167), and it was demonstrated that, despite long-term persistence of these anti­
bodies, no signs or symptoms of liver disease became apparent (151). However, 
others were unable to detect IgM anti-HBc in such patients (157,163,165). 
The conflicting data reported so far on the prevalence of IgM-class anti-HBc 
during various stages of hepatitis В infection call for a reliable measurement tech­
nique of IgM anti-HBc, which would allow differentiation of acute from chronic 
type В hepatitis. Although in the reports on the various testing methods publis­
hed to date, several serum dilutions and cut-off values have been proposed (148, 
168), these have not resulted in well characterized serologic patterns. The specifi­
city of IgM anti-HBc assays can be tested only if an internationally recognized 
quantified reference applicable to all techniques is available (169,170). 
1.8 Primary hepatocellular carcinoma 
With over 250,000 new cases each year, primary hepatocellular carcinoma (PHC) 
is one of the commonest malignancies in the world (104). Age-adjusted incidence 
is over 30 new cases per 100,000 in parts of Africa and Asia, whereas it is less than 
five new cases per 100,000 per year in North America, Australia and in most 
European countries (104). Among others, Steiner et al. suggested in 1957 that 
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viral hepatitis might be the cause of primary liver cell carcinoma (171), but not 
untili the early seventies was an etiological association between HBV infection 
and primary hepatocellular carcinoma recognized (172). Extensive epidemiologic 
surveys have since indeed confirmed the close association of chronic hepatitis В 
virus infection and P H C (173-176). Worldwide about 80% of P H C cases are 
considered to be attributable to infection with HBV (104). 
Evidence for the association of HBV infection and P H C includes: 
1. HBV serologic markers are present far more often in patients with P H C than 
in the general population. Many patients with P H C are chronic HBsAg car­
riers: HBsAg was found in over 35% of hepatocellular carcinoma cases in 
sub-Saharan Africa and South-East Asia (177-179), both regions with HBsAg 
carrier rates in excess of 10%, while in regions with low (<1%) HBsAg car­
rier rates, such as the US and Norhern Europe, HBsAg is identified in only 10 
to 20% of PHC cases (180). These differences may be explained by a dilution 
of HBV-related carcinomas by a much larger proportion of HBV-unrelated 
P H C cases in western countries (181). 
2. Geographic distribution of HBV infection is almost identical with that of 
P H C (180). 
3. Prospective studies have shown a relatively high risk for development of P H C 
among HBsAg-positive carriers. The study of Beasley et al. showed that HBV 
carriers in Taiwan had over 200 times the risk of developing P H C than non-
carriers (182). The period from acute hepatitis to the diagnosis of P H C may 
range from six to 20 years (182,183). 
4. Cell lines from human P H C were found to secrete HBsAg (184) and to con­
tain integrated HBV-DNA (185,186). 
5. Integration of the viral genome into liver cell and tumor cell genome has also 
been demonstrated in tissues obtained from patients with P H C (187,188). 
6. Although most cases of P H C occur in patients with liver cirrhosis (189), 
usually of the macronodular type (187), and in less than 10% in a histologi­
cally normal liver (190), data indicate that HBsAg-positive subjects with 
cirrhosis run a higher risk than HBsAg-negative cases (191). In 20-30% of 
P H C patients with HBsAg in serum, liver cancer occurs in the absence of 
underlying liver cirrhosis (192). However, the risk of development of P H C in 
HBsAg-positive patients with liver cirrhosis seems lower in intermediately 
endemic areas such as the UK as compared with Asia and Africa (193). 
7. Mothers of patients with PHC more often are chronic HBsAg carriers than 
mothers of individuals of similar age, living in the same area, without hepato­
cellular carcinoma (194). 
Although evidence has accumulated that HBV infection is an important factor in 
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the development of hepatocellular carcinoma, the precise events leading to malig­
nant transformation are still unknown. In this regard the role of promoting fac­
tors, such as occupation, food, exposure to aflatoxin, alcohol, smoking, genetics, 
sex and age, also have to be considered (195-199). 
1.9 Extrahepatic manifestations 
Immune complexes, containing HBsAg and anti-HBs, can often be detected in 
patients with hepatitis В virus infection. Although their mere presence is not 
necessarily associated with signs or symptoms of immune complex disease, these 
immune complexes are believed to be the cause of a variety of extrahepatic mani­
festations (200). 
The most frequent manifestations are: 
1 Acute serum sickness-like syndrome 
Signs or symptoms of a serum sickness-like syndrome, with skin eruptions and 
joint pain may develop in as many as 30% of patients with acute type В hepatitis 
(201,202). These events usually become manifest a few days to weeks prior to the 
onset of jaundice and persist for only a few days (203). Wands et al. were the first 
to suggest that circulating immune-complexes are involved in the pathogenesis of 
arthritis (204), while others reported that tissue-fixed immune complexes might 
be the cause of this syndrome (205). 
2 Polyarteritis nodosa 
The association between polyarteritis nodosa (PAN) and type В hepatitis was 
first reported in 1970 (206). It is estimated that 30 to 40% of PAN cases are asso­
ciated with HBV infection (207-210). However, presence of type В hepatitis 
prior to the onset of vasculitis is well-documented in only one study (210). 
3 Essential mixed cryoglobulinemia 
Early studies pointed to a major role for HBV infection in the pathogenesis of 
essential mixed cryoglobulinemia, a syndrome clinically characterized by purpu­
ra, arthralgia and weakness (211,212). However, more recent studies were unable 
to confirm this relationship (213, 214). Interestingly, in a population with a high 
HBsAg carrier rate, mixed cryoglobulinemia seems an important etiologic factor 
in Raynaud's disease (215). 
4 Membranous glomerulonephritis 
In 1971 Combes et al. first reported the association between type В hepatitis and 
membranous glomerulonephritis (216). This finding was subsequently confir-
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med by many reports (217-220). In children with membranous glomerulopa­
thies, hepatitis В surface antigenemia seems to be a frequent finding (221-223). 
The nature of the viral antigens and of the antibodies present in immune com­
plexes and their role in pathogenesis of renal disease, have long been debated. 
Takekoshi et al. (224) suggested that HBeAg rather than HBsAg-containing 
immune complexes are responsible for the renal damage, since HBeAg-contain-
ing immune complexes have a molecular weight of 300,000 daltons, permitting 
them to cross the basement membrane, contrary to the HBsAg-containing 
immune complexes (molecular weight 3,000,000 daltons). Furthermore, HBeAg 
containing immune complexes could be detected in glomeruli (225). It has also 
been reported that regression of renal disease activity occurred after loss of the e-
antigen (226). 
5 Other diseases 
Hepatitis В viral antigen-containing immune complexes may play a role in the 
pathogenesis of other diseases as well, such as aplastic anemia (227-229) and the 
Guillain-Barré syndrome (230). 
1.10 Treatment of chronic type В hepatitis 
Patients with chronic type В hepatitis and persistent viral replication often show 
rapid progression of liver inflammation (231) with an unfavorable prognosis 
(232). In addition, these patients are potentially infectious to their close contacts. 
As spontaneous cessation of viral replication occurs only in a small minority of 
patients (233), several efforts have been made to accelerate this process. Major 
approaches to the treatment of chronic viral hepatitis have been: 
1. modulation of cellular or humoral immunity (by corticosteroids, azathiopri-
ne, levamisole), and 
2. suppression of viral replication (by adenine arabinoside, aciclovir or inter­
ferons). 
1 Corticosteroids 
Results from studies in the early eighties have shown that long-term corticoste­
roid treatment (often in combination with azathioprine) of patients with chronic 
type В hepatitis is deleterious (234, 235). Immunosuppression was found to 
enhance viral replication (236) and to delay seroconversion from HBeAg to anti-
HBe (236-238). Yet, patients withdrawn from corticosteroids showed a high rate 
of beneficial response to antiviral therapy (239), and this prompted many investi­
gators to treat patients with a short course of prednisolone. However, results of 
short-term treatment are conflicting: persistent loss of HBeAg and hepatitis В 
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virus DNA was reported (240), although others found no beneficial effect and 
noted important side-effects (241). Perrillo recently suggested that short-term 
steroid treatment in the early course of chronic active hepatitis may be beneficial, 
whereas this approach may have a deleterious effect in patients with severely 
compromised liver parenchymal reserve (242). 
Although short-term treatment with steroids is not accepted as monotherapy in 
chronic type В hepatitis, such treatment is still used prior to or simultaneously 
with antiviral therapy (243). 
2 ARA-A/ARA-AMP 
Adenine arabinoside (ARA-Α) and the more water soluble compound, adenine 
arabinoside monophosphate (ARA-AMP), both purine analogs, exert an inhibi­
tory effect on viral DNA synthesis (244). 
In most studies with these agents, viral replication was suppressed, but the effect 
was only temporary (245,246), and trials had to be discontinued because of trou­
blesome side-effects (neuromuscular toxicity) (245). 
3 ACICLOVIR 
Treatment with aciclovir (acycloguanosine), an antiviral agent, was found to have 
only a weak effect on viral replication, and did not significantly accelerate sero­
conversion to anti-HBe (247, 248). However, results of combination of d-aciclo-
vir with interferons seem promising (249). 
4 Interferons 
Interferons (IF) have been shown to modulate a wide range of immune pheno­
mena: 
a. modulation of expression of major histocompatibility complex antigens; 
b. modulation of macrophage function; 
с modulation of cellular toxicity (250). 
There is now convincing evidence that the IF system is active in acute but defi­
cient in chronic viral hepatitis: both in vitro and in vivo studies suggest that 
patients with chronic viral hepatitis are unable to produce alpha- or gamma-IF in 
sufficient amounts (251-253). Several types of IF have been used for the treat­
ment of patients with chronic type В hepatitis, including buffy coat or recombi­
nant alpha-IF. In more recent trials, a permanent response appeared to require 
treatment for at least one to two months, and was often accompanied by transient 
elevation of serum aminotransferases and by exacerbation of inflammatory pro­
cesses in the liver, suggesting that alpha-IF acts both by inhibition of viral repli­
cation and by stimulation of the immune response (254). However, some studies 
have shown that the rates of seroconversion to anti-HBe were not much higher 
than the spontaneous seroconversion rate (255-258). Ongoing clinical trials 
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should determine whether combination of IF and an antiviral agent or steroids is 
superior to IF alone in inducing permanent loss of viral replication. 
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CHAPTER 2 
Methods for detection of HBV-DNA 
in blood and tissues 
2.1 Principles of molecular hybridization 
Molecular hybridization is based on the fact that denaturation of nucleic acids is 
a reversible process in which double-stranded DNA is converted into single 
strands at high temperature and alkaline p H (1). Single-stranded nucleic DNA 
can, under appropriate conditions, form stable duplexes (DNA-DNA or DNA-
RNA) if they encounter complementary sequences. 
Hybridization can be used to detect viral DNA or RNA sequences in serum or 
tissue. First, DNA has to be extracted from the clinical specimen, and proteins 
should be removed. The viral DNA in question has to be available as a labeled 
hybridization probe, and for this purpose the so-called nick translation proce­
dure has been most widely used. With this procedure, DNAse introduces nicks 
into double-stranded viral DNA, which has mostly been obtained by cloning in 
a bacterial host. Thereafter, radioactively or non-radioactively labeled nucleoti­
des are allowed to incorporate into this viral DNA by the enzyme DNA polyme­
rase, resulting in a double-stranded labeled probe. 
DNA obtained from the specimen can be immobilized on nitrocellulose paper. 
After incubation of the filter with the probe, binding of the probe onto D N A or 
RNA immobilized on the filter can be determined. 
2.2 Detection of HBV-DNA in serum (fig. 2.1) 
For the detection of HBV-DNA in serum we have used two dot-blot methods: 
1. The phenol extraction technique as described initially by Berninger et al. (2), 
with slight modifications. 
2. Direct spotting of pretreated serum specimens on nitrocellulose filter sheets. 
2.2.1 Phenol extraction technique 
This method was carried out as follows: 
150 microliters of serum, in a final volume of 200 μϊ, were incubated at 70 0 C for 
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one hour in 25 mM NaAc (pH 6.5), 2.5 mM Na ethylenediaminotetraacetic acid 
(EDTA), 0.5% sodium dodecyl sulfate (SDS), 12.5 μg/ml sheared herring sperm 
DNA, 25 //.mg/ml yeast t-RNA and 2.5 mg/ml proteinase K. After cooling this 
mixture to room temperature, four volumes of TE buffer (TE =10 mM Tris-
HC1, p H 7.5, 1 mM EDTA), and eight volumes of water-saturated phenol res­
pectively were added. This was mixed and eight volumes of chloroform :isoamyl 
(24:1) were added. After centrifugation (5000/min, 15 minutes), the aqueous 
phase, free of interphase material, was removed. 
200 μΐ of the aquaous phase was then mixed with an equal volume of 1.0 M 
N a O H + 10 mM EDTA and incubated, at 60 "C, for 10 minutes. After rapid 
cooling on ice, one volume of 1.0 M Tris-HCl, pH 7.0, plus 1.5 M NaCl followed 
by one volume of 0.5 M HCl plus 2.5 M NaCl were added to neutralize the 
sample. 
Immediately after neutralization, the mixture was applied to a nitrocellulose fil­
ter sheet layered in a filtration apparatus. Aspiration was provided by gentle 
vacuum produced by a water vacuum pump. The nitrocellulose filter had been 
soaked previously in 6 χ SSC (1 χ SSC =0.15 M NaCl, 0.015 Na citrate (pH 7.0)), 
and was washed again with 6 χ SSC after application of the DNA mixture. 
The filter was allowed to dry at room temperature and then baked under vacuum 
for two hours at 80 0 C . Prehybridization was carried out by incubating the filter, 
in the absence of the HBV-DNA probe, for two hours at 42 0 C in a buffer solu­
tion containing deionized formamide (50%), 50 mM phosphate buffer (pH 6.8), 
5 χ Denhardt's solution (1 χ Denhardt = 0.02 % bovine serum albumin, 0.02% 
polyvidone, 0.02% ficoll 400), salmon sperm DNA (0.25 mg/ml), 5 mM EDTA 
and 5 χ SSC. Hybridization was carried at 42 0 C overnight in a buffer solution 
containing deionized formamide (50%), 20 mM phosphate buffer (pH 6.8), Den­
hardt's solution, salmon sperm DNA (0.1 mg/ml), 5 mM EDTA, 5 χ SSC, and 
the 3 2 P labeled probe. 
After removal of the buffer solution, the filter was washed two times for one 
hour at 42 "С with a buffer solution containing: deionized formamide (50%), 5 χ 
SSC, 20 mM phosphate buffer, Denhardt's solution, 5 mM EDTA and 0.1 mg/ml 
herring sperm DNA. Finally the filter was washed for 15 min in 2 χ SSC/0.1% 
SDS and for 15 min in 0.2 χ SSC/0.1% SDS, and dried at 42 "С. Autoradiography 
of the filter was performed with Lightning-Plus intensifying screen at minus 80 
"С on Kodak XAR-2 film for at least three days. 
The HBV-DNA probe was purified HBV-DNA of 3,000 base pairs length, isola­
ted by agarose gel electrophoresis of EcoRl restriction enzyme-treated plasmid 
p A O l , originally supplied by Dr. J. Summers (Institute for Cancer Research, 
Fox Chase Cancer Center, Philadelphia PA, USA) and kindly provided by Dr. 
DA Shafritz (Liver Research Center, Albert Einstein College of Medicine, New 
York, NY, USA). Nick translation was performed by means of a modification of 
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the procedure originally described by Rigby et al. (3). (Alpha-32P) dCTP was 
used as a labeled nucleotide. The specific activity of the HBV-DNA probe was 
approximately 2 χ IO8 dpm/pig DNA. In a series of diluted samples a known 
amount of plasmid hepatitis В virus DNA, as well as a negative control were 
applied to each filter, allowing an estimation of the amount of HBV-DNA pre­
sent in the tested specimens. This method enabled the detection of less than 1 pg 
of HBV-DNA (see figure 1). 
Technique 
S E R U M 
I 
D N A 
PROBE (cloned HBV DNA labeled with «p) 
(nitrocellulose filter) 
v 
HYBRIDIZATION 
I 
AUTORADIOGRAPHY 
Figure 2.1· HBV-DNA detection m serum. Serum DNA is extracted and immobilized onto the 
nitrocellulose filter DNA is then hybridized with the nick translation product of cloned HBV-
DNA Ubeled with 32P. Hybridization is made visible by the presence of spots on an autoradio­
gram. 
2.2.2 Direct spotting technique 
The phenol extraction technique is relatively time-consuming and, therefore, not 
suitable for routine purposes; in addition, HBV-DNA may occasionally be pre­
sent in the phenol phase during DNA extraction of serum (4). Some investigators 
reported that about two thirds of HBV-DNA in serum was lost during the phe­
nol extraction and ethanol precipitation procedures (5). Simpler techniques for 
the detection of HBV-DNA in serum have, therefore, been developed, and are 
now in use on a wide scale (4-8). These techniques have in common that pretrea-
ted serum samples are spotted directly on nitrocellulose or nylon filter sheets. 
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We have adopted the method as described by Shimizu (6): 
25 μ.1 of serum was denaturated in 25 /il of 2M NaCl and 100 μΐ of 1 M N a O H 
for at least 30 minutes at room temperature. Prior to application of the samples, 
the nitrocellulose filter was rinsed in 6 χ SSC (1 χ SSC (standard saline citrate): 
0.15 M NaCl, 0.015 M Na citrate). After application of the mixture, 100 μΐ of 3 M 
NaCl, 0.5 M Tris-HCl (pH 7.4) was passed through a filtration apparatus under 
slightly negative presure. The filter was removed from the apparatus, rinsed in 6 
χ SSC, dried at room temperature and baked at 80 "C for two hours. The next 
procedures were identical with those for the phenol extraction technique. On 
each filter a standard series of plasmid DNA, diluted with 10 χ SSC, was inclu­
ded, allowing an estimate of the amount of viral DNA present in the samples. 
With this technique less than 2.5 pg of HBV-DNA could be detected. 
The factors influencing sensitivity and specificity with the aforementioned tech­
niques have recently been analyzed (9). The presence of proteins in serum sam­
ples or standards was found to reduce the hybridization signal. However, treat­
ment with proteinase K, which has been advocated by several investigators, also 
resulted in reduction of the hybridization signal (9). The type of filter sheets does 
not seem to be of great importance for the quality of the hybridization signal (9, 
10), although nitrocellulose sheets more often showed non-specific hybridization 
(9). Amplification of the hybridization by use of polyethylene glycol (11) was 
found to increase non-specific hybridization (9). Comparison of several techni­
ques indicated that optimal pretreatment is achieved with NaCl, N a O H , form­
aldehyde and detergent, and that a maximum signal can be obtained after 36-48 
hours hybridization at 68 0 C (9). The sensitivity of the direct spot hybridization 
technique is limited by the volume that can be applied to the filter: large volumes 
will often fail to pass through the filter, and serum specimens exceeding 25 μΐ 
sometimes gave a false positive reaction (6). It is essential to prepare the standard 
series (from cloned HBV-DNA) by diluting it with SSC, as dilution with nega­
tive control serum will inhibit binding to the filter (12). 
These techniques are more easier to perform and would allow routine detection 
of HBV-DNA. However, the necessity to use 3 2 P radiolabeled nucleotides con­
tributes a serious limitation, owing to the potential health hazards, the relatively 
long exposure time needed (1-2 days on average), and the short half-life (14 
days). Yet, 2P-labeled probes have been most widely used, because such probes 
provide highly specific activity, values up to 10e-109 counts per minute per 
microgram of nucleic acid (13). Moreover, the autoradiography time can be pro­
longed, thereby enhancing sensitivity. Use of î2P-probes enables the detection of 
less than 1 pg of viral nucleic acid. However, in view of the forementioned short-
comings, non-radioactive, especially biotin-labeled probes are gaining in popula-
rity. Biotin-labeled nucleotides can be incorporated into double-stranded DNA 
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by nick translation. Although the sensitivity of biotin-labeled probes is some-
what lower than that of 32P-labeled probes (14), such probes could detect as little 
as 1 pg of viral DNA (14,15). Sensitivity was found to be comparable with that of 
32P-labeled probes when assay-time was similar (14). Biotin probes could be sto-
red at -20 0C for more than one year without loss of sensitivity or specificity (13), 
which is a great advantage over 32P-labeled probes which must be used within 
two weeks after nicktranslation. However, a major drawback of the use of bio-
tin-labeled probes is that it is not possible to reuse the nucleic acid immobilized 
on the filters for hybridization because of permanent enzymatic staining (16). 
Liver J 
DNA 
endonucleases 
D N A fragments 
1 
Electrophoresis and transfer 
to nitrocellulose filter 
+ 3ZP HBV DNA Probe 
Hybridizat ion 
1 
Autoradiography 
Figure 2 2: HBV-DNA detection m liver tissue by means of Southern blotting. Liver DNA is 
extracted and digested with restriction endonucleases. DNA fragments are then electrophoresed 
m agarose gel, transferred to a nitrocellulose filter, and hybridized with the nick translation pro-
duct of cloned HBV-DNA Ubeled with }2P Hybridization is made visible by the presence of 
bands on an autoradiogram. 
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2.3 Detection of HBV-DNA in liver tissue 
2.3.1 The Southern blot technique 
2.3.1.1 Principle 
Hepatitis В virus-DNA can be found in two distinct forms in the liver cell: (i) as 
integrated into the host genome DNA, and (ii) as free (episomal) viral DNA. The 
state of viral DNA in the liver can be assessed by means of Southern blot analysis. 
Free HBV genomes can be differentiated from integrated viral DNA sequences 
by treating cellular DNA with restriction enzymes (endonucleases). The two 
endonucleases that have been used most widely for this purpose are H I N D III 
and EcoRl. The strategy employed is as follows: 
Free viral DNA will migrate during gel electrophoresis as a single band at 3.2-3.0 
kilo base pairs (kb). EcoRl, which recognizes a single sequence of nucleotides 
within the HBV genome, linearizes all circular HBV-DNA molecules, resulting 
in a band with approximately the same position as the 3.2 kb band. 
In case HBV-DNA has become integrated into the host genome, undigested cel­
lular DNA would appear as a diffuse hybridization band in the high molecular 
weight region (higher than 15 kb). After treatment with H I N D III, which does 
not cut HBV-DNA, discrete bands can be observed. If almost the whole viral 
genome is integrated, such bands can be found at molecular weight positions 
exceeding 3.2 kb, whereas if only fragments of the viral genome have become 
integrated, these bands may also appear at a position below 3.2 kb.EcoRl treat­
ment of samples with integrated DNA results in bands distinct from the 3.2 kb-
band. 
2.3.1.2 Detection technique 
Specimens of frozen liver tissue were homogenized in 4-5 volumes of 0.1 M 
NaCl, 0.05 M Tris HCl p H 7.5, 1 mM EDTA and 3% p-aminosalicylic acid. 
Total nucleic acid was extracted by means of 2.5 volumes of phenol-cresol solu­
tion (80% w/v phenol, 11% m-cresol, 9% H2O and 0.09% 8-hydroxychinoline), 
followed by chloroform and isoamylalcohol (25:1 v/v) at room temperature. 
D N A was precipitated with two volumes of absolute ethanol and 0.1 volume of 
3M NaCl. The nucleic acid precipitate was resuspended in 10 mM Tris-HCl (pH 
7.5) and 1 mM EDTA, and treated with RNAse (final concentration 20 ju.g/ml 
and proteinase К (final concentration 100 /¿g/ml) respectively in the presence of 
sodium dodecyl sulfate (SDS, final concentration 0.5%). The DNA was reextrac-
ted by the chloroform-isoamylalcohol mixture and precipitated with ethanol. 
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Figure 2.3: Autoradiogram of Southern blot analysis of HBV-DNA m liver tissue DNA. 
Integrated molecules containing HBV-DNA sequences would be Urger than the HBV genome 
(approximately 3,250-3,000 base pairs) after HIND III digestion, except for smaller fragments, 
while free (extrachromosomal) HBV-DNA would appear as a single linear band of 3,250-3,300 
base pairs length. In this example, nP-HB V-DNA probe was hybridized to various DNA samples 
extracted from: 1) PLC/PRF/5 hepatoma cell line (integrated HBV-DNA), 2) liver of negative 
control, 3) liver with free HBV-DNA, 4) liver with integrated viral DNA, 5) liver with integra­
ted as well as free viral DNA. 
E: EcoRl endonuclease digested, H: HIND III digested. 
Numbers to the left of the figure refer to DNA size in kilobases. 
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For restriction endonuclease analysis, DNA was digested with EcoRl and 
H I N D III. Purified DNA restriction endonucleases were purchased from Boeh-
ringer, Mannheim, FRG. Prior to digestion, DNA was electrophoretically sized 
to make sure that the sample was not degraded. Digestion conditions were those 
recommended by the manufacturer. Strategy for restriction enzyme analysis of 
HBV-DNA was as described by Shafritz and Kew (17). The final DNA sample 
(20 μg) was dissolved in a buffer solution (40 mM Tris-HCl (pH 7.8), 10 mM 
EDTA, 10% glycerol, 0.5% SDS , 0.05% bromephenol blue, and 0.2% agarose), 
incubated at 450C for two minutes and transferred to a 0.5% agarose gel. Elec­
trophoresis was carried out with the gel submerged in 40 mM Tris-HCl (pH 7.8), 
50 mM sodium acetate, 1 mM EDTA at 30 volts for 40 to 48 hours. DNA was 
transferred to 0.45- /u.m nitrocellulose filter sheets (Schleicher & Schuil, Dassel, 
FRG) according to the Southern's procedure (18). The filters were dried, and 
baked in a vacuum oven at 80 "С for two hours. Further procedures were the 
same as those described in section 2.2.1. Autoradiography was performed at 
— 80oC for at least one week. 
Blot hybridization patterns were classified as free, integrated, or both free and 
integrated DNA. An example of the results of HBV-DNA detection in liver 
specimens is given in figure 2.3 (p. 43). 
2.3.2 The in situ cytohybridization technique (fig. 2.4) 
2.3.2.1 Principle 
As outlined above, the use of radioactive DNA probes has great limitations in 
clinical practice. In situ cyto-hybridization can be performed with non-radio­
active probes, and this technique permits the detection of viral nucleic sequences 
at the cellular level in fresh frozen tissue, as well as in formaldehyde-fixed, paraf­
fin-embedded tissue (19). A preferable method, first attained by Ward et al.(20), 
is based on the finding that the vitamin biotin can be directly incorporated into 
the nucleic acid probe, using biotinylated derivatives of uridine triphosphate 
(UTP) and deoxyuridine triphosphate (dUTP). 
2.3.2.2 Detection technique 
Liver specimens were fixed as for routine histologic analysis in 4% buffered 
formaldehyde and embedded in paraffin. Five-micron thick sections were floated 
on a solution containing 0.5% (wt/vol) gelatin, 0.05% (wt/vol) chromalum, and 
0.02% sodium azide, and stretched on slides which had been previously cleaned 
with ethanol. The slides were baked overnight at 60 "C to prevent the tissue sec-
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tions getting off during the hybridization assay. The sections were dewaxed by 
two 10-minute incubations in xylene and placed for another 10 minutes in metha­
nol containing 1.0% (vol/vol) H2O2 for inactivation of endogenous peroxidase 
activity and for removal of residual formalin crystals. After washing in absolute 
ethanol for 10 minutes, the sections were hydrated by sequential five-minute 
incubations in еіЬапоІ-НгО mixtures containing 95%, 80%, 60%, 30% and 0% 
ethanol respectively. The slides were then treated with proteinase К (Merck, 
Darmstadt, FRG) in a solution containing 0.01 mg proteinase K/ ml, 20 mM Tris 
HCl (pH 7.4), 2 mM СаСЬ and incubated at 370C for 15 minutes. After washings 
in phosphate-buffered saline solution (PBS: 0.13 M NaCl, 0.01 M sodium phos­
phate (pH 7.4)) containing 0.2% glycin for stopping proteinase К activity, the 
slides were submerged in PBS containing 4% paraformaldehyde to stabilize the 
DNA as reported by Haase et al. (21). Residual paraformaldehyde was removed 
by washings in PBS containing 0.2% glycin. After dehydration through a graded 
«ЬапоІ-НгО series containing 50%, 70%, 80%, 90%, and 100% ethanol, the 
slides were air-dried. Hybridization was carried out with cloned HBV-DNA as 
described previously, but labeled with biotin. For this labeling, the d'ITP was 
replaced by an equimolar amount of Bio-11-dUTP (ENZO, Biochem, New 
York, NY) in the nick translation assay as described by Rigby et al. (3). In order 
to estimate the incorporation of Bio-dUTP into the nick translation product, a 
small amount of 3H-dATP was added to a final activity of 3.5 χ IO6 cpm/^mol. 
Nick translations were regarded as optimal if incorporation of more than 50% of 
the 3H-dATP was obtained. Unincorporated nucleotides were removed by 
means of Sephadex G50 column chromatography. The labeled DNA probe was 
divided into aliquote and stored at —20 "С until later use. 
Air-dried sections were hybridized in a medium containing 50% (vol/vol) deio-
nized formamide (Baker, Philipsburg, USA), 10% (wt/vol) dextran sulfate (Phar­
macia Fine Chemicals), 3 χ SSC, 800 /u.g/ml sonicated carrier DNA (herring 
sperm, Boehringer Mannheim, FRG) and 2 /¿g/ml of biotin-labeled probe DNA, 
which had previously been denatured at 100 CC for three minutes in an equal 
volume of formamide, and quick-cooled on ice. Each tissue section was overlaid 
with 10 /il of the hybridization mixture and a cover glass was placed over the sec-
tion. The slides were then transferred to a stainless steel humid chamber, the inte-
rior of which was covered with filter pads, and soaked in formamide buffer (50% 
(vol/vol) formamide and 3 χ SSC (pH 7.4)). Under these circumstances, it was 
not necessary to seal the cover slips. After incubation at 80oC for five minutes 
(for denaturing the DNA), the humid chamber was incubated at 370C overnight. 
After hybridization, the slides were immersed in 2 χ SSC, and after removal of 
the coverslips, washed for three minutes at 32 0 C , for three minutes in PBS con­
taining 0.1% (vol/vol) Triton-X 100 (BDH, Poole, UK), and finally in PBS for 
three minutes. 
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In a humid chamber at 37 0 C , the slides were covered with 200 μΐ of the 1:250 
diluted streptavidin-biotin-horseradish peroxidase complex (ENZO, Biochem, 
New York) in PBS containing 1% (wt/vol) bovine serum albumin for 30 minutes 
as described by the manufacturer. The slides were washed in freshly prepared 
PBS containing 0.1% (vol/vol) Triton-X 100 for three minutes, twice in PBS for 
three minutes, and were developed with the use of a freshly prepared PBS mix­
ture containing 0.5 mg/ml diaminobenzidine tetrachloride (Sigma, St. Louis, Mo) 
and 0.01% H2O2 for 20 minutes at room temperature. The reaction was stopped 
by washing the slides with PBS. The slides were stained with haematoxilyn, 
dehydrated and mounted. 
In situ hybf idizat ion of b i o t i r y l a t e d Detection of b iotmyla led DNA probe with 
HBV DNAprobe with v i rus DNA t h e a v i d m biolm-peroxit iase complex 
Figure 2.4· HBV-DNA detection m formaldehyde-fixed liver tissue sections by means of in situ 
hybridization with a biotin-Ubeled HBV-DNA probe 
A In situ hybridization of btotmyUted HBV-DNA probe with HBV-DNA sequences present in 
liver tissue. B. Detection of btotmyUted DNA probe with the avidin-biotin-peroxidase complex. 
2.4 Detection of HBV-DNA in white blood cells 
2.4.1 Technique 
For the isolation of lymphocytes, 10 to 20 ml of freshly collected heparinized 
blood was used. The blood sample was diluted with two volumes of buffer solu­
tion (final concentrations: 13 mM Na2HP04.2H2O, 3 mM КНгРО-,, 5 mM KCl, 
5 mM glucose). After gentle mixing, one volume of a metrizoate/dextran solution 
(Lympho-paque, density 1.086, Nyegaard & Co, Oslo, Norway) was carefully 
brought under the mixture. After centrifugation at 4 "С for 20 minutes (2000/ 
min), white blood cells appeared as a band at the interface between blood and 
Lympho-paque. This band, containing predominantly lymphocytes, was remov­
ed with a Pasteur pipette, and diluted (1:1) with the buffer solution. After centri-
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fugation at 4 "С for 10 minutes, the supernatant was removed, and the white 
blood cell pellet was washed three times at 4 °C for 10 minutes at 2000/min with 
a buffer solution containing 5% bovine serum albumin (final concentratitons: 
140 mM NaCl, 5 mM KCl, 4.2 mM N a H C O j , 0.37 mM Na 2 H P 0 2 . 2 H 2 0 , 0.44 
mM KH2PO4.O H2O, 5 mM glucose) to remove any plasma contamination. The 
pellet was then stored at —80 0 C until further analysis. 
Extraction of DNA and further processing of the sample were the same as de­
scribed for liver specimens (see section 2.3.1.2). In this procedure contamination 
with blood platelets and monocytes is low. According to the manufacturer, the 
use of Lympho-paque enables a yield of lymphocytes exceeding 95%, and conta­
mination with red blood cells in the lymphocyte suspension is between 1-5%. 
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CHAPTER 3 
Hepatitis В virus DNA in serum 
3.1 Hepatitis В virus DNA in serum and relation to conventional HBV 
serologic markers 
Summary 
Hepatitis В virus DNA (HBV-DNA) was determined in sera obtained from 388 
patients with various combinations of serologic markers of HBV infection and in 
80 HBV-negative controls. A strong correlation could be shown between the 
presence of HBV-DNA and HBeAg in serum, irrespective of histologic and/or 
clinical manifestations of liver disease. However, in 15% of anti-HBe-positive 
HBsAg carriers, viral DNA could still be detected in serum. In addition, HBV-
DNA was present in one patient with anti-HBc as the sole serologic marker of 
infection. In patients with convalescent antibodies - both anti-HBc and anti-HBs 
positive - HBV-DNA was undetectable in serum. Detection of HBV-DNA can 
be considered as the most sensitive and specific method to determine infectivity 
of serum. 
3.1.1 Introduction 
The diagnosis of hepatitis В virus infection has for many years been based on 
serologic assays for hepatitis В surface antigen, the coat protein which is pro­
duced in large excess of the complete virion (Dane particle) itself. The presence of 
HBeAg in sera of HBsAg-positive subjects was found to be associated with intra­
hepatic expression of HBcAg (1), and with infectivity of such carriers. However, 
the production of HBsAg and HBeAg cannot always be correlated with the 
number of circulating virus particles and with infectivity (2). Transmission of the 
infection after disappearance of the e-antigen from serum could still occur (3, 4). 
HBV-specific DNA polymerase and HBcAg are also markers of circulating 
Dane particles, but detection of DNA polymerase is not very sensitive (5, 6), 
while the HBcAg assay is hampered by a considerable loss of antigenic activity 
during separation of Dane particles from anti-HBc (7). Advances in molecular 
biology have permitted the detection of viral DNA in serum, liver and other 
tissues. Detection of viral DNA is a direct measure of viral particles, while 
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detection of HBeAg is dependent on the relative excess of the antigen over the 
homologous antibody present at the time of sampling (8). The presence of HBV-
DNA sequences in serum has, therefore, been considered a better marker of 
infectivity than the presence of the e-antigen (9,10). With the currently available 
HBV-DNA assays, fractions of picograms of viral DNA, equivalent to a concen­
tration of 1 χ lOVirions can be detected (8), and its presence has been demonstra­
ted in as little as 0,003 microliters of serum (11). 
The aim of our study was to investigate the sensitivity and specificity of hepatitis 
В virus DNA detection in serum, and to determine the relationship with 'con­
ventional' HBV serologic markers. 
3.1.2 Subjects and methods 
During the period of 1980 to 1988, serum samples of 468 subjects were examined 
for the presence of hepatitis В virus DNA (HBV-DNA). These sera were collect­
ed from patients visiting the outpatient clinic or during their stay in our hospital. 
In addition, serum samples were also obtained from patients examined in hospi­
tals elsewhere. 
Of many patients more than one serum sample was examined during this survey, 
but only the first sample obtained was included in this study. 
Based on conventional HBV serologic findings, these sera could be divided into 
six groups (table 3.1.1). 
Detection technique 
HBV serologic parameters were determined by means of commercial enzyme 
immunoassays (AUSZYME-II, AUSAB, CORAB/CORZYME, ABBOTT-
HBe, Abbott Laboratories, North Chicago, IL). 
HBV-DNA detection 
Determination of HBV-DNA in serum was carried out either with the phenol 
extraction technique or by direct spotting of pretreated serum samples on nitro­
cellulose filter sheets as outlined in chapter 2. 
Statistical analysis 
Mantel-Hanszel's chi-square test was used for the statistical comparison of the 
results of HBV-DNA detection between groups of patients. 
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3.1.3 Results 
The results of the HBV-DNA detection in sera obtained from 388 patients with 
HBV serologic markers and from 80 patients or healthy controls without HBV 
markers are shown in table 3.1.1. 
In HBsAg-positive/HBeAg-positive patients (fig. 3.1.1), HBV-DNA could be 
detected in 65.7% of sera obtained during acute hepatitis. HBV-DNA was pre­
sent in 88.9 and 82.4% of serum samples obtained from patients with chronic 
persistent hepatitis (CPH) or chronic active hepatitis (САН) respectively. Two 
out of sixpatientswith primary hepatocellular carcinoma (PHC) had detectable 
viral DNA. HBV-DNA was also positive in the large majority of chronic HBsAg 
carriers whose liver histology was not available. Overall, 72.5% of samples were 
positive for HBV-DNA in this group. 
Table 3.1.1 Results of HBV-DNA detection in 468 serum samples according to 
HB V serologic markers 
Group 
I 
II 
III 
IV 
V 
VI 
Serologic markers 
(+) 
HBsAg 
HBeAg 
anti-HBc 
HBsAg 
anti-HBe 
anti-HBc 
HBsAg 
anti-HBc 
anti-HBc 
(anti-HBe pos. or neg.) 
anti-HBc 
anti-HBs 
No HBV markers 
η 
91 
113 
25 
73 
86 
40 (*) 
12(+) 
28 Π 
HBV-DNA 
(+) 
66 
17 
1 
1 
0 
0 
0 
0 
(%) 
(72.5) 
(15.0) 
(4 .0) 
( 1.4) 
( 0 ) 
( 0 ) 
( о ) 
( 0 ) 
* : patients with chronic liver disease 
+ : patients with other diseases 
0
 : healthy controls 
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/о - -
100-
75-
50-
25-
liver histology liver histology 
unknown 
СРН 
1 ota I 
CAH/C 
PHC 
AH 
CAR ι 
n=91 n = 18 n=17 n = 6 n=35 n = 15 
Figure 3.1.1: Serum HBV-DNA in HBsAg-positive/HBeAg-positivepatients (Group I). 
CPH : chronic persistent hepatitis 
CAH/C : chronic active hepatitis or cirrhosis 
PHC : primary hepatocellular carcinoma 
% 
AH : acute hepatitis 
CAR : chronic HBsAg-posittve carrier 
iver histology 
100 
IS­
SO 
25-
liver histology 
unknown 
PHC 
total CPH 
CAH/C 
AH 
CAR 
n = 113 n = 12 n = 17 n=5 n = 23 n = 56 
Figure 3.1.2. Serum HBV-DNA in HBsAg-postttve/anti-HBe- positive patients (Group II). 
CPH • chronic persistent hepatitis AH : acute hepatitis 
CAH/C : chronic active hepatitis or cirrhosis 
PHC : primary hepatocellular carcinoma 
CAR : chrome HBsAg positive carrier 
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In serum samples obtained from anti-HBe-positive/HBsAg-positive patients 
(fig. 3.1.2), HBV-DNA could be detected in only 26.1% of sera obtained during 
acute hepatitis, whereas up to 16.7% of chronic HBsAg carriers were HBV-
DNA positive. However, three out of five patients with P H C had viral DNA in 
their sera. In HBsAg carriers with unknown liver histology, serum aminotrans­
ferase values were available for analysis in 39 cases; although the large majority of 
these carriers (36/39) had normal aminotransferase values, viral DNA could be 
detected in 2/36 cases (5.6%). 
In HBeAg-negative/anti-HBe-negative HBsAg carriers (fig. 3.1.3), one out of six 
patients with acute hepatitis had viral DNA in his serum, whereas no viral DNA 
was found in chronic carriers, who, in general (16/17), had normal serum amino­
transferase values at the time of serum sampling. 
In patients with anti-HBc as the sole serologic marker (some samples being posi­
tive for anti-HBe as well) (fig. 3.1.4), HBV-DNA was negative in all sera obtai­
ned during the window phase after acute hepatitis (n=9), as well as in all speci­
mens from patients with chronic liver disease (n=8) or P H C (n=2). However, 
n = 2 5 n = 6 
Figure 3 13- Serum HBV-DNA in HBeAg-negattve, anti-HВe -negative, HBsAg-posttwe 
patients (Croup III) 
AH: acute hepatitis 
Serum HBV-DNA was undetectable in chronic HBsAg-positive earners (n = J9, data not shown). 
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n=73 n=54 
FigureJ 1 4- Serum HBV-DNA m antt-HBc-positivepatients (HBsAg-negative/anti-HBs-nega-
tive) (Group IV). 
SCR: patients with normal serum aminotransferase values; anti-HBc was found positive during 
screening. 
Serum HBV-DNA was undetectable m patients with chrome hepatitis or cirrhosis (n=8), m 
patients with primary hepatocellular carcinoma (n=2), and m patients during the wmdow-penod 
after acute hepatitis (n=9) 
one patient with anti-HBc as the sole serologic marker of HBV infection had 
HBV-DNA in his serum on several occasions. The history of this particular 
patient is described in section 3.5. 
Viral DNA was negative in serum samples obtained both from patients with 
chronic liver disease or other diseases and from healthy controls, in whom no 
HBsAg or antibodies against HBV were found (table 3.1.1). 
3.1.4 Discussion 
The results of this study indicate the strong correlation between the presence of 
HBeAg and of HBV-DNA in serum, irrespective of liver histology. However, in 
acute hepatitis, only 65% of patients had detectable viral DNA in their sera. The 
absence of HBV-DNA during the acute phase •was observed especially in subjects 
with markedly elevated serum aminotransferase values (data not shown). A 
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degradation of DNA material caused by the fulminant character of the hepatitis 
has been suggested as responsible for this finding (12). Still, HBV-DNA could 
also have disappeared from the sera of a considerable number of such patients at 
the time of serologic examination, regardless of serum biochemical findings. 
These results are in agreement with those described in the literature for acute 
type В hepatitis (13-16). The prevalence of serum HBV-DNA in acute hepatitis 
reportedly ranges from 25.5 (15) to 79.5% (13) during the e antigen-positive 
phase, and depends on the duration of symptoms at the time of presentation (14). 
During the early phase of acute type В hepatitis, a low level of HBV-DNA can be 
detected in about 50% of the patients (13-18). HBV-DNA becomes undetectable 
one to eight weeks before, or simultaneously with, elimination of HBeAg (19-
21), usually shortly before peak values of serum aminotransferases are reached 
(22). 
In chronic HBsAg-carriers, we found HBV-DNA in 76.8% of HBeAg-positive 
cases. These findings are also in accordance with those reported in the literature 
(23-27). Several studies have shown the presence of HBV-DNA in sera of almost 
all HBeAg-positive asymptomatic, chronic HBsAg carriers (23, 25, 28). The 
presence of HBV-DNA also correlated with the presence of HBeAg in the liver 
(29-31) and with elevation of serum aminotransferase values (23, 32). However, 
viral DNA may also be present in anti-HBe-positive carriers (33-38). In this stu­
dy, we found HBV-DNA in 16.7 and 5.9% of anti-HBe-positive patients with 
chronic persistent and chronic active hepatitis or cirrhosis respectively. In larger 
studies, involving anti-HBe-positive carriers from South European countries or 
from the Far East, HBV-DNA was detected in up to 21.1% of asymptomatic 
anti-HBe-positive carriers (39-41), whereas figures for HBeAg-negative, 
HBsAg- positive carriers with chronic liver disease ranged from 26 to 95% (24, 
26, 42,43). Since in anti-HBe-positive chronic HBsAg carriers a prevalence simi­
lar to ours was found in Canada (30) and in Northern Europe (35, 44, 45), the 
persistence of HBV-DNA in anti-HBe positive chronic HBsAg carriers seems to 
depend on racial origin. 
In chronic HBsAg carriers, seroconversion from HBeAg to anti-HBe is usually 
accompanied by disappearance of HBV-DNA from serum. The HBV-DNA 
assay is capable of indicating the onset of HBV elimination earlier than any other 
HBV serologic marker (40). In some cases, HBV-DNA could, however, be 
detected in serum for up to 40 months after seroconversion (46). Although disap­
pearance of HBeAg and HBV-DNA from serum and development of anti-HBe 
are in general associated with loss of infectivity and disease activity (33), serologic 
markers, including HBV-DNA, associated with infectivity and reactivation of 
liver disease may reappear. Initially such reactivations were noted especially 
during immunosuppressive therapy (47,48), but spontaneous reactivation of dis­
ease, with reappearance of HBeAg and HBV-DNA in serum, now appears to be 
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a not uncommon event in chronic HBsAg carriers (49-51). Lok et al. reported 
spontaneous reactivation in 32.2% of parients who had initially lost HBeAg (52). 
Elderly patients with long duration of chronic liver disease seemed preferably 
prone to such reactivation (50). 
Although HBV-DNA is usually not detectable in sera of patients with anti-HBc 
as the sole marker, we demonstrated HBV-DNA in serum of one such patient 
(see section 3.5). In patients with both anti-HBc- and anti-HBs-antibodies, 
HBV-DNA is not detectable according to most studies, including ours. Howe-
ver, Bréchot et al. (53) in their study reported the presence of viral DNA in 4/39 
patients with chronic liver disease and anti-HBc and anti-HBs as markers of pre-
vious infection. 
We may therefore conclude from these findings that detection of HBV-DNA in 
serum is an excellent method to indicate infectivity of an HBsAg carrier and is 
probably better in this regard than the HBeAg assay. In addition, with HBV-
DNA determination in serum it is possible to demonstrate the onset of HBV eli-
mination earlier than that of any other serologic marker. 
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3.2 Serum hepatitis В virus DNA determination and the 
prevention of posttransfusion hepatitis 
Summary 
In order to determine whether sera obtained from apparently healthy donors, 
negative for HBsAg, could harbor HBV-DNA, entailing a risk of transmission of 
HBV, we analyzed blood samples drawn from 1,413 potential blood donors for 
the presence of viral DNA. None of these specimens was found to be positive 
and none of the donors developed clinically manifest hepatitis. No post-transfu­
sion hepatitis was noted in any of the patients receiving blood from these donors. 
We conclude that in a community with a low prevalence of HBV infection, rou­
tine testing for HBsAg in sera from apparently healthy donors is effective in pre­
venting post-transfusion hepatitis due to HBV. Routine screening with the much 
more sensitive but time-consuming hybridization technique is, therefore, not 
justified. 
3.2.1 Introduction 
Shortly after the discovery of the Australia antigen, Gocke and co-workers 
demonstrated that up to 74% of patients receiving HBsAg-containing blood 
developed hepatitis (1). This observation has initiated the widespread use of sen­
sitive systems for the detection of hepatitis В virus infection in screening poten­
tial blood donors. This screening policy as well as the exclusion of commercial 
donors have resulted in a clear cut reduction in the incidence of post-transfusion 
hepatitis (PTH) due to HBV (2). It has now become clear that most cases of PTH 
are due to infection with non-Α, non-B viral agents, and HBV is thought to be 
responsible for only 10-13% of PTH cases (2). However, recent studies have 
indicated a relatively high frequency of the presence of hepatitis В virus DNA in 
HBsAg-negative sera (3), and it has been suggested that some of the HBsAg-
negative PTH cases might actually be due to HBV infection that cannot be detec­
ted with the available conventional techniques. 
In our blood bank, serum samnles of potential donors are screened for HBsAg 
by means of a micro-ELISA technique (Hepanostika, Organon Teknika, Bel­
gium). Using this method, we might fail to detect subjects with anti-HBc as the 
sole marker of HBV infection, a serologic state in which transmission of the 
infection may occur (4). In order to determine whether sera obtained from appa­
rently healthy donors negative for HBsAg could harbor HBV-DNA, entailing a 
risk of transmission of the virus, we analyzed blood samples drawn from poten­
tial blood donors for the presence of HBV-DNA. 
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3.2.2 Materials en methods 
Serum specimens from a total of 1,413 donors were tested under code for the pre­
sence of HBV-DNA. Testing was carried out by means of the phenol-extraction 
technique as described in section 2.2.1. 
3.2.3 Results and discussion 
Post-transfusion hepatitis continues to be a hazard to patients receiving blood or 
blood products, despite additional measures such as freezing, deglycerolizing 
and washing of blood products, globulin prophylaxis, and evaluation of alanine 
aminotransferase (ALT) values (5,6). In this study, none of the serum specimens, 
obtained from subjects with negative results on HBsAg testing, was found posi­
tive for HBV-DNA. Furthermore, none of the donors developed clinically mani­
fest hepatitis, nor was post-transfusion hepatitis noted in any of the patients after 
receiving blood from these donors. 
These results indicate that, in a community with a low prevalence of HBV infec­
tion, routine testing for HBsAg of sera obtained from apparently healthy volun­
teers is effective in preventing post-transfusion hepatitis due to HBV. Since the 
risk of HBV transmission by these HBsAg-negative blood donors is very low, 
routine screening with the much more sensitive but time-consuming and expen­
sive hybridization technique is, therefore, not justified. 
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3.3 Detection of hepatitis В virus DNA in serum and relation to 
IgM class anti-HBc titers in patients with hepatitis В virus infection 
Summary 
We examined sera from six groups of patients with different serologic markers 
and clinical manifestations of HBV infection for hepatitis В virus DNA (HBV-
DNA) using a molecular hybridization technique, and for IgM class anti-HBc 
using an ELISA based on the antibody capture principle. Results of the HBV-
DNA assay were generally in agreement with the presence of HBeAg. However, 
HBV-DNA was found in 13.3% of anti-HBe-positive sera and in one patient 
with anti-HBc as the sole marker. 
IgM anti-HBc was detected in high titers in patients with acute hepatitis, and was 
invariably present during the 'window period'. This marker was also found in 
patients with chronic hepatitis В as well as in healthy HBsAg carriers, though less 
frequently when HBV-DNA or HBeAg was absent. From these findings we 
may, therefore, conclude that the HBV-DNA assay provides a reliable method to 
detect the infectious agent, particularly in anti-HBe-positive sera and in sera with 
anti-HBc as the sole marker. 
The assay for IgM anti-HBc is useful for establishing the diagnosis of recent type 
В hepatitis, especially in cases when HBsAg has been cleared from serum, or 
when reactivation of hepatitis in a chronic HBsAg carrier has to be differentiated 
from other agents causing liver injury. 
3.3.1 Introduction 
Chronic hepatitis В virus (HBV) carriers are at high risk of developing chronic 
liver disease and are the major source of infection. The use of highly sensitive 
tests for detection of HBV antigens and antibodies has enabled the identification 
of various manifestations of HBV infection (1). Markers of active HBV replica­
tion include the presence of DNA polymerase activity (2), hepatitis В core anti­
gen (HBeAg) (3), hepatitis В e antigen (HBeAg) (4), and cytoplasmic expression 
of HBeAg in hepatocytes by immunofluorescence (5). None of these markers, 
however, represents a quantitative measure of the virus in serum of HBsAg-posi-
tive carriers. 
Detection of IgM class antibodies against hepatitis В core antigen (IgM-anti-
HBc) has been introduced and was thought to be a serologic marker of recent or 
ongoing HBV infection (6). Nevertheless, longitudinal studies have shown that 
high levels of IgM anti-HBc are found early during the acute phase of hepatitis В 
virus infection, and decline after a few months regardless of the state of circulat-
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ing hepatitis В surface antigen (7). The detection of hepatitis В virus-DNA 
through its ability to hybridize with 32P-labeled DNA, prepared from recombi­
nant plasmids containing the HBV genome, permits a new approach to the 
understanding of HBV infection regarding infectivity and chronic HBsAg carrier 
state. 
The present study aimed to investigate the specificity and the clinical significance 
of this technique for detection of HBV-DNA in serum and to determine the rela­
tionship between the presence of serum HBV-DNA and the results of HBeAg 
and IgM class anti-HBc assays. 
3.3.2 Patients and methods 
3.3.2.1 Source of serum samples 
Serum samples were collected from patients referred to our hospital because of 
liver disease or other diseases. In addition, serum specimens from subjects with 
Table 3.3.1 Serum IgM class anti-HBc and HB V-DNA in six groups of patients 
•with different HB V serologic markers 
Group Serologic markers η HBV- (%) IgM anti- (%) 
D N A ( + ) H B c ( + ) 
I HBsAg 
HBeAg 109 77 
anti-HBc 
II HBsAg 
anti-HBe 98 13 
anti-HBc 
HI HBsAg 
anti-HBc 25 1 
IV anti-HBc 
(anti-HBe positive 51 1 
or negative) 
V anti-HBc 
anti-HBs 82 0 
VI no HBV markers 10 0 
(70.6) 73 (67.0) 
(13.3) 38 (38.8) 
( 4.0) 6 (24.0) 
( 2.0) 11 (21.6) 
( 0 ) 8 ( 9.8) 
( 0 ) 0 ( 0 ) 
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HBV markers were also received from hospitals elsewhere. Based on HBV sero-
logic findings, the samples were classified into six groups (table 3.3.1). 
3.3.2.2 Detection of HBV-DNA in serum 
Determination of HBV-DNA in serum was carried out as described in chapter 2. 
3.3.2.3 IgM anti-HBc (ELISA) 
The method is an enzyme-linked immunosorbent assay (ELISA) based on the 
antibody capture principle described earlier for IgM antibody to hepatitis A virus 
(8). The test system was adapted for the detection of IgM antibody to HBcAg. 
All specimens tested for IgM anti-HBc antibodies in a previous study (9), were 
reevaluated by means of a test system that had been modified to improve diffe-
rentiation between sera obtained during the acute phase of hepatitis and those 
obtained from chronic HBsAg carriers. 
The sample and controls are diluted to 1:100 in PBS-Tween buffer containing 2% 
normal human serum, and incubated at 37 0C for one hour in a microtitration 
plate, which had previously been coated with sheep immunoglobulins against 
human IgM (/[¿-specific). After washing away the unbound material with PBS-
Tween buffer, a mixture of the HBcAg:anti-HBc:peroxidase conjugate is incuba-
ted at 37 0C for one hour. After another wash step, the substrate reaction is per-
formed as before. The cut-off calculation is based on 0.7 [absorbance of the nega-
tive and the positive control]. This calculation reduces the test sensitivity to posi-
tive results primarily during the acute phase of HBV infection. Interference by 
IgG anti-HBc is excluded by the use of an IgM/A-specific capture technique 
during the first incubation. The specificity was confirmed by a negative result for 
samples containing high titers of IgG anti-HBc. 
3.3.2.4 Other HBV serologic markers 
The presence of HBsAg, anti-HBs, anti-HBc, HBeAg, and anti-HBe was deter-
mined by means of commercial enzyme immunoassays (AUSZYME-II, 
AUSAB, CORAB/CORZYME, ABBOTT-HBe, Abbott Laboratories, North 
Chicago, IL.) 
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3.3.2.5 Statistical analysis 
Mantel-HanszePs chi-square test was used for the statistical comparison of the 
results of HBV serologic markers and of HBV-DNA. 
3.3.3 Results 
The results of the detection of HBV-DNA and of IgM class anti-HBc in sera 
obtained from six groups of patients with different HBV serologic markers are 
shown in table 3.3.1. 
In patients positive for both HBsAg and HBeAg (group I), HBV-DNA could be 
detected in 23/35 (65.7%) of patients with acute type В hepatitis, as well as in the 
large majority of patients with chronic hepatitis, cirrhosis, primary liver cell car­
cinoma or chronic HBsAg positive carriers with unknown liver histology (fig. 
3.3.1). IgM class anti-HBc was present in nearly all of these patients' sera obtain­
ed during acute hepatitis, but was undetectable in three patients with primary 
hepatocellular carcinoma. In patients with chronic hepatitis or liver cirrhosis the 
prevalence of IgM anti-HBc was comparable. 
· / . 1 
liver histology liver histology 
unknown 
t o t a l CAH/C CPH PHC AH CAR 
100-1 
I i IgM anti-HBc pos patients 
Figure 3.3 1· Serum HBV-DNA and IgM cUss anti-HBc m HBsAg- positive/H BeAg-postttve 
patients (Group I) 
CAH/C: chronic active hepatitis or cirrhosis AH : acute hepatitis 
CPH : chronic persistent hepatitis CAR • chronic HBsAg-posittve earner 
PHC : primary hepatocellular carcinoma 
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Overall, in this HBsAg-positive/HBeAg-positive group, HBV-DNA was detec­
table in almost 71% of patients, while IgM class anti-HBc could be detected in 
67.0% of cases. 
A representative profile of biochemical data, serologic markers and HBV-DNA 
in a patient with acute type В hepatitis is shown in figure 3.3.2. 
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Figure 3.3.2: Profile of some biochemical data, ΗBV serologic markers, and HBV-DNA status in 
a patient with acute type В hepatitis. 
In sera obtained from HBsAg-positive patients with anti-HBe (group II), HBV-
DNA could be demonstrated in only five out of 20 patients despite the presence 
of IgM class anti-HBc at high titers in all cases with acute hepatitis (fig. 3.3.3). In 
patients with chronic hepatitis or cirrhosis and in chronic HBsAg carriers with 
unknown liver histology, viral DNA was detectable in up to 11.1 % of cases only. 
However, three out of five patients with liver cell carcinoma had viral D N A in 
their sera. Although IgM class anti-HBc was found in all cases during acute hepa­
titis, it was detectable only in a minority of chronic HBsAg-positive patients, 
irrespective of liver histology. 
In total, HBV-DNA and IgM class anti-HBc were present in this group in 13.3 
and 38.8% respectively. 
Although the number of patients is relatively small, HBV-DNA was significant­
ly more often present in sera obtained from patients with primary hepatocellular 
carcinoma than in specimens from patients with chronic hepatitis (p <0.05). 
In HBsAg-positive patients without serum HBeAg or anti-HBe (group III), nei-
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Figure 3 3 3 Serum HB V-DNA and IgM cUss anti-HBc in HBsAg- positive/antt-HBe-positive 
patients (Croup II). 
САН/С chronic active hepatitis or cirrhosis 
СРН chronic persistent hepatitis 
РНС · primary hepatocellular carcinoma 
AH • acute hepatitis 
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Figure 3 3 4 Serum HBV-DNA and IgM cUss anti-HBc in HBsAg-negattve/antt-HBe-negati-
ve, H BsAg-positive patients (Group IV) 
AH acute hepatitis 
Neither HBV-DNA nor IgM class anti-HBc were detectable m any of the specimens (n = 19) 
obtained from chronic H BsAg-positive carriers with unknown liver histology. 
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Figure 3.3.5: Serum HB V-DNA and IgM cUss anti-HBc in anti-HBc- positive patients (HBsAg-
negative, anti-HBs-negative) (Group IV). 
CH/C : chronic hepatitis or cirrhosis 
window period: patients during the window period after acute type В hepatitis 
SCR : patients with normal serum aminotransferase values; anti-HBc found positive 
during screening. 
In serum obtained from two patients with primary hepatocellular carcinoma neither HBV-DNA 
nor IgM anti-HBc were detectable (data not shown). 
ther HBV-DNA nor IgM anti-HBc was detected in chronic HBsAg carriers. 
However, the serum of one out of six patients with acute type В hepatitis 
contained viral DNA (fig. 3.3.4). 
In patients with anti-HBc antibodies but negative for HBsAg and anti-HBs 
(group IV), HBV-DNA was detected in only one patient. This particular patient 
had reactivation of hepatitis during immunosuppressive therapy, and is described 
in detail in section 3.5. Sera from eight patients collected during the 'window 
phase' (see general Introduction) showed IgM class anti-HBc at high titers. 
However, viral DNA was not detectable in any of these serum samples (fig. 
3.3.5). 
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In subjects with both anti-HBc-and anti-HBs-antibodies (group V), no viral 
DNA could be detected in serum, regardless of the findings of liver histology, 
whereas IgM class anti-HBc was found only in a minority of patients (fig. 3.3.6). 
In all patients without HBV markers (chronic hepatitis, n=7; primary hepatocel-
lular carcinoma, n=3), HBV-DNA or IgM anti-HBc was undetectable in serum 
(data not shown). 
liver histology 
unknown 
total 
75-
50-
25-
n=82 n=67 
HBV DNA pos patients 
I j IgM anti-HBc pos patients 
Figure 3 3 6 Serum HBV-DNA and IgM class anti-HBc m patients positive for both anti-HBc 
and antt-HBs (Group V). 
Neither HBV-DNA nor IgM anti-HBc were detectable in any of the samples obtained from 
patients with chronic hepatitis or cirrhosis (n=ll) or from patients with primary hepatocellular 
carcinoma (=4) 
3.3.4 Discussion 
In this study we demonstrated that the results of HBV-DNA assay as determined 
by the molecular hybridization technique, are generally in agreement with sero-
logic markers indicative of the presence of HBV as reported earlier (10). In acute 
or chronic liver disease, the presence of HBeAg indicates active viral replication. 
Blood of such patients must be considered highly infectious (11), and HBV-
7. 
100-, 
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DNA can be detected in most of these sera (12-14). However, in serum speci­
mens obtained from patients during the acute phase of type В hepatitis - when 
HBeAg is usually present - HBV-DNA may be undetectable. The absence of 
viral DNA during the acute phase was observed especially in subjects with mar­
kedly elevated serum aminotransferase values. Degradation of DNA material 
caused by the fulminant character of the hepatitis has been suggested as a factor 
responsible for this finding (9). However, HBV-DNA could also have disappear­
ed in a considerable number of patients with acute type В hepatitis at the time of 
serologic examination, regardless of serum biochemistry (15-17). 
Disappearance of HBeAg and development of anti-HBe in general indicate a 
good prognosis (18). Most of such patients (group II) indeed showed recovery 
from the disease after variable intervals. Nevertheless, disappearance of HBeAg 
and development of anti-HBe do not always reflect complete clearance of HBV 
(10,19). In this group of patients HBV-DNA could be detected in 13.3% of sera. 
The presence of HBV-DNA in HBsAg-positive/anti-HBe-positive subjects 
seems to depend on racial origin. Higher percentages, up to 50, have been found 
in such patients from South European countries (10, 20), Africa, the Middle East 
and the Far East (21), than in patients from North European countries. 
High titers of IgM anti-HBe, originally proposed as a marker of recent hepatitis 
В virus infection (6), were measured during the early phase of HBs antigenemia 
(fig 3.3.2, acute hepatitis). In sera obtained from patients in the window period of 
acute hepatitis, IgM anti-HBe was also present at high titers. The potential infec-
tivity of patients during the window period has been reported (22). However, we 
could not detect viral DNA in any of eight patients during this phase, thereby 
confirming that, in general, viral replication is absent or has fallen to undetectable 
levels during the window period. 
In chronic HBsAg carriers, IgM anti-HBe can be found, in low titers, despite the 
absence of HBeAg and HBV-DNA from serum. The IgM anti-HBe in these 
patients must be considered specific and is not caused by cross-reactivity with 
IgG anti-HBe, as been suggested for a different ELISA by Bänninger et al. (23). 
A recent study indicates that differentiating recent from current hepatitis В infec­
tion is possible by means of a radioimmunoassay with sera tested at 1:5,000 dilu­
tion (7) (see also general Introduction). However, IgM anti-HBe was found in 
the present study in most HBsAg/HBeAg-positive patients, in contrast to 
HBeAg-negative HBsAg carriers, or HBsAg-negative patients. In both groups 
IgM anti-HBe was positive in only a minority, irrespective of liver histology. 
From the results in this study, we conclude that the HBV-DNA hybridization 
assay is a reliable method for monitoring the clearance of HBV. The assay is par­
ticularly important for detecting the infectious agent in anti-HBe-positive sera or 
sera with anti-HBe as the sole marker. The IgM anti-HBe assay is usefull to 
establish the diagnosis of acute type В hepatitis, especially in cases where HBsAg 
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has already been cleared from serum, and in cases where a reactivation of hepati­
tis in a chronic HBsAg carrier has to be differentiated from other viral agents cau­
sing liver damage. In the latter cases, the IgM anti-HBc titer is usually low or 
absent. 
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3.4 Serum hepatitis В pre-S proteins and anti-pre-S2-antibodies: 
clinical significance and relation to serum hepatitis В virus DNA 
Summary 
Pre-S proteins may have an important role in virus assembly and virus entry into 
the host cell. The presence of pre-S proteins in serum is also thought to correlate 
with active viral replication, whereas anti-pre-S2-antibodies have been considered 
as early markers of recovery from liver disease due to HBV infection. 
To investigate whether detection of pre-S proteins or anti-pre-S2-antibodies 
might have additional diagnostic and/or prognostic value in HBV infection, sera 
of six groups of patients (total 373) were examined for the presene of pre-S pro­
teins, and sera of three groups (total 163) for the additional presence of anti-pre-
S2-antibodies) using micro-ELISA systems. Pre-Sl and pre-S2 proteins were sig­
nificantly more often present in sera of HBV-DNA-positive than in sera of 
HBV-DNA-negative HBsAg carriers. However, pre-S proteins were also detec­
table in HBV-DNA-negative HBsAg carriers irrespective of serum HBeAg/anti-
HBe, serum aminotransferase values, or liver histologic findings. Anti-pre-S2-
antibodies could be detected in sera of the majority of anti-HBc-/anti-HBs-posi-
tive patients, but were also present in approximately 50% of HBsAg-positive 
carriers, regardless of the presence of HBeAg or HBV-DNA in serum, or of liver 
histology. We may conclude from these findings that the presence of pre-S pro­
teins in serum is not equivalent to HBV-DNA as a marker of viral replication, 
and that anti-pre-S2 is not an early marker of recovery from HBV infection. 
However, further comparative studies using different test systems are required. 
3.4.1 Introduction 
The open reading frame of the S gene of hepatitis В virus (HBV) DNA contains 
three ATG (adenine, thymidine, guanosine) initiator codons for protein synthe­
sis. The most downstream situated initiation site generates the major HBsAg 
containing 226 amino acids (25 kilodaltons, also called P24 and GP28 (in the gly­
cosylated form), see figure 3.4.1). The second ATG site, 165 bases upstream, ini­
tiates the production of the major protein extended with a 55 amino acid 
sequence known as pre-S2, thus yielding the HBsAg middle protein (GP33, 
GP36). The third ATG codon on the S gene, 357 bases further upstream, codes 
for another 119-128 amino acid extension known as the pre-Sl antigen, thus 
coding for the HBsAg large protein (42-45 kilobases). The large protein therefore 
contains the S, pre-S2 and pre-Sl antigenic determinants (1,2). 
The middle protein, GP33/GP36, has the ability to bind polymerized human 
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serum albumin, and this binding, dependent on the pre-S2 extension, is presumed 
to have a function in virus entry into the host cell (3,4). Both pre-Sl and pre-S2 
antigens may have an important role in virus assembly (5,6). 
In chronic HBsAg carriers, pre-Sl can be found in Dane particles (7,8), whereas 
pre-S2 containing proteins are present in the small spherical particles as well (8). 
The presence of pre-Sl in serum is thought to correlate well with active virus 
replication (9, 10). The pre-S2 antigen has an immunodominant epitope, while 
antibodies to pre-S2 may reveal an early marker for recovery after HBV infection 
(11,12), and pre-S2 antigen may have additional value in vaccines (13). 
The aim of the present study was to investigate whether the detection of pre-S 
encoded proteins and/or anti-pre-S2 antibodies in serum has diagnostic and/or 
prognostic value in staging of HBV infection. 
3.4.2 Patients and methods 
Sera 
Sera obtained from 363 subjects with various serologic and histologic manifesta­
tions of HBV infection, and from 10 patients with HBV unrelated forms of chro­
nic liver disease were examined under code for the presence of pre-Sl and pre-S2 
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Table 3.4.1 Pre-Sl, pre-S2 and HBV-DNA in six groups of sera obtained from 
373 subjects with different conventional HBV serologic markers. 
Group Serologic η HBV- (%) pre-Sl (%) pre-S2 (%) 
marker (+) D N A ( + ) (+) (+) 
I HBsAg 
HBeAg 109 77 (70.6) 102 (93.6) 100 (91.7) 
anti-HBc 
II 
III 
IV 
V 
VI 
HBsAg 
anti-HBe 
anti-HBc 
HBsAg 
anti-HBc 
anti-HBc 
(anti-HBe 
pos. or neg.) 
anti-HBc 
anti-HBs 
N o H B V 
markers 
98 
25 
49 
82 
10 
13 
1 
1 
0 
0 
(13.3) 
( 4.0) 
(2 .0) 
( 0 ) 
( 0 ) 
79 
3 
1 
4 
0 
(80.6) 
(12.0) 
(2 .0) 
(4 .9) 
( 0 ) 
87 
9 
1 
5 
0 
(88.8) 
(36.0) 
(2 .0) 
(6 .1) 
( 0 ) 
proteins. One hundred and sixty three coded specimens from three out of the six 
serologic groups (table 3.4.1) that had been analyzed for pre-S proteins, were fur­
ther examined for the presence of anti-pre-S2 antibodies. These serologic groups 
included a) HBsAg-positive/HBeAg-positive specimens, b) HBsAg-positive/ 
anti-HBe-positive specimens, and c) specimens positive for both anti-HBc and 
anti-HBs. 
Serology 
Serologic tests for conventional HBV markers were carried out by means of com­
mercial enzyme immuno assays (Abbott Lab, IL.) 
Detection of serum HBV-DNA was performed by means of either the phenol-
extraction technique or by direct spotting of pretreated serum samples on nitro­
cellulose filter sheets as described in section 2.2. 
Statistical methods 
Mantel Hanszel's chi-square test was used for the statistical analysis of data. 
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3.4.2.1 Detection ofpre-Sl andpre-S2proteins 
General 
Experimental micro-ELISAs tests for pre-Sl and pre-S2 were prepared as descri­
bed earlier (14) and according to details below. 
Pre-S peptides 
Two peptides, representing parts of the amino acid sequences of the pre-S 
domain of the hepatitis В surface antigen (HBsAg) were synthesized on a p-alko-
xybenzylalcohol resin with a VEGA automated peptide synthesizer. The pepti­
des corresponded to the sequences [12-32] (adw2 subtype) and [126-145] (adw 
subtype) respectively (13,15). Part of the resulting peptides was acetylated with 
N-succinimidyl-S-acetylthioacetate to give an acetyl thiacetate (ATA) group. 
Coupling of carrier proteins to peptides 
Carrier protein, key hole limpet hemocyanin (KLH) was treated with succinimi-
dyl-4-(N-maleimidomethyl)-cyclohexane-l-carboxylate for incorporation of 
active maleimide groups. Coupling the peptides with the C-terminal ATA-group 
to the activated carrier proteins or HRP was accomplished by the formation of 
stable disulfide bonds after deacetylation of the ATA group with hydroxylamine. 
Polyclonal antibodies (PCAs) 
Specific PCAs against the S domain of HBsAg were produced in sheep by injec­
tion of purified serum derived HBsAg, in which the pre-S determinant was des­
troyed by pepsin digestion. Anti-s specificity was confirmed by testing HBsAg 
before and after reductive treatment with 2-mercaptoethanol, which affects the 
major S-determinant (16). Pre-S specific antibodies were induced by immunizing 
sheep with the peptides coupled to KLH. 
Monoclonal antibodies (MCAs) 
Murine monoclonal antibodies (MCA) were applied as solid phase antibodies in 
a micro-ELISA for HBsAg and preselected on the basis of reactivity with 12 
HBsAg subtypes (17). Anti-HBs MCAs which were nonreactive with pepsin 
digested HBsAg were considered pre-S specific, whereas MCAs that were a) 
reactive with all 12 HBsAg subtypes, b) reactive with pepsin digested HBsAg, 
and 3) showed decreased reactivity with HBsAg treated with 2-mercaptoethanol, 
were considered S-domain specific. Anti-pre-S2 specific MCAs were further 
selected by their propensity to become blocked by the pre-S [126-145] peptide. 
Pre-S specific micro-ELISAs 
Pre-S specific micro-ELISAs were carried out by using an anti-pre-S solid phase 
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and HRP-labeled anti-HBs. For specificity reasons the respective antibodies 
were either PCA and MCA (pre-Sl test) or MCA and PCA (pre-S2 test). Polys­
tyrene microplate wells were coated by adsorption of the specific immune globu­
lin preparations, washed and dried. In the test procedure, coated wells were incu­
bated with 100 μ\ of serum samples for one hour at 37 0 C , washed and incubated 
with HRP-labeled anti-HBs-antibodies for one hour at 37 0 C . After washing 
away the unbound label, the wells were incubated for 30 minutes at 18-25 "С 
with substrate solution (tetramethylbenzidine and urea peroxide). The reaction 
was stopped by addition of sulfuric acid, and the absorbance was read at 450 nm. 
Cut-off determination and control sera 
Results were considered positive if the absorbance of the test sample was at least 
three standard deviations above the mean of the negative controls. Pooled normal 
human serum, free from hepatitis В markers and negative for antibodies against 
human deficiency virus (HIV), served as negative controls. HBsAg produced by 
the PLC/PRF/5 human hepatoma cell line, known to contain pre-S2 sequences 
(18), was used as a positive control in the pre-Sl test, while HBsAg and HBeAg-
positive sera, reactive in the micro-ELISA for pre-S2 and blocked by addition of 
pre-S [12-32] peptide were used as a positive control in the pre-Sl test. 
3.4.2.2 Detection of anti-pre-S2-antibodies 
An enzyme immunoassay was used for detection of anti-pre-S2-antibodies. In 
the assay a synthetic peptide analog corresponding to the [120-150] sequence of 
the pre-S antigen (kindly provided by Dr. Ph. Adamowicz, Institute Pasteur, 
Paris) on the solid phase captures anti-pre-S2 antibodies of the specimen. These 
pre-S2 antibodies are subsequently recognized by a monoclonal antibody to anti-
human IgG, covalently linked with HRP (conjugate). 
Two-hundred μΐ of synthetic pre-S2 peptide (120-150 amino acids), final concen­
tration 250 ng/ml, was added to microplate wells. After emptying of the wells, 
250 μΐ of a solution containing 1% BSA was added to each well, followed by 
incubation at room temperature for 90 minutes. The wells were emptied, washed 
with PBS containing Tween 20 (0.1%). Next, the wells were filled with 100 μΙ of 
PBS containing Tween 20 (0.1%) and 100 μΙ of undiluted serum specimens, fol­
lowed by incubation for 90 minutes at 37 0 C . After emptying of the wells and 
washing with PBS/Tween solution, 200 μ\ of a 1:60,000 diluted conjugate solu­
tion was added to each well and incubated for 90 min at 37 0 C . After washing the 
wells with PBS/Tween 20 (0.1%), the wells were filled with 200 /u.1 of substrate 
buffer solution (citrate 0.05 M, pH 5.6, H2O2 0.03%), in which chromogen (or-
tho-phenylenediamine) was dissolved. After incubation at room temperature for 
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30 minutes, the reaction was stopped by adding 50 μ.1 of 4N sulfuric acid solution 
to each well. Absorbance was read at 492 nm within 60 min after stopping the 
reaction. The anti-pre-S2 response was quantitated by titrating a reference serum 
parallel with the specimens. 
3.4.3 Results 
3.4.3.1 Pre-S proteins 
The results of determination of pre-Sl and pre-S2 proteins and HBV-DNA in 
serum samples obtained from 373 subjects are listed in table 3.4.1. Pre-Sl and 
pre-S2 proteins could be detected in nearly all HBsAg-positive/HBeAg-positive 
sera (group I). As shown in figure 3.4.2, pre-S antigens were present in sera of 
patients having acute hepatitis as well as in sera obtained from patients with long­
standing HBs antigenemia, regardless of the various forms of liver disease. HBV-
DNA was found in 70.6% of these serum samples. In group II, HBsAg-positive/ 
anti-HBe-positive patients, pre-Sl- and pre-S2-antigens were also frequently 
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Figure 3.4.2: Pre-Sl, pre-S2 and HBV-DNA m sera obtained from HBsAg-postttve/HBeAg-
positive patients (Group I). 
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Figure 3.4.3: Pre-Sl, pre-S2 and HBV-DNA in sera obtained from HBsAg-posttive/anti-HBe-
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Figure 3.4.4: Pre-Sl, pre-S2 and HBV-DNA in sera obtained from HBeAg-negative/anti-HBe-
negative, HBsAg-positive patients (Group III). 
AH: acute hepatitis CAR: chronic HBsAg-positive carrier 
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Figure 3.4 5: Pre-Sì, pre-S2 and HBV-DNA m sera obtained from anti-HBc-posttive patients 
(HBsAg-negative, anti-HBs-negative) (Group IV). 
CH/CIR. chronic hepatitis or cirrhosis 
HBV-DNA, pre-SI, and pre-S2 were undetectable in sera obtained from patients with primary 
hepatocellular carcinoma (n=2), and m sera from patients during the window phase of acute 
hepatitis (n=6) (data not shown). 
found despite the absence of HBV-DNA in the majority of sera and regardless of 
the type of liver disease (fig. 3.4.3). When groups I and II were taken together, 
87.4% of sera were positive for pre-SI, and 90.3% were positive for pre-S2 pro-
teins. 
In contrast, in HBeAg-negative/anti-HBe-negative HBsAg carriers (group III), 
pre-SI and pre-S2 proteins were found in only a minority of chronic HBsAg-
positive carriers (fig. 3.4.4). Both pre-SI and pre-S2 were found in serum of only 
one patient in the HBsAG-negative and anti-HBc-positive group (irrespective 
the anti-HBe status) (group IV, fig. 3.4.5). This particular patient, whose serum 
was also HBV-DNA-positive, suffered from chronic persistent hepatitis, reflec-
ted by moderate elevation of serum aminotransferase values. In this regard it is 
interesting to note that in all (n=8) sera obtained during the window phase after 
acute hepatitis, neither HBV-DNA nor pre-S proteins were detectable. 
In anti-HBc-/anti-HBs-positive sera (group V, fig. 3.4.6), pre-SI and/or pre-S2 
proteins were found in two patients with chronic liver disease and in two other 
patients during the reconvalescent phase after acute hepatitis. 
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Figure 3 4 6 Pre-Sl, pre-S2 and HBV-DNA m sera obtained from patients with both anti-HBc-
and antt-HBs-antibodtes (Group V) 
CH/CIR chronic hepatitis or cirrhosis 
PHC primary hepatocellular carcinoma 
Table 3.4.2 Serum pre-S-protems m relation to serum HBV-DNA m HBsAg-
positive patients 
η Pre-Sl + (%) Pre-S2+(%) 
HBsAg+ sera -anti-HBe+ 
-HBeAg+< 
HBeAg-/ 
— anti-HBe" 
/HBV-DNA* 77 73 ( 94 8) 74 ( 96 1) 
4HBV-DNA" 32 29 ( 90 6) 27 ( 84 4) 
^HBV-DNA* 13 13 (100 ) 13 (100 ) 
^HBV-DNA 85 66 ( 77 6) 76 ( 89 4) 
,ΗΒν-DNA* 1 1 1 
XHBV-DNA" 24 2 ( 8 3 ) 7 ( 29 2) 
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As shown in table 3.4.2, both pre-S proteins were present in most HBeAg- or 
anti-HBe-positive specimens, whereas in sera of HBeAg-negative/anti-HBe-
negative patients pre-Sl and pre-S2 were not frequently detectable. Pre-Sl pro­
teins were found in 87/91 HBsAg-positive/HBV-DNA-positive subjects (95.6% 
vs. 97/141 HBsAg-positive/HBV-DNA-negative cases (68.8%) (p < 0.0001), 
and pre-S2 proteins were detected in 88/91 (96.7%) HBsAg-positive/HBV-
DNA-positive patients compared with 110/141 (78.6%) HBsAg-positive/HBV-
DNA-negative cases (p < 0.0001). Sera from patients without HBV serologic 
markers were negative for both pre-S proteins. 
3.4.3.2 Anti-pre-S2 antibodies 
The results of anti-pre-S2 antibody determinations in serum of 163 patients from 
three of the six serologic groups are shown in table 3.4.3. 
Table 3.4.3 Anti-pre-S2 and HBV-DNA in three groups of sera obtained from 
patients with different conventional HBV serologic markers 
Group Serologic η HBV- (%) anti-pre- (%) 
marker (+) D N A ( + ) S2 (+) 
I-a HBsAg 
HBeAg 52 39 (75.0) 31 (59.6) 
anti-HBc 
Il-a HBsAg 
anti-HBe 61 6 ( 9.8) 28 (45.9) 
anti-HBc 
V-a anti-HBc 
anti-HBs 50 0 ( 0 ) 44 (88.0) 
In HBsAg-positive/HBeAg-positive patients (fig. 3.4.7), the anti-pre-S2 test was 
found to be positive in approximately 40-80% of patients having various forms 
of chronic liver disease, including chronic HBsAg carriers with unknown liver 
histology. In the 25 chronic HBsAg carriers with unknown liver histology, 
serum aminotransferase values at the time of serologic examination were availa­
ble in 21 cases. The frequency of anti-pre-S2-positive carriers with normal or 
near normal aminotransferase values (12/15), was comparable with that in car-
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Figure 3 4 8 Anti-pre-S2 and HBV-DNA m sera obtained from HBsAg-positive/anti-HBe-posi-
tive patients (Group ¡I-a) 
CAH/C chronic active hepatitis or cirrhosis 
CPH chronic persistent hepatitis 
PHC primary hepatocelluUr carcinoma 
AH acute hepatitis 
CAR chronic HBsAg-positive carrier 
93 
·/.— 
liver histology 
total CH/CIR PHC 
uu -
75-
50-
25-
-
-
liver histology 
unknown 
n=50 η = β n=:3 n = 39 
^ ^ HBV DNA pos patients 
Г П anti-preS2 pos patients 
Figure 3 4 9: Anti-pre-S2 and HB V-DNA in sera obtained from patients with both antt-HBc and 
anti-HBs-antibodies (Croup V-a) 
CH/CIR. chronic hepatitis or cirrhosis 
PHC primary hepatocellular carcinoma 
Table 3.4.4 Precence of anti-pre-S2 antibodies m sera obtained from chronic 
HBsAg carriers or from reconvalescent subjects 
anti-pre (%) 
S2+ 
HBV-DNA + 37 22 (59.5) 
-HBeAg+< 
Chronic HBsAg carrier 
·— HBeAg-
Patients anti-HBc+/ 
anti-HBs+ 
Ή Β V-DNA" 12 (66.7) 
^ B V - D N A * 
VHBV-DNA-
5 
52 
50 
1 
20 
44 
(20.0) 
(38.5) 
(88.0) 
94 
a n t i - p r e S2 ant ibody t i ter (units) 
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Figure 3.4.10: Anti-pre-S2 antibody titer m reUtton to HBV serologic markers and liver histolo­
gy 
riers with aminotransferase values more than twice the upper limit of normal (5/ 
6). Both patients with acute hepatitis in the HBsAg-positive/HBeAg-positive 
group were anti-pre-S2-negative. In HBsAg-positive/anti-HBe-positive sera 
(fig. 3.4.8), up to 50% of longstanding HBsAg carriers had also detectable anti-
pre-S2. Three out of four patients with acute hepatitis were anti-pre-S2 positive. 
In chronic HBsAg carriers the presence or absence of HBeAg or HBV-DNA was 
found not to be related to the presence of anti-pre-S2-antibodies (table 3.4.4.). In 
sera from patients with both anti-HBc and anti-HBs antibodies, anti-pre-S2 anti­
bodies were present in the large majority of cases (fig. 3.4.9), usually with very 
high titers, regardless of liver histology (fig. 3.4.10). 
3.4.4 Discussion 
Most of the studies on the presence of pre-S antigens and antibodies focused on 
patients with acute type В hepatitis (9,12,19). The serologic events during acute 
hepatitis and reconvalescence occur as illustrated in figure 3.4.11. The very early 
phase of acute hepatitis is serologically characterized by the presence of pre-S2 
antigen and HBsAg (9, 20, 21), when HBV-DNA is still negative (19). Pre-S2 
antigen titers increase rapidly when HBV-DNA becomes detectable in serum 
and become negative shortly after disappearance of serum HBV-DNA (9). Per­
sistence of pre-S2 antigen for a period longer than four months was found to be 
correlated with chronic hepatitis (11). 
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Figure 3 4 11· HBV markers including pre-S-proteins, HBV-DNA, and antt-pre-S-antibodies 
during the course of uncomplicated acute type В hepatitis. 
Pre-Sl antigen can also be detected during the early course of acute hepatitis, two 
weeks after the appearance of HBsAg in serum (9). This antigen is, however, no 
longer detectable when HBsAg production is maximal, i.e. usually soon after the 
disappearance of HBV-DNA and HBeAg from serum (10). 
At the time when HBsAg is still present but HBV-DNA has already disappeared 
from serum, antibodies against pre-S2 (anti-pre-S2) become detectable in serum 
(11, 12, 19). Patients who recover and become HBsAg-negative, develop anti-
pre-S2 prior to the disappearance of HBsAg from serum (11), whereas in cases 
showing chronicity of the disease with continuing viral replication, anti-pre-Sl-
(22) and anti-pre-S2-antibodies (23) are undetectable. 
In this study (tables 3.4.1 and 3.4.2.), the presence of pre-Sl and pre-S2 proteins 
in serum correlated well with the presence of HBsAg in serum, irrespective of 
liver histologic or biochemical parameters indicative of liver inflammation. 
Although in the present study pre-S proteins were significantly more often pre­
sent in serum of patients with evidence of active viral replication (HBeAg- and 
HBV-DNA-positive), our results are at variance with those of Hadziyannis et al. 
(24), who recently reported a strong correlation between the presence of pre-S 
proteins in serum and active chronic liver disease. 
As in our study pre-S proteins were detectable in 85.5% of HBV-DNA-negative 
chronic HBsAg carriers with normal or slightly elevated serum aminotransfera­
ses, the presence of such proteins in serum does not seem to reflect the presence 
of active viral replication or active liver inflammation. In contrast, pre-Sl and 
pre-S2 were found in 79.3 and 84.5% respectively of HBsAg-positive specimens 
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vs. 3.8 and 4.6% of HBsAg-negative sera, suggesting that the presence of pre-S 
proteins in serum is strongly correlated with that of HBsAg. Our findings are, 
therefore, in agreement with those reported by Budkowska et al. (25), who sho­
wed that 65% of sera from anti-HBe-positive chronic HBsAg carriers reacted 
positively to the pre-S determinant, and with those of Hu et al. (26), who recently 
demonstrated that the presence of pre-S proteins in serum is only a function of 
the plasma HBsAg titer. Finding of pre-S in the absence of viral replication is also 
supported by an in vitro study which demonstrated that pre-S proteins are pre­
sent in the supernatant of a PLC/PRF/5 cell line producing HBsAg but no viral 
particles (26, 27). 
It has also been suggested that antibodies to pre-S2 may represent early markers 
of recovery after HBV infection (11, 12). In our study, the anti-pre-S2 test gave 
indeed high titers with sera from reconvalescent patients with both anti-HBc and 
anti-HBs. However, the anti-pre-S2 antibody test was also positive in 50% of 
chronic HBsAg carriers, irrespective of the presence of HBV-DNA in serum, or 
of evidence of active liver disease. 
In contrast, experimental sandwich micro-ELISA tests (Organon Teknika Diag­
nostics Research Laboratories), using pre-S peptides on the solid phase as well as 
the label, gave a considerably lower frequency of positive reactions with HBsAg-
positive and with anti-HBs-positive sera (14). Although an explanation for this 
discrepancy is not yet available at this moment, this discordance may be due to 
the different specificities of the test systems. 
From the present study, however, we may conclude that despite the strong corre­
lation between the presence of pre-S proteins and of markers indicative of active 
viral replication, pre-S proteins cannot simply be regarded as markers of viral 
replication and of infectivity, since these proteins persist in serum of the vast 
majority of patients after disappearance of HBeAg and HBV-DNA from serum. 
Furthermore, the presence of these proteins does not reflect active chronic liver 
disease. Reactivity in the described test for antibodies to pre-S2 has no predictive 
value for the chronicity of HBV infection. However, further comparative studies 
using different test systems remain required. 
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3.5 Hepatitis В virus DNA detection in a patient receiving 
immunosuppressive drugs 
Summary 
Conventional serologic markers are not always capable of detection the replica­
tive phase of hepatitis В virus infection. This infection may become clinically 
manifest during or after immunosuppressive treatment. Data are presented of a 
patient who showed 'reactivation' of hepatitis В virus infection under these cir­
cumstances. The impact of the presence of HBV serologic markers and the role of 
hepatitis В virus DNA detection in patients eligible for immunosuppressive 
therapy, are discussed. 
3.5.1 Introduction 
Malignant diseases and the uremic state are both conditions which may be 
accompanied by impairment of immunologic mechanisms resulting in significant 
susceptibility to infections. Among the factors responsible for this inability of the 
immune system to eliminate infectious agents are changes in immune response 
due to underlying disease as well as effects of cytotoxic or immunosuppressive 
drugs. Hepatitis В virus (HBV) infection has been recognized as a hazard in 
many patients receiving immunosuppressive therapy (1). Retrospective analysis 
showed that some of these patients were asymptomatic carriers or had antibodies 
as sole markers of HBV infection when immunosuppression was started. Reacti­
vation of HBV infection resulting in acute hepatitis and/or reappearance of sero­
logic markers indicative of viral replication is also known as an important cause 
of liver disease in this group of patients. 
We present data on a patient who showed a change of serologic markers pointing 
to reactivation of HBV infection as a result of immunosuppressive therapy. In 
this patient the HBV-DNA determination before immunosuppressive therapy 
might have predicted the development of hepatitis or seroconversion after im-
muno-suppressive therapy and consequently has a prognostic value. 
Methods 
HBsAg, anti-HBs, anti-HBc, HBeAg and anti-HBe were determined by enzyme 
immunoassays (Abbott Laboratories, North Chicago, 111., USA). 
Detection of HBV-DNA was performed by the phenol-extraction technique as 
described in chapter 2. 
IgM anti-HBc was determined with an enzyme-linked immunosorbent assay 
(ELISA) (2). 
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3.5.2 Case history 
A 40-year-old male was admitted to a hospital elsewhere with anemia and 
hemorrhagic diathesis. After examination of a bone marrow aspirate, the diagno­
sis of acute myeloid leukemia was made and the patient was referred to our hos­
pital for further treatment. 
On admission, routine laboratory studies showed normal values of serum amino­
transferase values and bilirubin, while at that time anti-HBc was found as the 
only serologic marker of HBV infecton (Fig. 3.5.1). There was a history of hepa­
titis with jaundice during a stay in Africa in 1976, but there was no history of 
illicit drug abuse, homosexual contacts or blood transfusions. After two courses 
of chemotherapy complete remission of the leukemia was obtained and an allo­
geneic bone marrow transplantation (BMT) was planned. Transplantation was 
performed with marrow from a histocompatible sibling. This donor had no sero­
logic markers of HBV infecton. To prevent graft-versus-host disease (GVHD), 
lymphocyte depletion of the marrow graft was prepared by counterflow centri-
fugation and intravenous methotrexate was given after grafting according to the 
Seattle protocol (3). The patient did not develop any signs of acute or chronic 
GVHD. Transplantation was performed ten months after the diagnosis was 
made. Five months after BMT - three months after discontinuation of methotre­
xate therapy - the patient developed acute icteric hepatitis. During this period 
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Figure 3.5.1: Serologic markers of hepatitis В virus infection, serum HBV-DNA, and serum aL·-
mne aminotransferase (ALT) profile of a patient with acute myeloid leukemia before and after an 
allogeneic bone marrow transpUntation and immunosuppressive therapy. 
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serum alanine aminotransferase levels were increased to 990 U/l (normal <25 U/ 
1). At the same time HBsAg and HBeAg were positive in serum; IgM class anti­
bodies to hepatitis A were negative. Over the next few months serum amino­
transferase values gradually improved and normalized. Both HBeAg and HBsAg 
became undetectable and no development of detectable anti-HBs was observed, 
so that anti-HBc was again the only serologic marker of HBV infection. How­
ever, retrospective analysis showed that hepatitis В virus DNA was present in 
serum samples collected from this patient before and after BMT. The quantity of 
HBV-DNA was smaller in sera with anti-HBc as a sole marker than in HBsAg-
positive/HBeAg-positive sera. IgM anti-HBc was found at high titers during the 
acute hepatitis, while titers lower than IO4 were found in HBV-DNA-positive 
sera during the preceding period. Eight months after the episode of acute hepati­
tis, HBsAg and HBeAg reappeared in serum while the patient was still in good 
health without any therapy. Serum aminotransferase values were markedly 
increased. Eighteen months after reappearance of HBeAg in serum, HBV-DNA 
was no longer detectable. However, in all serum specimens examined since then, 
HBsAg and HBeAg were invariably present. Serum aminotransferase values 
were about two times the upper limit of normal. N o permission for liver biopsy 
was obtained. The patient is still symptomless and free of malignant disease six 
years after transplantation. 
3.5.3 Discussion 
The often deleterious outcome of chronic type В hepatitis during immuno­
suppression is well known. Among the best documented cases were those from 
recipients of a kidney transplant. The importance of liver disease for the long-
term prognosis of patients with a kidney transplant has been recognized with 
increasing frequency during the past twelve years (4, 5). Although infection with 
HBV is one of the leading causes of liver disease in patients with chronic renal 
diseases (6), recent data indicate that infection with non-A, non-B virus(es) is the 
major cause of liver disease in kidney transplant recipients (7, 8). Reactivation of 
HBV infection as manifested by acute viral hepatitis and/or reappearance of sero­
logic markers indicative of viral replication, is responsible for liver disease in 
some patients with a kidney graft as well as in other patients treated with im­
munosuppressive agents (9-12). 
In our patient HBV-DNA was found in serum at a time when anti-HBc was the 
only serologic marker and immunosuppressive therapy had not been started. 
Several recent studies have made it clear that the essential part of the infectious 
agent (HBV-DNA) can be found in the majority of HBeAg-positive sera 
(2,13,14), but may also be present in specimens from anti-HBe-positive HBsAg 
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carriers (2,15) and even in sera lacking viral antigens (16). In other words, active 
viral replication may continue not only after seroconversion to anti-HBe, but 
even in subjects lacking viral antigens, or in the absence of any serologic marker 
of HBV infection. The present case history underscores the importance of the 
HBV-DNA assay as evidence of active viral replication in patients with anti-HBe 
as the sole marker, confirming previous findings regarding the possible infecti-
vity of such sera (17). The results in this patient are of particular interest because 
he became HBsAg-positive/HBeAg-positive for a second time, more than eleven 
months after discontinuation of immunosuppressive therapy. 
Enhancement of viral synthesis and depression of host immunity during im­
munosuppressive treatment, followed by an increase in immune response after 
cessation of therapy, are probably responsible for the 'reactivation' (18). In some 
reports on reactivation of HBV infection, the patients were asymptomatic 
chronic carriers of HBsAg. However, reactivation was also documented in 
patients lacking viral antigens in serum. 
serologic marker of HBV infection (11), as was the case in our patient. Sponta­
neous reactivation may also occur in a considerable number of patients with 
chronic type В hepatitis, especially during the first year after seroconversion to 
anti-HBe (19-21). Since the persistence of HBV-DNA in serum is indicative of 
serious chronic liver disease (22), the outcome in these patients strongly indicates 
that spontaneous reactivation is not merely a serologic landmark, but in some of 
these patients is indicative of the onset of severe chronic liver sequelae. There­
fore, it seems not only that the immunocompromised status may be conducive to 
perpetuation of the HBsAg carrier state, but that the replicative status may return 
even in those patients who initially lack detectable viral antigens in serum. 
Although 'reactivation' suggests an active initial phase of HBV infection - and 
some patients with HBV markers indeed are in such a phase -, new techniques for 
detection of viral products, such as detection of HBV-DNA in liver and serum 
and the use of monoclonals for detection of HBsAg, have made it clear that con­
ventional serologic tests are not always capable of detecting the replicative phase 
of infection. It can therefore be argued that many states of infection formerly 
designated inactive, actually represented states with low viral replication, as 
illustrated in our patient. However, from a practical point of view the immuno­
compromised host should receive special attention when serologic markers of 
HBV infection are present. Evaluation of HBV markers, including HBV-DNA 
assay in serum and in a liver biopsy if necessary, should be performed before 
treatment is started. These evaluations may indicate the replicative phase of infec­
tion, allowing proper measures to be taken for the patient and the environment. 
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CHAPTER 4 
Hepatitis В virus DNA in serum of 
mentally handicapped 
4.1 Hepatitis В virus infection in an institution for the mentally retar­
ded: results of cross-sectional and longitudinal studies of hepatitis В 
virus serologic markers and DNA in 493 male residents. 
Summary 
A cross-sectional survey on the prevalence of hepatitis В serologic markers and 
hepatitis В virus DNA was performed in a population of 493 mentally handicap­
ped males. Special interest was focused on age-related variables such as age at 
entry into the institution and on duration of residency. Furthermore, the differ­
ences with regard to the prevalence of hepatitis В markers found in Down's syn­
drome residents and other mentally retarded persons were analyzed. In a longitu­
dinal study, the impact of the presence of hepatitis В virus DNA in serum was 
studied. Overall, 62.1% of residents had serologic evidence of infection with 
hepatitis В virus, while 16.7% of those residents with markers of infection were 
positive for hepatitis В surface antigen (HBsAg). Hepatitis В virus DNA was 
found in 24% of HBsAg carriers (all positive for hepatitis В e antigen (HBeAg)). 
In residents whose age at entry was less than 15 years, those with Down's syn­
drome were more often carriers of HBsAg than other mentally retarded resi­
dents. In addition, Down's syndrome residents more often had serum hepatitis В 
virus DNA compared with residents with other forms of mental retardation. A 
young age at entry was recognized as an important factor with regard to the pre­
valence of hepatitis В markers. From the longitudinal studies, it appeared that 
loss of hepatitis В virus DNA from serum indicated imminent loss of HBeAg and 
normalization of alanine aminotransferase values. Knowledge of the hepatitis В 
virus DNA status of HBsAg carriers in these institutions may therefore provide 
a valuable tool in attempts to reduce the transmission of this infection. 
4.1.1 Introduction 
Hepatitis В virus infection has long been recognized as a hazard in institutions 
for the mentally handicapped. Residents of these institutions, particularly those 
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with Down's syndrome, have been reported to have a high prevalence of hepatitis 
В surface antigenaemia (1-5), even in areas with a relatively low incidence of 
hepatitis В virus infection. Knowledge of the serologic markers of this infection 
seems therefore of considerable importance for the control of hepatitis В virus 
transmission in such institutions. Epidemiologic data have demonstrated that the 
presence of hepatitis В e antigen (HBeAg) indicates the active phase of viral repli­
cation, and that subjects who harbor this antigen in their sera are more infectious 
than HBeAg-negative hepatitis В surface antigen carriers (6, 7). However, by 
means of a molecular hybridization method, it was shown that hepatitis В virus 
D N A may be absent in HBeAg-positive serum specimens but may be found in 
some antibody to hepatitis В e antigen (anti-HBe)-positive sera (8-10). The latter 
category was often considered as not being or seldom infectious. The aim of the 
present study was to investigate the relation between the presence of conventio­
nal hepatitis В serologic markers and of HBV-DNA in sera of institutionalized 
mentally handicapped persons. Institutions for the mentally retarded are regar­
ded as an excellent model for epidemiologic studies of hepatitis В infection, since 
in most of these institutions the prevalence of this infection is high, the popula­
tion in many aspects is homogeneous and most residents are sooner or later in­
fected with the virus (11). In the present study, special interest was focused on the 
question whether the reported higher prevalence of HBsAg among Down's syn­
drome residents than among other mentally retarded residents was also reflected 
in a higher prevalence of hepatitis В virus DNA in their sera. In addition, Down's 
syndrome residents were compared with residents with other forms of mental 
retardation with regard to age-related prevalence of hepatitis В infection and 
HBsAg. 
4.1.2 Study population and methods 
Subjects 
In 1980, serum specimens were collected from all residents in an institution for 
mentally handicapped males. These specimens were examined for HBsAg, anti-
HBc and anti-HBs. HBsAg-positive samples were further examined for the pres­
ence of HBeAg and anti-HBe. Hepatitis В serologic markers were determined by 
commercial enzyme-linked immunosorbent assays (Abbott Laboratories, North 
Chicago, IL, U.S.A.). All specimens were coded and tested for the presence of 
hepatitis В virus DNA. 
The survey was extended to 1983 when serum samples were drawn from all 
newly admitted residents as well as from those who in 1980 a) were HBsAg posi­
tive; b) had anti-HBc or anti-HBs as sole marker; c) were anti-HBc-positive and 
anti-HBs-positive but with low titers for either anti-HBc or anti-HBs (anti-
112 
HBs+/anti-HBc± or anti-HBs±/anti-HBc+); or d) had no hepatitis В markers. 
These specimens were examined for hepatitis В serologic markers as well as for 
HBV-DNA. 
Finally, in 1986 all HBsAg carriers were re-tested for hepatitis В serologic 
markers, alanine aminotransferase, and the presence of HBV-DNA. Meanwhile, 
all seronegative residents were vaccinated. 
In 1980, the population of the institution consisted of 493 males: 117 residents 
had Down's syndrome (23.7%), and 376 (76.3%) had other forms of mental 
retardation, such as that due to perinatal asphyxia or phenylketonuria. The pro­
portion of residents with Down's syndrome was comparable in all categories 
with respect to age at entry, age at time the serum specimens were drawn, and 
length of residency. 
Results have been analyzed in terms of hepatitis В serologic status in 1980 (cross-
sectional study) followed by analysis of data obtained from repeated sample 
testing in part of the population in 1983 and 1986 (longitudinal study). 
For further analysis of differences in prevalence of hepatitis В markers between 
Down's syndrome residents and residents with other forms of mental retarda­
tion, serum samples obtained from the 117 residents with Down's syndrome 
were matched with specimens from other mentally retarded persons on duration 
of residency (± two years) and age at entry into the institution (± two years). 
Methods 
Determination of HBV-DNA 
Determination of serum-HBV-DNA was performed by means of direct spotting 
of pretreated serum specimens on nitrocellulose filter sheets as described in sec­
tion 2.2.2. 
Determination of serum alanine aminotransferase values 
Alanine aminotransferase was determined by means of a centrifugal analyzer 
(Multistat Instrumentation, Lexington, MA). The results were expressed in units 
per liter. 
Statistical analysis 
For the statistical comparison of the prevalence of serologic data between groups, 
we used Mantel-Haenszel's chi-square test (12). Differences in age, duration of 
residency, and age at residency were tested by means of the unpaired Wilcoxon 
test. The results of the statistical test are given by two-sided p-values. If each ρ 
value was equal to or below 0.05, the difference between two percentages or two 
distributions is considered statistically significant. 
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Table 4.1.1 Hepatitis В serologic markers in mentally retarded residents, m 
1980,1983, and 1986 
year of 
examination 
1980 
1983 
1986 
year of 
examination 
1980 
1983 
1986 
No of resi­
dents tested/ 
retested 
493 
292* 
48t 
No of resi­
dents 
HBsAg+ 
51 
51 
46 
Distribution 
HBsAg+ 
51 
51 
46 
Distribution 
HBeAg+ 
20 
9 
7 
of hepatitis В 
anti-HBcV 
anti-HBs+ 
247 
33 
serologic markers 
anti-HBc+ anti-HBs+ 
(sole (sole 
marker) marker) 
3 5 
5 
absence of 
hepatitis В 
markers 
187 
203 
1 
of HBeAg and anti-HBe in HBsAg-positive residents 
anti-HBe+ 
25 
31 
29 
HBeAg"/ 
anti-HBe-
6 
11 
10 
* Number of residents (including newly admitted residents) examined All other residents were posi­
tive for anti-HBs and anti-HBc as determined in 1980 (see text under Subjects) 
t Number of residents (including newly admitted residents) examined, 44/48 residents were 
H B s A g -positive in 1983 
Table 4.1.2 Distribution of hepatitis В serologic markers m 493 mentally retar­
ded males, by age 
Age (years) 
0-15 
16-20 
21-25 
26-30 
31-35 
>35 
No. of 
residents 
38 
61 
113 
150 
96 
35 
Positive for 
any hepatitis В 
marker 
η 
4 
37 
75 
114 
61 
15 
% 
10.5 
60.7 
66.4 
76.0 
63.5 
42.9 
HBsAg-
n 
1 
9 
13 
16 
8 
4 
•positive 
% with any 
hepatitis В 
marker 
25.0 
24.3 
17.3 
14.0 
13.1 
26.7 
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4.1.3 Results 
4.1.3.1 Prevalence of hepatitis В serologic markers 
The distribution of serologic markers of hepatitis В infection in the 493 male resi­
dents is shown in table 4.1.1. Of 493 residents, 306 (62.1%) had serologic evi­
dence of past or current hepatitis В virus infection. Fifty-one (16.7%) of these 
306 residents were positive for HBsAg. As shown in table 4.1.2, the prevalence of 
hepatitis В markers seemed to increase with age up to age 30. HBsAg positivity, 
however, seemed to be relatively lower in the age groups 21-35 years compared 
with the age groups 0-20 years and more than 35 years (13-17 versus 24-27% of 
residents with any hepatitis В marker). These differences were statistically not 
significant (table 4.1.2). 
Hepatitis В serologic markers in relation to age at entry 
With regard to age at entry into the institution, the highest prevalence of hepatitis 
В markers could be observed in those residents admitted at ages 11-15 years; 
however, the proportion of HBsAg-positive subjects in this age group was com­
parable with that of the other age groups (table 4.1.3). 
Hepatitis В serologic markers in reUtion to duration of residency 
Table 4.1.4 shows that the prevalence of hepatitis В serologic markers was nearly 
steady up to 10 years of institutionalization, after which a sharp rise occurred. 
Prevalence of HBsAg appeared to be independent of the duration of residency. 
Table 4.1.3 Distribution of hepatitis В serologic markers in 493 mentally retar­
ded males, by age at entry 
Positive for HBsAg-positive 
any hepatitis В 
marker"' 
Age at entry No. of η % η % with any 
(years) residents hepatitis В 
marker 
0-10 140 84 60.0 15 17.9 
11-15 226 162 71.7 27 16.7 
>15 127 60 47.2 9 15.0 
* Significant differences were recognized between the prevalences of hepatitis В serologic 
markers in the age groups 0-10 and 11-15 years (X2 test, ρ < 0.003) and in the age groups 11-
15 and > 15 years (X2 test, ρ <0.00001 ). 
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Table 4.1.4 Distribution of hepatitis В serologic markers in 493 mentally retar­
ded males, by duration of residency 
Duration of 
residency 
(years) 
0- 5 
6-10 
11-15 
>15 
N o . of 
residents 
77 
89 
180 
147 
Positive for 
any hepatitis В 
marker4" 
η 
26 
30 
145 
105 
% 
33.8 
33.7 
80.6 
71.4 
HBsAg 
η 
5 
4 
24 
18 
-positive 
% with any 
hepatitis В 
marker 
19.2 
13.3 
16.6 
17.1 
A significant difference was found between the prevalence of hepatitis В serologic markers in 
the age groups 0-5 plus 6-10 years and 11-15 plus >15 years (X2 test,;» < 0.00001). 
4.1.3.2 HBV-DNA status 
From the samples obtained from 493 residents in 1980, HBV-DNA was tested in 
specimens of 490 residents and was exclusively found in HBsAg-positive speci­
mens (total number of HBsAg-positive specimens tested for HBV-DNA was 
49). Nineteen HBsAg carriers had HBeAg, and 30 were anti-HBe-positive. 
Twelve of the 19 HBsAg/HBeAg-positive carriers had detectable HBV-DNA in 
serum, whereas in the remaining seven HBsAg/HBeAg-positive carriers, and in 
the 30 anti-HBe-positive HBsAg carriers virus DNA was undetectable. Of the 12 
residents positive for HBV-DNA, nine had Down's syndrome (37.5% of 24 
HBsAg-positive Down's syndrome residents), while three had other forms of 
mental retardation (12% of 25 HBsAg-positive residents with other forms of 
mental retardation). The difference in hepatitis В virus DNA positivity among 
HBsAg-positive Down's syndrome residents and other mentally retarded resi­
dents was statistically not significant. From these findings, however, it is interest­
ing to note that 83.3% of HBV-DNA-positive subjects had been admitted to this 
institution at ages 11-15 years, although those who entered at these ages accoun­
ted for only 45.8% of total residents. 
The mean duration of residency of HBeAg-positive/HBV-DNA-positive resi­
dents was shorter than that of HBeAg-positive/HBV-DNA-negative residents 
(11 vs. 19 years); the mean age of HBeAg-positive/HBV-DNA-positive resi­
dents was lower than that of HBeAg-positive/HBV-DNA-negative residents 
(24.5 vs. 30 years). However, these differences were statistically not significant 
(unpaired Wilcoxon test). 
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4.1.3.3 Longitudinal study 
In 1983, specimens from 292 residents were examined for hepatitis В markers. 
This group consisted of a) 48 of the 51 HBsAg-positive residents in 1980 (one 
resident died because of liver failure as the result of chronic type В hepatitis; no 
specimen was obtained from two residents), b) the three residents with anti-HBc, 
and four of the five residents with anti-HBs as the sole serologic marker of hepa­
titis infection, c) 29 subjects with low anti-HBc-or anti-HBs-titers in 1980, d) 177 
residents without any hepatitis В marker in 1980; and e) 31 residents admitted 
between 1980 and 1983. 
In the 1983 survey, 48 HBsAg carriers (of the 51 examined in 1980) were retested 
(table 4.1.5). 
Table 4.1.5 Follow-up hepatitis В virus (HBV) markers in HBsAg-positive resi­
dents (1980-1986) 
Hepatitis В markers 1980 (n) 1983 (n) 1986 (n) 
HBeAg+/HBV-DNA+ 11 
HBeAg+/HBV-DNA- 6 
HBeAg-/HBV-DNA- 30 
HBeAg-/HBV-DNA not tested 
1 
anti-HBc+/anti-HBs+ 
* two residents lost to follow up 
f one resident lost to follow-up 
φ not retested in 1986 
Only one resident (HBeAg-negative and not tested for HBV-DNA), had sero­
conversion to anti-HBs in 1983. However, of the 17 HBsAg/HBeAg-positive 
carriers in 1980 ( n = l l , HBV-DNA-positive; n=6, HBV-DNA-negative), eight 
were no longer positive for HBeAg in 1983 (47.1%, mean age 31 years), while 
nine residents (52.9%) remained HBeAg-positive. The serologic pattern of 30 
HBeAg-negative/HBsAg-positive carriers was unchanged. HBV-DNA was 
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detected only in HBeAg-positive residents. Thus, it is interesting to note that all 
residents who were still HBeAg-positive in 1983 had had detectable HBV-DNA 
in serum in 1980, whereas of those who were not HBeAg-positive in 1983, only 
25.0% were positive for HBV-DNA in 1980. HBV-DNA had become undetec­
table in all residents (n=8) who became HBeAg-negative. In addition, alanine 
aminotransferase values normalized in five of these eight subjects. 
The results in the group HBsAg-negative residents (as determined in 1980) and in 
newly admitted residents are shown in table 4.1.6. Twelve patients who were 
negative for hepatitis В markers in 1980 became positive in 1983 (anti-HBc as 
sole marker (n=3); anti-HBc-l-/anti-HBs+ (n=6); HBsAg+/HBeAg- (n=3). 
Table 4.1.6 Follow-up hepatitis В serologic markers in HBsAg-negative resi­
dents (1980-1983)* 
1980 serologic profile 
(no. of residents) 
a. anti-HBc + (sole marker) (3) 
b. anti-HBs+ (sole marker) (4) 
с anti-HBs+/anti-HBc± (19) 
a. anti-HBs±/anti-HBc+ (10) 
e. No hepatitis В markers (177) 
f. Newly admitted after 1980 (31) 
1983 serologic profile 
(no. of residents) 
anti HBc+ (sole marker) (13) 
anti-HBs±/anti-HBc+ (1) 
anti-HBs+ (25) 
HBsAg+/HBeAg- (4) 
No hepatitis В markers (201) 
Initial 
a(l) 
a(l) 
a(l) 
1 serologic profilet 
b(4) 
d(9) 
d(l) 
c(19) 
e(3) 
e(6) 
e(3) 
e(165) f(31) 
* Residents with both anti-HBc and anti-HBs, as investigated in 1980, were not included in this 
study. 
t Initial profile of hepatitis В serologic markers as determined in 1980. Letters a-f refer to first 
column of table; numbers in parentheses represent number of residents. 
In 1986, 44 out of 51 HBsAg carriers, as determined in 1983, were retested for 
hepatitis В serologic markers, alanine aminotransferase values, and the presence 
of HBV-DNA (table 4.1.5). This survey from 1980 to 1986 disclosed that all 
(n=6) HBV-DNA-negative/HBeAg-positive carriers (five with Down's syn­
drome, one with another form of mental retardation), as determined in 1980, 
were HBeAg-negative in 1986. On the contrary, six (all with Down's syndrome) 
of nine residents with HBV-DNA in 1980 were persistently positive for HBeAg 
in 1986 (p <0.05). One HBeAg-positive carrier in 1980 (HBV-DNA status not 
tested), who was HBsAg- and anti-HBe-positive but HBV-DNA-negative in 
1983, was again found positive for both HBeAg and HBV-DNA in 1986 (data 
not shown). 
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Prevalence of hepatitis В markers m residents with Down's syndrome compared 
with that in residents with other forms of mental deficiency. 
We compared the prevalence of hepatitis В markers in 117 residents with Down's 
syndrome as investigated in 1980, with that in 117 residents with other forms of 
mental retardation, by matching both groups on age at entry and duration of resi­
dency. Serologic evidence for exposure to hepatitis В virus was found in 70.9% 
of Down's syndrome residents and in 63.2% of other mentally handicapped (the 
difference is statistically not significant). However, HBsAg carrier status was 
more prevalent in Down's syndrome residents than in those with other forms of 
mental retardation (31.3% vs. 13.5%) (p <0.02). The frequency of one or more 
hepatitis В serologic markers in each group of age at entry (table 4.1.7) or dura­
tion of residency (table 4.1.8) was approximately the same for both categories of 
residents. 
Nevertheless, prevalence of HBsAg was significantly higher in Down's syn­
drome residents than in those with other forms of mental retardation when age at 
entry was less than 11 years (p <0.03, table 4.1.7). With regard to length of resi-
Table 4.1.7 Prevalence of hepatitis В serologic markers, by age at entry, m 
Down's syndrome vs. other mentally retarded residents'1' 
Age 
(years) at entry 
0-10 
Down's syndrome 
Other 
11-15 
Down's syndrome 
Other 
>15 
Down's syndrome 
Other 
No. of 
residents 
34 
36 
55 
54 
28 
27 
Positive for any 
hepatitis 
η 
23 
22 
45 
39 
15 
12 
В marker 
% 
67.7 
61.1 
81.8 
72.2 
53.6 
44.4 
HBsAg-positivet 
η 
8 
1 
15 
5 
3 
3 
% with any 
hepatitis В 
marker 
34.8 
4.5 
33.3 
12.8 
20.0 
25.0 
Results are from matching 117 residents with Down's syndrome with 117 residents with 
other forms of mental redardation on age at entry and duration of residency 
In the group 0-10 years of age at entry, a significant difference was found between the preva­
lence of HBsAg in Down's syndrome residents compared with other mentally handicapped 
residents (X2 test, ρ < 0 03). 
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Table 4.1.8 PreveUnce of hepatitis В serologic markers, by duration of residen­
cy, in Down's syndrome vs. other mentally retarded residents* 
Positive for any HBsAg-positive 
hepatitis В 
marker 
Duration (years) 
of residency 
No. of 
residents 
% % with any 
hepatitis В 
marker 
0- 5 
Down's syndrome 19 
Other 22 
6-10 
Down's syndrome 22 
Other 19 
11-15 
Down's syndrome 40 
Other 37 
16-20 
Down's syndrome 24 
Other 31 
>20 
Down's syndrome 12 
Other 8 
8 
7 
8 
7 
36 
29 
20 
24 
11 
7 
42.1 
31.8 
36.4 
36.8 
90.0 
78.4 
83.3 
77.4 
91.7 
87.5 
2 
1 
2 
1 
13 
4 
6 
3 
3 
1 
25.0 
14.3 
25.0 
14.3 
36.1 
13.8 
30.0 
12.5 
27.3 
14.3 
* Results are from matching 117 residents with Down's syndrome with 117 residents with 
other forms of mental redardation, on age at entry and duration of residency. 
dency, in all categories Down's syndrome subjects were shown to have a higher 
prevalence of HBsAg than those with other forms of mental retardation (table 
4.1.8). 
Hepatitis В virus DNA was found in nine (37.5%) of 24 HBsAg carriers with 
Down's syndrome and in three of 10 (30%) carriers with other forms of mental 
retardation (the difference is statistically not significant). In 1983, when 111 pairs 
of the 117 matched pairs were reevaluated, serologic evidence of exposure to 
hepatitis В was found 76.4% of Down's syndrome residents and in 66.4% of 
other mentally handicapped residents. HBsAg was found in 25 of 85 Down's 
syndrome residents versus 12 of 74 other mentally handicapped residents with 
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hepatitis В markers; HBV-DNA was found in seven of 23 Down's syndrome 
residents versus one of 12 HBsAg-positive other mentally handicapped residents 
(both differences statistically not significant). 
4.1.4 Discussion 
In this study, the presence of conventional hepatitis В serologic markers and 
hepatitis В virus DNA was evaluated in a large number of institutionalized men­
tally handicapped males. To our knowledge, this is the first survey of the hepati­
tis В virus DNA serologic status of residents of such an institution. The overall 
prevalence of markers of hepatitis В virus infection in this population was 62.1%, 
and the proportion of HBsAg carriers among those with hepatitis В markers was 
16.7%. The risk for seronegative residents of acquiring serologic evidence of 
hepatitis В infection from 1980 to 1983 was 2.3% per year (12 per 177 residents). 
Our results clearly show that residents aged 11-15 years at entry have the highest 
prevalence of any hepatitis marker, although this did not reflect a higher rate of 
HBsAg in this age group than in the other age categories. However, in their sur­
vey on mentally handicapped males and females, Szmuness and Prince (11) 
reported a 3.4 fold greater risk of becoming a chronic carrier after admission at an 
early age (<5 years). 
HBeAg, one of the important serologic markers for viral replication, was found 
in the present study in 39.2% of HBsAg carriers. Hepatitis В virus DNA was 
detected in 63.2% of HBeAg-positive serum specimens, which is lower than that 
reported in our previous study (10) and in other reports (9,13,14). Furthermore, 
HBV-DNA was detected exclusively in HBeAg-positive HBsAg carriers. From 
the results of hepatitis В virus DNA determination, it is interesting to note that 
six HBV-DNA-negative, HBeAg-positive carriers, as determined in 1980, had 
become HBeAg-negative in 1986, whereas six of nine residents with HBV-DNA 
in serum in 1980 continued to be positive for HBeAg in 1986. These findings sug­
gest that chronic HBsAg carriers become negative for hepatitis В virus D N A 
before they become HBeAg-negative. Determination of hepatitis В virus DNA 
would therefore predict the chronicity of infection, the presence of hepatitis В 
markers, and perhaps prognosis. The prevalence of hepatitis В serologic markers 
in residents with Down's syndrome has been reported in some studies (15,16) to 
be comparable with that in residents with other forms of mental retardation. In 
this study, we demonstrated that Down's syndrome residents (overall) slightly 
more often had hepatitis В markers than did other mentally handicapped resi­
dents (70.1 and 59.6% respectively), although this difference was statistically not 
significant. In addition, Down's syndrome residents were shown to have a signif­
icantly higher (31.7%) prevalence of HBsAg than other mentally retarded resi-
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dents (11.2%) and more often had markers indicative of active viral replication 
(HBeAg: 61.5% for Down's syndrome vs. 16.0% for other mentally handicap­
ped persons; hepatitis В virus DNA: 37.5% for Down's syndrome vs. 12.0% for 
other mentally retarded persons. These findings are consistent with those of 
Boughton et al. (17) and Williamson et al. (18). 
In an attempt to examine the possible factors for the differential prevalence of 
hepatitis В serologic markers that indicated exposure to hepatitis В virus and of 
those that indicated viral replication in Down's syndrome residents and in resi­
dents with other forms of mental retardation, 117 residents from both categories 
were matched on age at entry and duration of residency. The HBsAg carrier sta­
tus in Down's syndrome residents aged 0-10 years was found to be significantly 
higher than that in the other category of residents (table 4.1.7). This finding indi­
cates that Down's syndrome residents at young ages are more susceptible to the 
HBsAg carrier state than other mentally handicapped residents. However, since 
comparable percentages of residents in both categories had been admitted at ages 
0-10 years (27.4% for Down's syndrome residents, 28.7% for other mentally 
retarded), a young age at entry cannot explain the strikingly higher prevalence of 
HBsAg in subjects with Down's syndrome. Since both categories of residents 
were living in the same institution under apparently identical conditions, we 
believe that environmental conditions do not account for the differential preval­
ence of HBsAg among residents. 
Because the exact mechanisms involved in the development of a chronic HBsAg 
carrier state after exposure to hepatitis В virus still have not been elucidated, fac­
tors that might increase susceptibility of the virus and facilitate its persistence in 
subjects with Down's syndrome are also unknown. Although some studies have 
shown that the humoral immune response in these subjects is normal (19, 20), 
the role of cellular immune mechanisms, which are probably more essential in 
clearing the infective agent (21), have not been defined to date. Regardless of 
whether these cellular immune mechanisms, or other mechanisms, may be res­
ponsible for the high prevalence of HBsAg in Down's syndrome patients, we can 
conclude from our current findings that hepatitis В virus DNA determination, in 
addition to the conventional serologic markers, is useful for predicting a chronic 
carrier state and provides valuable information for developing strategy, including 
vaccination, to prevent hepatitis В infection. 
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4.2 The prevalence of serologic markers and DNA of hepatitis В virus and 
elevated serum aminotransferase values in institutionalized male and 
female mentally handicapped: an epidemiologic study of HBV infec­
tion in residents with Down's syndrome or other forms of mental 
deficiency 
Summary 
Conventional HBV serologic markers as well as serum alanine aminotransferase 
(ALT) and hepatitis В virus DNA (HBV-DNA) were studied in a population of 
667 institutionalized mentally handicapped, both males and females, and in 676 
staff members. The role of Down's syndrome (DS), sex and age-related factors 
with respect to the prevalence of these markers was analyzed. 
A young age at admission was found as one of the important factors in the devel­
opment of the chronic HBsAg carrier state in females. The well-known higher 
prevalence of the HBsAg carrier state in DS patients appeared to be restricted to 
males. Markers indicative of viral replication - HBeAg and HBV-DNA - were 
also more prevalent in male than in female DS residents or other mentally retar­
ded residents (OMR). These findings indicate that the phase of active viral repli­
cation is prolonged in male HBsAg carriers with DS. However, only 66.7% of 
HBV-DNA-positive and 26.2% of HBsAg-positive residents had abnormal 
serum alanine aminotransferase values. In addition, more than 50% of residents 
with elevated ALT values were negative for HBV serologic markers. It is conclu­
ded that male DS residents are the main source of HBV infection in institutions 
for the mentally retarded, and that determination of ALT values is not very use­
ful in identifying those HBsAg carriers capable of transmission of the infection. 
4.2.1 Introduction 
Epidemiologic data on the transmission of HBV infection have shown that only 
part of the HBsAg carriers is capable of transmitting the infection. HBeAg and, 
to a lesser extent, DNA polymerase activity in serum were previously considered 
to be the most representative markers of infectivity in these HBsAg carriers. 
However, recent developments in molecular biology have allowed the detection 
of hepatitis В virus D N A (HBV-DNA) which has subsequently been shown to 
represent a more sensitive and reliable marker of active viral replication than 
other markers (1,2). Knowledge of the HBV-DNA status of HBsAg carriers in 
institutions for the mentally retarded therefore provides a valuable tool in 
attempts to reduce the transmission of this infection. In a previous study, we 
demonstrated that loss of HBV-DNA from serum in residents of an institution 
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for male mentally handicapped was indicative of imminent loss of HBeAg and 
normalization of alanine aminotransferase values (3). 
In this study, we have examined the prevalence of HBV serologic markers, serum 
HBV-DNA, and serum aminotransferases in a population of institutionalized 
mentally handicapped of both sexes and among staff members of this institution. 
The role of sex and age-related variables, such as age at entry into the institute 
and duration of residency, in the prevalence of markers of HBV infection and the 
development of the HBsAg carrier state was also analyzed. In addition the preva-
lence of markers of HBV infection in residents with Down's syndrome was com-
pared with that in residents suffering from other forms of mental retardation. 
4.2.2 Study population and methods 
In 1985 serum specimens were drawn from all residents and 65% (n=676) of staff 
members in an institution for the mentally handicapped. The population consist-
ed of 667 residents: 455 females (68.2%) and 212 males (31.8%); 143 residents 
had Down's syndrome (DS)(21.4% of total residents): 107 were females (74.8%), 
and 36 males (25.2%); 524 residents were suffering from other forms of mental 
deficiency: 348 females (66.4%) and 176 males (33.6%). The serum specimens 
were examined for HBsAg, anti-HBc and anti-HBs. HBsAg-positive specimens 
were further examined for the presence of HBeAg or anti-HBe. Screening for 
HBV markers was performed with commercial enzyme-linked immunosorbent 
assays (Abbott Laboratories, North Chicago, 111., USA). 
HBV-DNA detection 
All serum samples were analyzed under code for the presence of HBV-DNA. 
Detection of HBV-DNA in serum was performed by means of a molecular 
hybridization technique as described by Berninger et al., with slight modifica-
tions. The detection technique is described in section 2.2.1. 
Determination serum aUnine aminotransferase values 
Alanine aminotransferase values were determined in freshly obtained sera with a 
centrifugal analyzer (Multistat Instrumentation®). Determinations were carried 
out within six months after taking the blood sample for the serologic survey. 
Determination was carried out in each resident at least once in this period. 
Analysis of data 
To analyze the difference in prevalence of HBV markers between residents with 
Down's syndrome (DS) and residents with other forms of mental retardation 
(OMR), DS residents were matched with OMR residents with regard to sex, age 
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at entry into the institution as well as duration of residency (both for at most two 
years' difference). In total 129 pairs fulfilled the matching criteria. 
For the statistical analysis of data between groups, we used Mantel-Hanszel's 
chi-square test. The results of the statistical test are given by two-sided p-values. 
If the p-value is equal to or below 0.05, the difference is called statistically signif­
icant. 
4.2.3 Results 
4.2.3.1 Prevalence of HBV serologic markers 
The distribution of HBV serologic markers is shown in table 4.2.1: 242 residents 
(36.3%) had serologic evidence of hepatitis В virus infection, as manifested by 
the presence of at least one HBV serologic marker. Forty-two of these residents 
were positive for HBsAg (17.4% of 242 residents with HBV markers, 6.3% of 
the total population) (table 4.2.1). The prevalence of HBV serologic markers in 
Table 4.2.1 Distribution of HB V serologic markers in 667 residents of an institu­
tion for the mentally retarded 
Hepatitis В markers 
Any HBV marker pos. 
— HBsAg and anti-HBc pos. 
- anti-HBc pos. (sole marker) 
- anti-HBc and anti-HBs pos. 
HBV markers negative 
males 
(n=212) 
90/212 
24/ 90 
5/ 90 
61/ 90 
122/212 
females 
(n=455) 
152/455 
18/152 
17/152 
117/152 
303/455 
P-value 
<0.05 
<0.01 
NS 
<0.001 
<0.05 
Distribution ofHBeAg and anti-HBe in HBsAg-positive residents 
HBV marker males females P-value 
HBeAg-positive 13/24 2/18 <0.05 
anti-HBe-positive 3/24 2/18 NS 
HBeAg and anti-HBe-negative 8/24 14/18 <0.05 
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Table 4.2.2 Distribution of hepatitis В serologic markers in 667 mentally retar­
ded residents, by sex and age 
Age 
(years) 
0-15 
16-20 
21-25 
26-30 
31-35 
Sex 
M 
F 
M 
F 
M 
F 
M 
F 
M 
F 
No. 
of 
residents 
38 
29 
45 
57 
71 
66 
37 
88 
12 
80 
Positive for 
any hepatitis В 
marker 
η 
8 
9 
18 
25 
40 
20 
15 
27 
4 
28 
% 
21.1 
31.1 
40.0 
43.9 
57.1 
30.3 
40.5 
30.7 
33.3 
35.0 
HBsAg 
η 
3 
3 
4 
4 
12 
1 
2 
3 
1 
3 
-positive 
% with 
anyHBV 
marker 
37.5 
33.3 
22.2 
16.0 
30.0 
5.0 
13.3 
11.1 
25.0 
10.7 
0/oof 
total 
residents 
7.9 
10.3 
8.9 
7.0 
16.9 
1.5 
5.4 
3.4 
8.3 
3.8 
>35 M 10 5 50.0 2 40.0 20.0 
F 134 43 32.1 4 9.3 3.0 
Total 
numbers: 
M 
F 
213 
454 
90t 
152 
24* 
18 
26.7 
11.8 
f significant differences were recognized between the prevalence of any hepatitis В serologic 
marker in males and females (X 2-test )p < 0.05). 
HBsAg was found significantly more often in male than in female residents (X2-test, ρ < 
0.01). 
relation to sex and age is shown in table 4.2.2: 152 females (33.5% of total fema­
les) and 90 males (42.3% of total male population) had markers indicative of pre­
vious or current HBV infection (p <0.05). Male residents were more often 
HBsAg-positive (24/90, 26.7% of male residents with any HBV marker) than 
females (18/152,11.8%) (p <0.01). This difference in HBsAg-positivity could be 
observed in each age group (table 4.2.2). In addition HBeAg was significantly 
more often present in specimens obtained from male carriers than in those obtai­
ned from female HBsAg-carriers: 13/24, 54.2% vs. 2/18,11.1% (p <0.05). 
Of the 676 staff members (65% of total number) 47 were positive for one or more 
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HBV markers (7.0% of total staff members tested); HBsAg carrier state was 
found in only two subjects (4.3% ofthose with HBV markers, 0.3% of total staff 
members tested). None of the HBsAg-positive staff members (both anti-HBe-
positive) had detectable viral DNA in serum, in 8/47 anti-HBc was found as the 
sole serologic marker, and the remainder were positive for both anti-HBc and 
anti-HBs. 
HBV-markers in relation to age at entry 
With regard to the age at entry into the institution (table 4.2.3) it appeared that 
markers of HBV infection were found with approximately the same frequency in 
male residents of various groups. In contrast, serologic evidence of previous or 
current infection was found significantly more often in female residents in the 
category younger than 11 years at entry (p <0.01). The risk of chronic HBsAg 
carrier state in females appeared also to be higher when admission had taken 
Table 4.2.3 Distribution of hepatitis В serologic markers in 667 mentally retar­
ded residents, by sex and age at entry 
Age at 
entry 
(years 
0-5 
6-10 
11-15 
>15 
Sex 
M 
F 
M 
F 
M 
F 
M 
F 
No. 
of 
residents 
90 
104 
93 
193 
17 
72 
13 
139 
Positive for 
any hepatitis В 
marker 
n § 
35 
46 
43 
65 
7 
21 
5 
20 
% 
38.9 
44.2 
46.2 
46.8 
41.1 
29.2 
38.5 
14.4 
HBsAg 
n*t 
14 
10 
8 
4 
0 
2 
2 
2 
-positive 
% with 
any HBV 
marker 
40.0 
21.7 
18.6 
6.2 
0 
9.5 
40.0 
10.0 
%of 
total 
residents 
15.6 
9.6 
8.6 
2.9 
0 
2.8 
15.4 
1.5 
significant differences were found between the prevalences of HBsAg in females < 6 years of 
age at entry and those older than 6 years (X2-test, ρ < 0.05). 
in residents admitted before the age of 11 years, HBsAg was found significantly more often 
in males than in females (X2-test,p < 0.05). 
Females who had been admitted before age 11 years significantly more often had markers of 
HBV infection than those who had been admitted at age > 11 years (X2-test, ρ < 0.001). 
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place at a young age (younger than six years of age) as compared with the older 
group (p <0.05). However, in the category 0-10 years of age at entry, HBsAg 
was still significantly more prevalent in male than in female residents (p <0.05). 
In the other age groups, no statistical conclusions as to the prevalence of HBV 
markers could be made since the number of male residents was relatively small. 
HBV markers in relation to duration of residency 
Male residents were found to have a higher prevalence of any HBV marker than 
female residents regardless of the duration of residency (table 4.2.4). In addition, 
within each category the HBsAg carrier state was also found to be more preval­
ent in males. However, in both sexes the prevalence of the HBsAg carrier state 
was not significantly related to duration of stay. 
Table 4.2.4 Distribution of hepatitis В serologic markers in 667 mentally retar­
ded residents, by sex and duration of residency 
Duration 
of residency 
(years) 
0-5 
6-10 
11-15 
16-20 
>20 
Sex 
M 
F 
M 
F 
M 
F 
M 
F 
M 
F 
N o . 
of 
residents 
31 
27 
17 
67 
56 
145 
65 
76 
44 
139 
Positive for 
any hep 
marker 
η 
5 
5 
8 
14 
24 
34 
34 
26 
19 
73 
atitis В 
% 
16.1 
18.5 
47.1 
20.9 
42.9 
23.4 
52.3 
34.2 
43.2 
52.5 
HBsAg 
η 
2 
1 
1 
0 
6 
6 
11 
5 
3 
7 
-positive 
% with 
any HBV 
marker 
40.0 
20.0 
12.5 
25.0 
17.6 
32.4 
19.2 
15.8 
9.6 
%of 
total 
residents 
6.5 
3.7 
5.9 
10.7 
4.1 
16.9 
6.6 
6.8 
5.0 
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4.2.3.2 HBV-DNA status 
HBV-DNA was detected in serum of 12 residents. HBV-DNA positivity was 
restricted to HBsAg/HBeAg-positive residents. Thus, 12/42 HBsAg carriers had 
detectable HBV-DNA in serum (28.8%). HBV-DNA positivity was more pre­
valent in male than in female HBsAg-positive residents: 10/24, 41.7% for males 
vs. 2/18, 11.1% for females. However this difference did not reach statistical 
significance (p=0.07). 
4.2.3.3 Prevalence of HBV markers in Down's syndrome vs. other mentally 
retarded residents 
When the prevalences of HBV serologic markers in the total population of DS 
and OMR residents were compared, it was found that in female HBsAg-positive 
residents HBeAg was far more prevalent in DS (11/15, 73.3%) than in OMR (4/ 
27, 14.8%) (ρ <0.001). This difference in HBeAg prevalency was not found in 
male HBsAg-positive residents. However, HBV-DNA positivity was also more 
prevalent in DS (8/15, 53.3%) than in OMR HBsAg-carriers of both sexes (4/27, 
14.8%) (p <0.05). 
Prevalence of any HBV marker, HBsAg carrier state and serum HBV-DNA in 
129 pairs of residents with Down's syndrome or other forms of mental retardation. 
In order to determine whether DS residents, because of the nature of their dis­
ease, had a higher risk of HBsAg carrier state and of markers indicative of active 
viral replication as compared with residents with other forms of mental deficien­
cy, the results of HBV serologic markers and HBV-DNA in 129 pairs of resi­
dents were analyzed (table 4.2.5). 
HBV markers were found more frequently in DS (58/129, 45.0%) than in OMR 
residents (49/129, 38.0%). In both groups males more often had HBV serologic 
markers than did females. Furthermore, the HBsAg carrier state (in residents 
with any HBV marker) was higher in DS as compared with OMR residents (14/ 
58, 24.1% vs. 4/49, 8.2%). However, these differences were statistically not 
significant. In contrast, HBsAg was more prevalent in male DS residents with 
HBV markers than in OMR residents: 10/17, 58.8% vs. 2/16, 12.5% (p <0.05). 
In female residents no significant difference in the HBsAg carrier state was found 
between DS (4/41,9.8%) and OMR residents (2/33, 6.1%). 
Among DS residents with HBV serologic markers, males had a higher prevalence 
of the HBsAg carrier state than females, 10/17 and 4/41 respectively (p <0.001), 
and were more often HBeAg-positive than females (9/10 and 1/4 respectively, 
statistically not significant). 
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HBV-DNA was detected in eight of the 14 HBsAg-positive DS residents 
(57.1%) and in 0/4 HBsAg positive OMR residents. All HBV-DNA positive 
serum samples were positive for HBeAg as well. Among the HBV-DNA-posi-
tive residents, seven were males and one was female. 
Table 4.2.5 Distnbutton of hepatitis В serologic markers m Down's syndrome 
vs. other mentally handicapped residents. For this study 129 residents with 
Down's syndrome (DS) and 129 residents with other forms of mental deficiency 
(OMR) were matched for sex, age at admission and duration of residency (see 
study popuUtion and methods) 
Any HBV marker positive: 
HBs Ag-positive : 
(number, percentage as 
% of residents with 
any HBV marker) 
HBV-DNA-positive: 
(number, percentage as 
% of HBsAg-positive 
residents) 
males 
females 
males 
females 
males 
females 
DS-resi 
No. of 
pos./ 
total 
17/33 
41/96 
10/17 
4/41 
7/10 
1/4 
dents 
% 
(51.5) 
(42.7) 
(58.8):-
( 9.8)t 
(70.0) 
(25.0) 
OMR-1 
No. of 
pos./ 
total 
16/33 
33/96 
2/16 
2/33 
0/2 
0/2 
-esidents 
% 
(48.5) 
(34.4) 
(12.5) 
(6 .1) 
(-~) 
(-~) 
significant differences were recognized between the prevalence of HBsAg in male as compa­
red to female residents with Down's syndrome (X2-test, ρ < 0 001) 
in males with HBV markers, Down's syndrome residents significantly more often were car­
rier of HBsAg than residents with other forms of mental defiency (X2-test, ρ < 0 05) 
4.2.3.4 Serum aUmne aminotransferase values 
Forty-six residents from the whole populalation were found to have abnormal 
serum alanine aminotransferase values (6.9%). However, the majority of those 
with elevated ALT (27/46) had no HBV markers. ALT elevation was found in 11 
HBsAg-positive residents and in eight with both anti-HBc- and anti-HBs-anti-
bodies. Thus only 11/42,26.2% of HBsAg carriers (i.e. 10/15,66.7% of residents 
with HBeAg, 8/12, 66.7% of residents with HBV-DNA in serum) had elevation 
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of ALT values. In HBsAg-carriers with elevated ALT, the level of ALT could not 
discriminate between HBV-DNA-positive and HBV-DNA-negative residents. 
4.2.4 Discussion 
The recognition that active viral replication is present in only a subset of HBsAg 
carriers has initiated a survey on the prevalence of HBV-DNA in serum in a 
population with a high prevalence of HBV infection. Both the presence of HBV 
serologic markers and hepatitis В virus DNA in serum were evaluated in this 
study of a population of institutionalized mentally handicapped and their staff; 
36.6% of mentally retarded residents and 7.0% of staff members had serologic 
evidence of previous or current infection with hepatitis В vims. The prevalence 
of HBsAg among those with HBV markers was 17.4% for residents and 4.3% 
for staff members, the former prevalence being significantly higher than that 
found in the general population in the Netherlands (4). The age specific infection 
rate (any HBV marker positive) in mentally retarded males was found to be 
highest in the age category of 21-25 years, and for female residents in the group of 
16-20 years. The prevalence of the HBsAg carrier state was higher in male than in 
female residents regardless of age. In male residents, markers of HBV infection 
were found with approximately the same frequency in various groups of age at 
entry. In contrast, in females both serologic evidence of previous or current HBV 
infection and the chronic HBsAg carrier state were found significanty more often 
when admission had taken place at a young age. 
The overall prevalence of HBV-markers gradually increased with duration of 
residency in both sexes. However, the HBsAg carrier state was found to be unre­
lated to duration of residency. 
Although earlier surveys with regard to the prevalence of HBV markers in 
subjects with Down's syndrome as compared with other mentally handicapped 
provided conflicting results (5-11), there is strong evidence of an increased 
prevalence of the HBsAg carrier state in institutionalized subjects with Down's 
syndrome (5-7, 12-15). In order to exclude any role age-related variables could 
play in this finding, we also analyzed the data after careful matching of DS and 
OMR residents. The results showed that, based on the presence of at least one 
HBV serologic marker, DS and OMR residents had been fairly equally exposed 
to HBV infection in this institution. However, both HBsAg as well as markers of 
active viral replication were more prevalent in DS residents; in females, a young 
age at admission was found to favor the development of the chronic HBsAg 
carrier state. Moreover, male DS residents were more often HBsAg-positive than 
females, whereas in other mentally handicapped residents no significant sex-
related difference was found in this study. Although HBV infection at a young 
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age and in males might result in a higher frequency of the chronic HBV carrier 
state, as also demonstrated in this study, factors which may increase this suscepti­
bility and facilitate the persistence of the virus carrier state in subjects with DS 
have not been defined to date. 
In this survey we have found that HBV-DNA positivity was restricted to 
HBeAg-positive residents: 12/15 HBeAg-positive HBsAg carriers had detecta­
ble viral DNA in serum. These results are in accordance with those reported 
previously for HBeAg-positive chronic carriers (16, 17), and support the relative 
infrequent presence of viral DNA in serum of North European carriers with 
anti-HBe (18, 19). The small number of HBeAg-positive subjects in OMR as 
compared with DS residents did not allow us to draw statistical conclusions as to 
the prevalence of HBV-DNA in HBeAg-positive carriers in both categories of 
residents. 
Abnormal ALT levels were found in 46/667 residents in this survey. In the 
majority of residents with ALT elevation, HBV markers were surprisingly nega­
tive, while only 26.2% of HBsAg-positive residents had abnormal ALT values. 
Comparable results with regard to the prevalence of elevated ALT values in 
HBsAg carriers have been found by others (20). These findings demonstrate that 
even in a population with a high prevalence of HBV infection, elevation of ALT 
values is not related to this infection in the majority of cases. Moreover, the low 
percentage of carriers with elevated serum aminotransferase values indicates that 
most of the HBsAg carriers under study can be classified as 'asymptomatic car­
riers'. Furthermore, abnormal ALT values were found in only 66.7% of HBV-
DNA-positive residents. Determination of serum ALT is, therefore, not suitable 
for the detection of HBV carriers. The data further suggest that the reported high 
incidence of abnormal ALT values in HBV-DNA positive subjects (21) probably 
reflects the presence of chronic liver disease rather than the presence of active 
viral replication. 
From the present study we can therefore conclude that male DS residents are the 
main source of HBV infections in institutions for mentally handicapped and that 
determination of serum ALT is not very useful to identify HBsAg carriers 
capable of transmission this infection. Moreover, HBV-DNA determination in 
addition to HBeAg measurements in HBsAg carriers may provide knowledge on 
the distribution of infectious carriers and may therefore be of importance for 
developing a policy to reduce HBV transmission. 
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CHAPTER 5 
Hepatitis В virus DNA in the liver 
5.1 Liver HBV-DNA in chronic liver disease and primary hepatocellular 
carcinoma: Southern blot analysis of HBV-DNA sequences in liver 
biopsy specimens 
Summary 
DNA extracts from liver tissue of 49 patients with various serologic and histolo­
gic manifestations of HBV infection and of 20 patients with non-hepatitis В liver 
disease were examined for the presence and state of hepatitis В virus D N A by 
means of Southern blot analysis. HBV-DNA was detectable in all patients posi­
tive for HBsAg and HBeAg; in the majority of cases viral DNA was found as 
episomal forms when viral DNA was present in serum. In contrast, in HBeAg-
negative patients serum HBV-DNA was undetectable in most cases despite the 
presence of episomal forms of DNA in the liver, supporting the view that in this 
category of HBsAg carriers the level of viral replication is low. A strong correla­
tion was observed between the presence of integrated HBV-DNA sequences in 
the liver and primary hepatocellular carcinoma. However, integrated HBV-
DNA was also found in chronic HBsAg-positive carriers without this tumor, as 
well as in some HBsAg-negative subjects. The clinical significance of the pres­
ence and state of viral DNA in the liver is discussed. 
5.1.1 Introduction 
Acute and chronic inflammatory liver disease, including primary hepatocellular 
carcinoma, may develop after HBV infection. The mechanism of liver injury in 
HBV infection and the mechanism employed by hepatitis В virus to gain entry 
into the host cell hepatocyte are not well understood. Like other viruses, HBV is 
likely to avail itself of specific receptor molecules for adsorption, followed by 
penetration into the cytoplasm (1). Viral DNA is then converted in the cell 
nucleus into a double-stranded closed circular form, which will function as a 
template for viral replication. Although the various steps of viral replication seem 
to take place predominantly in the cytoplasm, the exact sites of these processes, 
the route of virus assembly, the time required for the production of the virus and 
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viral components, and the relation to liver injury have not been definitely deter-
mined (see general Introduction). However, Southern blot analysis and hybridi-
zation studies have shown that two distinct moitiés of HBV-DNA sequences can 
be observed in liver biopsies obtained from patients with HBV-related acute or 
chronic liver disease (2-4): a) viral DNA sequences which are integrated into the 
hepatocyt genome, b) viral DNA sequences which are not integrated into the 
hepatocyte genome - free or episomal HBV-DNA sequences - . 
The present study aimed to investigate the relationship between the presence and 
state of HBV-DNA in the liver and serologic as well as histologic manifestations 
of HBV infection. 
5.1.2 Patients and methods 
Sixty-nine liver biopsy specimens, obtained from 49 patients with various forms 
of HBV-related liver disease and from 20 patients with non-hepatitis В liver dis­
ease, were evaluated. Liver tissues were obtained by percutaneous needle biopsy, 
during surgical procedures, such as cholecystectomy and shuntoperations 
because of portal hypertension, or immediately postmortem. The tissue was 
rapidly frozen in liquid nitrogen and stored at —80 "C until utilized for analysis. 
The procedures used for DNA extraction and Southern-blot analysis are descri­
bed in section 2.3 
5.1.3 Results 
Based on HBV serologic findings we have divided the 69 patients into five groups 
(table 5.1.3). Histologic or clinical diagnoses of liver disease in these patients 
include: acute hepatitis (n=2) ) chronic persistent hepatitis (n=5), chronic active 
hepatitis or cirrhosis (n=22), primary hepatocellular carcinoma (n=28), and 
minor changes, such as steatosis or mild fibrosis, or normal liver histology 
(n=12). 
HBV-DNA was detected in liver samples of all (n=14) patients positive for 
HBsAg and HBeAg (group I). Six patients had episomal forms, five patients had 
both episomal and integrated HBV-DNA, while in three patients only integrated 
HBV-DNA was found. Serum HBV-DNA was detectable in eight out of ten 
patients with episomal viral DNA in the liver. Histologic diagnoses of the two 
patients without serum HBV-DNA included acute hepatitis and chronic active 
hepatitis. 
In patients positive for HBsAg and anti-HBe (group II), viral DNA in the liver 
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was present in 85.7% (11/14). In this group, episomal HBV-DNA was found 
almost exclusively in patients with chronic hepatitis or cirrhosis, whereas inte­
grated HBV-DNA was found only in patients with primary hepatocellular carci-
Table 5.1.1 Presence and status of HBV-DNA m the liver and relation to H BV 
serologic markers, serum HBV-DNA and liver histology 
Group 
I 
II 
III 
IV 
V 
HBV serologic 
markers (+) 
HBsAg 
HBeAg 
anti-HBc 
HBsAg 
anti-HBe 
anti-HBc 
anti-HBc 
anti-HBc 
anti-HBs 
No HBV 
markers 
Liver 
histology 
AH 
CPH 
CAH/Cir 
P H C 
Steatosis 
CAH/Cir 
P H C 
Cir 
P H C 
Fibrosis 
CAH/Cir 
P H C 
norm. 
minor abn. 
CAH/Cir 
CPH 
P H C 
norm./ 
minor abn. 
FH 
η 
1 
4 
4 
4 
1 
8 
6 
3 
3 
1 
4 
4 
6 
3 
1 
11 
4 
1 
HBV-DNA 
status in liver 
free 
1 
4 
3 
2 
1 
6 
1 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
inte­
grated 
1 
2 
1 
4 
0 
0 
5 
2 
2 
0 
1 
0 
0 
0 
0 
1 
0 
0 
serum HBV-
DNA (+) 
0/1 
4/4 
2/3 
2/3 
nt 
1/8 
1/5 
0/3 
0/2 
nt 
0/3 
0/3 
0/2 
0/1 
0/1 
0/4 
0/1 
0/1 
AH : acute hepatitis 
CPH : chrome persistent hepatitis 
CAH/Cir : chronic active hepatitis or cirrhosis 
PHC : primary hepatocellular carcinoma 
norm./mmor abn. : normal liver histology or only minor abnormalities (steatosis, fibrosis) 
FH . fulminant hepatitis 
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noma. Integrated HBV-DNA was also present in four out of the seven patients 
with anti-HBc as the sole marker of infection (group III), in one out of the 14 
patients positive for both anti-HBc and anti-HBs (group IV), and in one patient 
with primary hepatocellular carcinoma without HBV serologic markers (group 
V). Neither episomal HBV-DNA nor serum HBV-DNA was detectable in these 
three groups of HBsAg-negative patients. 
Table 5.1.2 Presence of integrated viral DNA sequences in the liver and reUtion 
to liver histology in patients with HBV serologic markers 
Liver histology η Integrated HBV-DNA (%) 
(50.0) 
(21.5) 
(64.7) 
( 0) 
CPH 
CAH/Cir 
P H C 
AH 
normal/minor abnormalities 
4 
19 
17 
1 
8 
2 
4 
11 
1 
0 
Thus, integrated viral DNA was found in 18 out of 49 patients (36.7%) with one 
or more HBV serologic markers, and in one of 20 patients without HBV markers. 
Eight patients with integrated HBV-DNA were positive for both HBsAg and 
HBeAg, five patients were anti-HBe-positive chronic HBsAg carriers, whereas 
serum HBsAg was negative in five patients. Table 5.1.2 shows the clinical or 
histologic diagnoses of 49 patients with HBV serologic markers. In 64.7% (11/ 
17) of HBV seropositive patients with primary hepatocellular carcinoma, inte­
grated HBV-DNA could be detected, while one patient who had integrated 
HBV-DNA and primary hepatocellular carcinoma, was seronegative. HBV sero­
logic markers of the 28 patients with primary hepatocellular carcinoma are 
shown in table 5.1.3: ten patients were HBsAg-positive (four HBeAg-positive 
and six anti-HBe positive). In all but one of these ten patients integrated HBV-
DNA was present in liver tissue, while episomal HBV-DNA was demonstrable 
in only three patients including one patient without integrated HBV-DNA. Inte­
grated HBV-DNA was found in only two out of the seven seropositive but 
HBsAg-negative patients, and in one patient without detectable HBV serologic 
markers in serum. 
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Table 5.1.3 HBV-DNA status in the liver of patients with primary hepatocellu-
lar carcinoma and region to MB V serologic markers 
HBV serologic markers HBV-DNA status in liver 
No. Age Sex HBsAg/ HBeAg/ anti- Inte- Episo- Serum 
anti-HBs antiHBe HBc grated mal HBV DNA 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19-28 
27 
34 
44 
32 
66 
49 
41 
62 
60 
40 
64 
56 
60 
55 
65 
72 
62 
46 
22-78 
f 
m 
f 
m 
f 
m 
m 
m 
m 
f 
m 
m 
m 
m 
m 
f 
m 
m 
4f/6m 
+/-
+/-
+/-
+/-
+/-
+/-
+/-
+/-
+/-
+/-
-/-
-/-
-/-
-/+ 
-/+ 
-/+ 
-/+ 
-/-
-/-
+/-
+/-
+/-
+/-
-/+ 
-/+ 
-/+ 
-/+ 
-/+ 
-/+ 
-/-
-/-
-/-
-/-
-/-
-/-
-/-
-/-
—/— 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
-
— 
+ 
+ 
+ 
+ 
+ 
-
+ 
+ 
+ 
+ 
+ 
-
+ 
-
-
-
-
+ 
— 
+ 
-
+ 
-
-
+ 
-
-
-
-
-
-
-
-
-
-
-
-
— 
+ 
-
+ 
nt 
-
+ 
-
-
-
nt 
-
-
nt 
-
-
-
nt 
-
— 
5.1.4 Discussion 
In the present study, we detected episomal forms of HBV-DNA in the liver of 11 
out of 14 patients positive for HBsAg and HBeAg, and in seven out of 14 patients 
positive for HBsAg and anti-HBe. Episomal forms of HBV-DNA were not 
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detected in liver tissue from HBsAg-negative patients. In addition, serum HBV-
DNA could be detected in 88.9% of HBeAg-positive and in 28.6% of anti-HBe-
positive chronic HBsAg carriers with episomal forms of HBV-DNA, and in 
none of the patients without episomal HBV-DNA in the liver. These findings 
suggest that the presence of hepatitis В virus in the liver is not always correlated 
with HBeAg in serum. Appearance of anti-HBe in, or absence of HBV-DNA 
from serum does not reflect complete elimination of HBV. However, disappear­
ance of HBsAg from serum is probably a reliable marker for the absence of HBV 
from the liver, especially when HBV-DNA is not detectable either. The absence 
of serum HBV-DNA in patients with episomal viral DNA in the liver, which 
may be the case especially in anti-HBe positive HBsAg-carriers, can be accoun­
ted for by a very low titer of DNA, which is not detected by the current hybridi­
zation assays. 
The present finding of episomal HBV-DNA in type В chronic liver disease is in 
agreement with the results of Hadziyannis et al. (5), who reported a strong asso­
ciation between severe forms of liver inflammation and persistence of viral repli­
cation. However, the level of viral replication in anti-HBe-positive HBsAg car­
riers is low, since HBV-DNA in serum could be detected only in a minority of 
patients, despite the presence of episomal forms of HBV-DNA in the liver, as 
shown in the present study and by others (6-9). N o correlation was found 
between the presence of episomal forms of HBV-DNA and histologic manifesta­
tions of HBV infection. 
In this study, integrated HBV-DNA sequences in the liver were found in eight 
out of 14 patients positive for HBsAg and HBeAg, and in five out of 14 HBsAg/ 
anti-HBe-positive patients. Four out of these 13 patients with integrated HBV-
DNA also had episomal forms of viral DNA in the liver. Furthermore, integrated 
HBV-DNA sequences were found in five out of 21 HBsAg-negative patients 
(four had anti-HBe and one was positive for both anti-HBe and anti-HBs), and 
in one out of 20 patients without any HBV serologic marker. It is important to 
note that integrated HBV-DNA sequences were detected in the livers of 12/17 
(70.6%) patients with primary hepatocellular carcinoma (PHC) and HBV sero­
logic markers, although this group of patients made up only 34.7% of the total 
number of patients with HBV serologic markers. Since epidemiologic findings 
indicate that HBV infection is an important enologie factor in the development 
of PHC, and HBV-DNA is present in an integrated form in various cell lines 
derived from tumors obtained from patients with hepatocellular carcinoma (10, 
11), the finding of integrated HBV-DNA sequences in patients with P H C as 
demonstrated in the present as well as in other studies (12-14) has led to the 
hypothesis that, on the analogy of virus-induced malignant tumors in the animal 
model, viral integration might induce an important step in cellular transforma­
tion (15). Indeed, the presence of integrated HBV-DNA, showing up as discrete 
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bands on gel electrophoresis, indicates a clonal expansion of cells. Furthermore, 
significant rearrangements of cellular flanking regions and viral sequences have 
been found (16). These findings are consistent with observations on oncogenic 
viruses (17). However, a common mechanism that may lead to the development 
of PHC by integration of viral DNA into the host genome has not been elucida­
ted (17, 18). Integrated HBV-DNA sequences with discrete bands on gel elec­
trophoresis could also be found in patients without PHC (14, 19, 20). In our 
study, two patients with chronic persistent hepatitis, four patients suffering from 
chronic active hepatitis/cirrhosis and one patient with acute hepatitis demonstra­
ted integrated HBV-DNA in the liver. It is therefore believed that other condi­
tions (host or environmental circumstances) are also of importance in the devel­
opment of neoplasia. In contrast to the finding of episomal forms of HBV-DNA 
Table 5.1.4 Review of studies on the presence of integrated HB V-DNA in liver 
tissue m reUtion to HBVserologic markers 
A Patients 
Author 
Shafntz 
Koshy 
Brechot 
Chen 
Hino 
Imazeki 
Fowler 
with primary hepatocellular carcinoma 
year of 
publi­
cation 
'81 
'81 
'82 
•82 
*85 
'86 
'86 
η 
20 
6 
29 
5 
85 
18 
38 
Patients with integrated HBV-DNA 
HBsAg* 
patients 
12/12 
3/4 
10/10 
5/5 
19/23 
4/8 
13/28 
(%) 
(100 ) 
( 75 0) 
(100 ) 
(100 ) 
( 82.6) 
( 50.0) 
( 4 6 4) 
HBsAg-
patients 
3/8 
0/2 
12/12 
1/18 
1/10 
1/10 
(%) 
( 37.5) 
( 0 ) 
(100 ) 
(5.6) 
(10 0) 
(10.0) 
HBV-sero-
negative 
patients 
7/7 
3/44 
0/5 
(%) 
(100) 
( 6 8 ) 
( 0 ) 
Ref. 
(21) 
(22) 
(23) 
(12) 
(24) 
(25) 
( 9 ) 
В Patients with chronic liver disease 
Bréchot 
Shafntz 
Scotto 
Harrison 
Yokosuka 
Fowler 
'81 
'81 
'83 
'86 
'86 
'86 
17 
10 
13 
133 
14 
54 
3/3 
2/7 
5/15 
7/53 
7/14 
6/54 
(100 ) 
( 2 8 6) 
( 33.3) 
( 13 2) 
( 50.0) 
( 11-1) 
11/11 
3/3 
6/11 
3/80 
0/10 
(100 ) 
(100 ) 
( 54.5) 
( 3 8) 
( о ) 
3/3 
0/11 
(100) 
( 0) 
(14) 
(15) 
(26) 
( 8) 
( 3) 
( 9 ) 
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in the liver, which are restricted to HBsAg-positive patients, integrated HBV-
DNA has been found in HBsAg-positive as well as in HBsAg-negative patients. 
Moreover, integrated HBV-DNA was also found in a patient having hepatocel­
lular carcinoma without any HBV serologic marker. In addition, no correlation 
was found between the presence of integrated HBV-DNA and the severity of the 
inflammatory reaction during liver histology. These findings indicate that inte­
gration of HBV-DNA in the hepatocyte genome is not always associated with 
expression of viral antigens, and that viral antigens are not essential for the devel­
opment and maintenance of P H C . Integrated HBV-DNA is not essential for the 
development or maintenance of inflammatory liver disease either. These results 
are in accordance with findings of other investigators. A review of the literature 
on the presence of integrated viral DNA in various forms of liver disease is pre­
sented in table 5.1.4 (21-26). 
From the present study we may therefore conclude the follow: 
1. Determination of episomal forms of HBV in the liver represents the most 
sensitive method to gain knowledge about complete elimination of virus from 
the body, especially in anti-HBe positive HBsAg carriers. In HBsAg-negative 
patients, especially when HBV-DNA is negative, HBV is almost always 
absent from the liver. 
2. Integrated HBV-DNA is strongly associated with P H C . However, HBV-
DNA can also be found in the integrated form in other HBV-associated liver 
diseases. Whether this integration is an initial step, and whether other condi­
tions are also necessary for the development of PHC requires further investi­
gation. 
3. Integrated HBV-DNA sequences can be found in liver specimens from 
HBsAg-positive as well as from HBsAg-negative patients. However, HBsAg 
may also be positive in patients with only integrated HBV-DNA in the liver. 
Prior determination of the HBV-DNA status in the liver is therefore essential 
to determine whether antiviral agents are useful for treatment of HBsAg-posi­
tive patients. 
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5.2 HBV-DNA detection by the in situ cytohybridization technique. 
Summary 
To examine the relationship between the presence of hepatitis В virus DNA 
sequences in the liver, histopathologic features and antigenic markers, we deter­
mined the hepatocytic status of viral DNA by means of in situ hybridization in 
formaldehyde-fixed liver sections with a biotinylated probe in 45 patients with 
various forms of chronic liver disease. The results were compared retrospectively 
with HBV serologic markers and histopathologic features including the presence 
of ground-glass cells or Shikata staining positivity. The specificity of this in situ 
detection of HBV-DNA was proven to be excellent in a double-blind control 
study in 18 patients in whom liver HBV-DNA was also determined by DNA 
extraction, gel electrophoresis, and the Southern blotting technique. In 41 
patients, the findings of HBV-DNA and serologic markers were concordant (17 
positive and 24 negative). Twelve of the 20 HBV-DNA-positive patients were 
HBsAg-positive (six with chronic hepatitis, three with cirrhosis, and three with 
hepatocellular carcinoma). Ground-glass cells or Shikata positivity were found in 
10 of these 12 patients. HBV-DNA sequences were found in the liver of all 
patients with chronic liver disease and serologic positivity for HBV infection. In 
livers with normal histologic features, HBV-DNA was not demonstrable, despite 
the positive anti-HBc and anti-HBs reaction. However, HBV-DNA was found 
in three serologically negative patients. In another patient, interpretation of fin­
dings was impossible because of severe hemosiderosis. From this study, it is con­
cluded that in situ detection of HBV-DNA in formalin-fixed liver sections has 
clinical value and is suitable for routine use. 
5.2.1 Introduction 
The hepatitis В virus (HBV) is a DNA virus that causes a wide spectrum of acute 
and chronic liver disease in humans and some nonhuman primates. Epidemiolo­
gic data indicate that worldwide approximately 200 million persons are exposed 
to HBV and are chronic carriers (1). Chronic carriers of hepatitis В virus are at 
high risk of developing chronic liver disease and are the source of infection. The 
use of sensitive tests to detect HBV antigens and antibodies has enabled us to 
determine various manifestations of HBV infection (2-6). Detection of HBV-
DNA through its abilitiy to hybridize with radioactive or nonradioactive labeled 
D N A prepared from recombinant plasmids containing the HBV genome permits 
a new appproach to the understanding of HBV infection (7-10). Hepatitis В virus 
sequences in liver tissue are usually determined and analyzed by the technique of 
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DNA extraction from a liver specimen, gel electrophoresis. Southern blotting, 
and molecular hybridization with a radioactive labeled HBV-DNA probe (7-10). 
Because of the limitation of this technique (a significant amount, usually more 
than 10 mg of properly conserved, deep-frozen tissue is needed for this determi-
nation), the method is not suitable for routine clinical investigation. In the 
present study, we have applied the in situ hybridization technique using a bioti-
nylated HBV-DNA probe to detect HBV-DNA sequences in formalin-fixed 
liver biopsy specimens of 45 patients with various forms of chronic liver disease. 
The results were compared with the HBV serologic markers and with liver histo-
pathologic features, including the presence of ground-glass cells or Shikata stai-
ning positivity. 
5.2.2 Patients and methods 
Liver specimens 
Freshly frozen specimens for the determination of HBV-DNA sequences by 
means of the method of DNA extraction, gel electrophoresis, and molecular 
hybridization were obtained by percutaneous liver biopsy in 18 patients referred 
to our hospital because of chronic liver disease. The specimens were stored at 
—80 0C until analysis. The formaldehyde-fixed liver specimens for the in situ 
hybridization assay were collected from the same 18 patients and from an addi-
tional 27 patients who underwent a liver biopsy for routine clinical examination 
because of suspicion of chronic liver disease. The biopsies were taken between 
one and five years before the present study. 
Histologic analysis of liver specimens was performed by means of routine proce-
dures after formaldehyde fixation (4% buffered formaldehyde). 
HB V serologic markers 
Serologic HBV markers (HBsAg, anti-HBs, anti-HBc, HBeAg and anti-HBe) 
were determined by means of commercial enzyme immuno assays (AUSZYME-
II, AUSAB, CORAB/CORZYME,ABBOTT-HBe, Abbott Laboratories, 
North Chicago, 111.). The results of these studies and the histologic findings were 
not made available to the investigator at the time of DNA analysis. 
Southern blotting technique 
The methods applied in DNA extraction, gel electrophoresis, and molecular 
hybridization with a 32P-HBV-DNA probe are described in section 2.3.1. 
In situ cytohybridization technique 
The methods for detection of HBV-DNA sequences by means of the in situ cyto-
hybridization technique are described in section 2.3.2. 
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5.2.3 Results 
The specificity and the sensitivity of in situ hybridization for detection of HBV-
DNA sequences in liver sections were examined in 18 patients by comparing the 
results with the findings as determined by the method of DNA extraction and gel 
electrophoresis (table 5.2.1). Each in situ hybridization assay was considered 
valid only if control sections were found to contain the expected grain density. A 
known positive section contained positive cells with 10-40 grains, and a known 
negative section showed a background of fewer than two grains per cell (fig. 
5.2.1, 2 and 3). In seven patients in whom HBV-DNA sequences were detected 
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Figure 5.2.1: Detection of HBV-DNA sequences in liver tissue by means of DNA extraction, gel 
electrophoresis, and Southern blotting (left) and by means of'in situ hybridization in a section of 
formaldehyde-fixed, paraffin-embedded liver tissue (right) obtained from a patient with HBsAg/ 
HBeAg-positive hepatocellular carcinoma. Endonuclease EcoRl (lane E) and HIND III (lane H) 
digested DNA was fractionated on 0.5% agarose gel, transferred to nitrocellulose paper and 
hybridized with a 32P Ubeled HB V-DNA probe as described in section 2.3.1. The autoradiogram 
shows the presence of integrated (distinct bands in high molecuUr-weight regions) as well as free 
or episomal HBV-DNA sequences (diffuse hybridization pattern in regions below 3.4 kilobase 
pairs). In the liver tissue section, HBV-DNA sequences were detec ted by means of the in situ 
hybridization technique with a biotinylated HBV-DNA probe (right). The field shows hepatocy-
tes with positive, mainly cytoplasmic grains. Nuclear localization of grains (arrow) is also visible 
in this figure. In the original picture, hepatocytes were stained green, while the grains were 
brown, (bar = 10ßm). 
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Figure 5 2 2· Detection of HBV-DNA sequences in liver tissue by means of DNA extraction, gel 
electrophoresis, and Southern blotting (left), and by means of in situ hybridization m a section of 
formaldehyde-fixed, paraffin-embedded liver tissue (right) obtained from a patient with non-
HBV reUted chronic hepatitis. Hybridization methods and Ubeled HBV-DNA probe were as 
described m figure S.2.1. HBV-DNA sequences were undetectable by either of both methods. The 
field shows grains with a density lower than 1-2 grains per cell. 
(bar =10 μτη). 
by DNA extraction, gel electrophoresis, and Southern blotting, HBV-DNA 
sequences were also found in formaldehyde-fixed liver sections as demonstrated 
by in situ hybridization (table 5.2.1). Free and/or integrated HBV-DNA detected 
by in situ hybridization technique in this study was predominantly cytoplasmic, 
as shown in fig. 5.2.1. Positive cells were focally distributed with variable DNA 
content of different positive cells in the section. Eight patients with a negative 
result in the in situ hybridization assay had no detectable HBV-DNA either as 
determined by means of the other technique. However, one patient was found 
positive for episomal DNA by the blotting technique, but no HBV-DNA was 
demonstrable in the in situ hybridization assay. This patient was suffering from 
HBsAg-positive/HBeAg-positive chronic active hepatitis. In two other patients, 
HBV-DNA was found in small spots in the in situ hybridization assay, despite 
the negative finding in the blotting technique. Both patients were anti-HBc and 
anti-HBs-positive, and had hepatocellular carcinoma. To further investigate the 
7.5— 
5.9— 
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Figure 5.2.3: Detection of HBV-DNA sequences in the Alexander (PLC/PRF/Í) hepatoma cell 
line by means of m situ hybridization with a biotinylated HBV-DNA probe. Cells were fixed in 
4% buffered formaldehyde. The field shows cells with predominantly nuclear localization of 
grains. This PL C/PRF/5 cell line is known to contain only integrated HB V-DNA in the cell geno-
me. 
(bar = Wßm) 
possible false positivity of this technique for detection of HBV-DNA, liver sec-
tions with positive findings were reexamined with a DNA probe derived from 
plasmid DNA containing cytomegalovirus. In this control experiment, no grains 
were found in the liver sections, which indicated that there is no nonspecific posi-
tive result with streptavidin-biotin-horseradish peroxidase complex in these 
HBV-DNA-positive liver specimens. After this encouraging result concerning 
sensitivity and specificity, the clinical significance of this in situ hybridization of 
Table У 2.1 In situ hybridization versus Southern blotting technique in detec­
tion of HBV-DNA in 18 patients with chronic liver desease 
HBV-DNA as detected by 
In situ Southern blot- No. of 
hybridization ting technique patients 
HBV serologic markers 
HBsAgV HBeAgV anti-
anti-HBs+ anti-HBe+ HBc + 
+ + 
+ 
-
— 
7 
1 
2 
8 
4/1 
1/0 
0/2 
0/3 
3/1 
1/0 
0/0 
0/0 
7 
1 
2 
3 
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HBV-DNA detection in formalin-fixed liver biopsies was investigated in 45 
patients with various forms of liver disease. Liver specimens were obtained as 
paraffin-embedded sections for routine clinical investigation. The results were 
compared with HBV serologic markers and histopathologic features, including 
the presence of ground-glass cells or Shikata staining positivity. The histologic 
findings and serologic data of the 45 patients are shown in table 5.2.2. The 
patients included 25 males and 20 females ranging in age from 11 to 78 years. 
Twelve patients were serologically positive for HBsAg. Eight patients who were 
serologically negative for HBsAg were anti-HBc-positive. Three of these eight 
Table 5.2.2 Histologic findings of 45 patients with chronic liver disease 
A Patients with HBV serologic markers 
Histology anti-HBc HBsAg anti-HBs HBeAg anti-HBe 
P H C 
Cir 
CPH 
САН 
normal 
Total 
В Patients 
Histology 
P H C 
Cir 
CPH 
САН 
normal 
Total 
5 
4 
4 
4 
3 
20 
3 
3 
4 
2 
0 
12 
without HBV markers 
η 
3 
5 
5 
12 
0 
25 
2 
0 
0 
1 
2 
5 
2 
2 
3 
2 
0 
9 
0 
1 
0 
0 
0 
1 
PHC : primary hepatocellular carcinoma 
Cir : liver cirrhosis 
CPH : chronic persistent hepatitis 
САН : chronic active hepatitis 
158 
patients were anti-HBs-negative. In 20 patients with markers of HBV infection, 
histologic evaluation of the liver revealed chronic persistent hepatitis in four, 
chronic active hepatitis in four, liver cirrhosis in four, hepatocellular carcinoma 
in five, and histologically normal livers in three. Fifteen of these patients were 
males. 
Among the 25 patients without evidence of HBV infection, as demonstrated by 
the absence of HBV serologic markers, 15 were females and ten were males. Five 
patients had chronic persistent hepatitis and 12 patients had chronic active hepa­
titis. Cirrhosis was found in five, and hepatocellular carcinoma in three patients. 
In none of these patients was alcohol-induced chronic liver disease or primary 
biliary cirrhosis suspected. 
In 41 patients (table 5.2.3), the findings of HBV-DNA and serologic markers 
were concordant (17 positive and 24 negative). Twelve of the 20 HBV-DNA-
positive patients were HBsAg-positive (six chronic hepatitis, three liver cirrhosis, 
and three hepatocellular carcinoma). Ground-glass cells or Shikata staining posi-
tivity were found in 10 of these 12 patients. Three patients with HBV-DNA-
positive and HBsAg-negative, but anti-HBc-positive results (one of these 
Table 5.2.3 HBV-DNA status as detected by in situ hybndization and HBV 
serologic markers in 45 patients with chronic liver disease 
Number of HBsAg anti- Ground-glass HBV- Histologic study 
patients HBc cells/Shikata DNA 
staining 
positivity 
12 
5 
3 
3 
21 
+ + 
+ 
+ 
10 + 3 P H C , 3 Gir, 6 CPH 
or САН 
+ 5 CPH or САН 
— 3 normal 
+ 3 CPH or САН 
5 PHC, 6 Gir, 10 CPH 
or САН 
? CPH, severe 
hemosiderosis 
PHC : primary hepatocellular carcinoma 
Cir : liver cirrhosis 
CPH : chronic persistent hepatitis 
САН : chronic active hepatitis 
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patients was also anti-HBs-positive) were found to have integrated HBV-DNA 
as determined by means of DNA extraction, gel electrophoresis, and restriction 
endonuclease analysis (data not shown). Of the 24 patients without detectable 
HBV-DNA, 21 patients had no serologic markers of HBV infection, three 
patients were anti-HBc-positive, and two of these three patients were anti-HBs-
positive. In this study we also demonstrated positive HBV-DNA in three serolo-
gically negative patients. In one patient, the interpretation of the finding was not 
possible because of severe hemosiderosis. 
5.2.4 Discussion 
In transmission of HBV in humans and chimpanzees, it has been demonstrated 
that individuals contaminated with the infectious agents may develop acute hepa-
titis (11,12). In natural transmission, however, initial infection is often subclinical 
or unrecognized. After acute infection, some individuals become chronic carriers 
with or without liver sequelae. In the pathogenesis of chronic liver disease secon-
dary to HBV infection, immunologic and fibroplastic processes have been incri-
minated. Lymphocytotoxicity with or without contribution of antibodies has 
also been thought responsible for the persistence of liver cell necrosis. However, 
factors influencing the chronicity of the inflammatory reaction in the liver, per-
sistence of HBV replication and the development of chronic liver disease, inclu-
ding hepatocellular carcinoma, have not yet been elucidated. The widespread use 
of serologic markers of HBV infection, liver biopsy, and determination of serum 
aminotransferases has enabled us to determine acute infection, the chronic carrier 
state or previous infection, and to recognize histologic changes which may be 
associated with progression to cirrhosis. With the advent of newer techniques in 
molecular biology, highly sensitive methods to detect HBV-DNA sequences in 
liver cells have been developed (7, 9). In tumors of HBsAg-positive patients with 
hepatocellular carcinoma, HBV-DNA sequences were found to be integrated 
into the host genome (9, 13). Based on this finding and its analogy to viral carci-
nogens in general, it has been suggested that integration of HBV-DNA into the 
human genome occurs in conjunction with malignant transformation (14, 15). 
Nevertheless, integrated HBV-DNA has also been found by us (data not shown) 
as well as by others (7, 10) in patients with various forms of chronic liver disease 
without evidence of hepatocellular carcinoma. Because the exact mechanisms for 
the development of chronic sequelae in the liver as a result of HBV infection are 
still unknown, questions have arisen concerning the relationship of HBV-DNA 
to the occurrence, extent, and persistence of viral replication, to the expression of 
antigenic markers, to a specific immune defect, and to HBV-associated carcino-
genesis.. To answer these questions, molecular-biologic studies in conjunction 
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with morphologic investigations are necessary. The determination of the intrahe-
patocytic status of HBV-DNA sequences by DNA extraction, gel electrophore-
sis, and transfer to nitrocellulose filter sheets has limited clinical applicability 
because it requires a substantial amount of properly conserved liver specimen. In 
addition, a positive outcome detected by this technique would reflect only the 
average status of HBV-DNA in total DNA extract contributed by HBV-DNA-
positive and -negative hepatocytes, fibroblasts, and stroma cells. The ability to 
use the in situ hybridization technique in order to characterize HBV-DNA 
sequences in individual cells and in conjunction with the histologic findings, 
gives a new dimension to our effort to understand the pathobiology and persis-
tence of HBV infection. 
The major difficulty of the in situ hybridization method is the requirement that 
target molecules must be retained in a suitable state for hybridization while 
avoiding artefacts. Another limiting factor is the minute quantity of DNA or 
RNA in the cell and the steric hindrance produced by external and internal cell 
boundaries. As shown in this study, we have overcome these difficulties and uti-
lized a biotinylated probe and in situ hybridization in formaldehyde-fixed and 
paraffin-embedded tissue sections to study the intrahepatocytic status of HBV-
DNA sequences. In situ hybridization to detect viral sequences was described 
originally by Brahic and Haase (16) using 3H-labeled probes which take 10-40 
days in developing the grains. Although this handicap has recently been over-
come with the use of 35S-labeled probes (17), the relatively short functional half-
life of the radioisotopes, personnel safety, and isotope disposal problems make it 
desirable to have alternatives. The introduction of enzymatic synthesis of biotin-
labeled polynucleotides by Langer et al. (18) permits a new approach of labeling 
a DNA probe and the development of rapid, sensitive and specific diagnostic 
tests for viral infection such as that due to cytomegalovirus (19). In this study we 
applied the same technique to detect HBV-DNA sequences in liver biopsy speci-
mens. This technique of HBV-DNA detection in liver sections does not require 
fresh-frozen tissue. In addition, the HBV-DNA probe is labeled with a non-
radioactive marker and can be stored for a longer period; it is therefore very 
suitable for routine investigation. The total procedure can be performed within 
24 hours, and numerous samples can be processed simultaneously. Although we 
have not yet performed a comparative study on the sensitivity for detecting 
HBV-DNA sequences in the in situ hybridization assay with a biotin or radio-
isotope labeled probe, excellent specificity was found when the results of the 
technique with a biotinylated probe were compared with those of DNA extrac-
tion, gel electrophoresis, and Southern blotting in liver specimens of 18 patients. 
Three patients with only integrated HBV-DNA, whose sera were HBsAg-nega-
tive but anti-HBc-positive, were also positive for HBV-DNA as detected by the 
in situ hybridization. A false-negative result was found in one patient. This nega-
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tive finding in an HBsAg-positive/HBeAg-positive patient was probably due to 
a sampling error rather than to the insensitivity of this technique, since two other 
patients with negative findings in blot hybridization were found to be positive by 
the in situ hybridization method (table 5.2.1). In another patient, interpretation 
of findings was impossible because of hemosiderosis. Although the current 
results are encouraging, it is still not possible by means of this technique to 
distinguish between the presence of chromosomal and that of episomal DNA. In 
patients with integrated HBV-DNA, grains were found not only in the nucleus 
but also in the cytoplasm of the cells as in other patients who were positive only 
for episomal HBV-DNA. This finding may be due to the formation of DNA­
DNA and DNA-RNA hybrids. 
It is important to note that in the present study HBV-DNA sequences were 
found in the livers of all patients with chronic liver disease and serologic markers 
of HBV infection. In histologic normal liver, however, HBV-DNA was not 
demonstrable despite the presence of anti-HBc and anti-HBs in serum. 
Furthermore, HBV-DNA sequences were also detected in three patients with 
chronic hepatitis without any serologic marker of previous HBV infection. In 
view of the stringency of assay conditions and of the specificity of the method as 
demonstrated in the control study, the positive finding in these three particular 
patients must be considered to indicate the presence of HBV-DNA sequences in 
the liver. The presence of HBV-DNA in livers of some patients without HBV 
serologic markers has also been reported by other investigators using the blot 
hybridization method (20). Although the existence of structural homology of 
nucleic acids between HBV and some types of non-A, non-B transmitting agents 
is possible, as suggested by Wands et al. (21), the clinical significance of our 
finding in these three patients is not yet clear. Further studies remain to clarify 
this. From the foregoing results, however, we may conclude that in situ detection 
of HBV-DNA in formaldehyde-fixed liver tissue sections has clinical value and is 
suitable for routine use. 
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5.2.6 Addendum 
The study of hepatitis В virus DNA detected by in situ hybridization in form­
aldehyde-fixed liver specimens and the relation to serologic markers and histopa­
thologic features in chronic liver disease has now been extended to 89 patients. 
Liver specimens were obtained as paraffin-embedded sections for routine clinical 
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investigation as described for the first 45 patients (section 5.2.2). The biopsies 
from subsequent 44 patients were taken between one and 16 years prior to the 
HBV-DNA assay. 
The histologic findings and serologic data of the 89 patients are shown in table 
5.2.6.1. The patients included 49 males and 40 females ranging in age from 11 to 
78 years. Forty-nine patients were serologically positive for HBsAg. Twelve 
patients who were serologically negative for HBsAg were anti-HBc-positive; 
four of these 12 patients were anti-HBs-negative. In 61 patients with markers of 
HBV infection, histologic studies revealed chronic persistent hepatitis in 11, 
Table 5.2.6.1 Histologic findings of 89 patients 
A Patients wii 
Histology 
CPH 
CAH/C 
P H C 
AH 
Normal/minor 
abnormalities 
Total 
th HBV markers 
anti-HBc 
11 
28 
7 
7 
8 
61 
HBsAg 
9(11) 
24(28) 
5 ( 7 ) 
7(7) 
4( 8) 
49(61) 
anti-HBs 
1(11) 
1(28) 
2(7) 
0 ( 7 ) 
4( 8) 
8(61) 
HBeAg 
6( 8) 
9(17) 
3 ( 6 ) 
^ ( 7 ) 
2 ( 7 ) 
25(45) 
anti-HBe 
0( 8) 
3(17) 
1 ( 6 ) 
4 7) 
И 7) 
6(45) 
В Patients without HBV markers 
Histology η 
CPH 
CAH/C 
P H C 
AH 
6 
13 
4 
5 
Total 28 
CPH : chronic persistent hepatitis 
CAH/C: chronic active hepatitis/cirrhosis 
PHC : primary hepatocellular carcinoma 
AH ¡ acute hepatitis 
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chronic active hepatitis with or without cirrhosis in 28, primary hepatocellular 
carcinoma in seven, acute hepatitis in seven, and histologically normal liver or 
only slight abnormalities in eight. 
Among the 27 patients without HBV serologic markers there were 16 females 
and 11 males. Five patients had chronic persistent hepatitis, chronic active hepati­
tis with or without cirrhosis was found in 13, primary hepatocellular carcinoma 
in four, and acute hepatitis in five patients. None of these patients had chronic 
liver disease due to alcohol abuse or primary billiary cirrhosis. 
As shown in table 5.2.6.2, the findings of HBV-DNA and HBV serologic mar­
kers were concordant in 63 patients (33 patients were positive for HBsAg, six 
patients were anti-HBc-positive with or without anti-HBs, and 24 patients were 
without HBV serologic markers). Of the 42 HBV-DNA-positive patients, seven 
had chronic persistent hepatitis, 23 patients had chronic active hepatitis with or 
without cirrhosis, seven suffered from primary hepatocellular carcinoma, two 
had acute hepatitis, and normal histology (with or without minor abnormalities) 
was found in three patients. 
Table 5.2.6.2 HBV-DNA status as detected by in situ cyto-hybrtdizatton and 
ИBV serologic markers in 89 patients 
Liver histology 
No of HBs- anti- Ground-glass cells/ HBV CPH САН/С PHC AH Norm 
patients Ag HBc Shikata staining DNA 
positivity 
33 
16 
6 
3 
6 
24 
1 
+ 
+ 
-
-
-
-
-
+ 
+ 
+ 
-
+ 
-
-
16 
2 
0 
0 
0 
0(20) 
0 
+ 
-
+ 
+ 
-
-
' ( • · ) 
6 
3 
1 
0 
1 
4 
1 
18 
6 
3 
2 
1 
11 
4 
1 
2 
1 
0 
4 
2 
5 
0 
0 
0 
5 
3 
1 
0 
0 
4 
0 
(total numbers tested in parentheses) 
CPH : chronic persistent hepatitis 
CAH/C : chronic active hepatitis/cirrhosis 
PHC : primary hepatocellular carcinoma 
AH : acute hepatitis 
Norm . normal liver histology or minor abnormalities 
* : interpretation of findings not possible because of hemosiderosis 
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Ground-glass cells or Shikata staining positivity were found in 16 of the 33 
HBsAg-positive and HBV-DNA-positive patients. However, liver specimens 
from two of the 16 HBsAg-positive, HBV-DNA-negative patients were also 
found to be positive for Shikata staining, whereas Shikata staining was negative in 
specimens from HBsAg-negative patients. 
Of the 46 patients without detectable HBV-DNA, 24 patients had no serologic 
markers of HBV infection, 16 patients were HBsAg-positive (CPH: three, 
CAH/Cirrhosis: six, PHC: one, acute hepatitis: five, normal histology: one), 
and six patients were anti-HBc-positive (five of these six patients were anti-HBs-
positive). 
As described previously (section 5.2.3), HBV-DNA was detected in three serolo-
gically negative patients; in one patient interpretation of the findings was not 
possible because of severe hemosiderosis. 
The HBeAg/anti-HBe status and liver histologic findings in the 16 HBsAg-posi-
tive patients without detectable HBV-DNA are shown in table 5.2.6.3. Of the six 
HBeAg-positive patients, three had been biopsied during an acute hepatitis, two 
were suffering from chronic active hepatitis or cirrhosis and one had primary 
hepatocellular carcinoma. Three out of six HBeAg-negative patients had chronic 
active hepatitis or cirrhosis, two had acute hepatitis, and one patient had normal 
liver histology. The HBeAg/anti-HBe status of four patients (three with chronic 
persistent hepatitis, one with liver cirrhosis) had not been tested. 
In this extended study, viral DNA could be detected in liver specimens of 33/49 
HBsAg-positive patients, 6/12 HBsAg-negative patients with HBV markers and 
Table 5.2.6.3 HBeAg/anti-HBe status and liver histologic findings in 16 
HBsAg-positive patients without detectable HBV-DNA 
No. of patients Liver histology 
- HBeAg-positive 
- anti-HBe-positive 
- HBeAg negative/ 
anti-HBe-negative 
- HBeAg/anti-HBe 
not tested 
6 
4 
AH 3, CAH/C 2, PHC 1 
AH 1, CAH/C 2, Normal 1 
A H : acute hepatitis 
C A H / C : chronic active hepatitis or cirrhosis 
C P H : chronic persistent hepatitis 
P H C : primary hepatocellular carcinoma 
AH 1, CAH/C 1 
CPH 3, liver cirrhosis 1 
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in 3/27 patients without HBV serologic markers. In patients with one or more 
HBV serologic markers and histologically proven chronic liver disease, 34/46 
cases (73.9%) had detectable HBV-DNA. In patients with chronic liver disease 
no significant difference was found between the prevalence of HBV-DNA in 
HBsAg-positive (28/38, 73.7%) and that in HBsAg-negative cases with HBV 
markers (6/8, 75.0%). 
These results are in agreement with those reported by Michitaka et al. who found 
HBV-DNA in 78.9% of HBsAg-positive cases with chronic hepatitis (1), 
although other studies, involving smaller number of patients, reported positive 
results with the in situ hybridization technique in only 37-53% of patients (2,3). 
Our data further show that viral DNA sequences are present in liver specimens 
from only a minority of patients with acute type В hepatitis, supporting data on 
the presence of HBV-DNA in serum of such patients (section 3.1). From the 
foregoing findings we may conclude that in situ cytohybridization is a specifi-
cand sensitive technique to detect viral DNA sequences in the livers of patients 
with chronic liver disease due to HBV infection, even under circumstances when 
viral antigens are no longer detectable in serum. However, in acute hepatitis or in 
status where elemination of HBV is in progress, as shown by elevation of serum 
aminotransferase levels or seroconcersion to anti-HBe, HBV-DNA is usually 
not detectable in the liver, although viral antigens are still present in serum. 
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CHAPTER 6 
Hepatitis В virus DNA 
in peripheral blood lymphocytes 
Summary 
By means of Southern blot analysis, the presence and the state of hepatitis В virus 
DNA (HBV-DNA) were examined in peripheral blood lymphocytes of 51 
patients with HBV-related or non-hepatitis В chronic liver diseases. Results 
show that HBV-DNA sequences may be present in lymphocytes of patients with 
current HBV infection as well as in lymphocytes of patients with previous HBV 
infection. Viral DNA in these cells is present as extrachromosomal forms, 
although these forms are distinct from those found in the liver or in serum. The 
biologic and clinical significance of these viral DNA sequences is still unknown, 
however. Since HBV-DNA sequences can frequently be found in lymphocytes 
obtained from patients without HBV-DNA in serum or from patients with con­
valescent antibodies, we believe that HBV-DNA sequences in peripheral blood 
lymphocytes do not represent viral particles or infectious agents. In addition, no 
relationship with histologic manifestations of the disease was found. 
6.1 Introduction 
Since the discovery of the Australia antigen (HBsAg) by Blumberg et al. in 1965 
(1), there have been great advances in basic and clinical research into hepatitis В 
virus infection. Application of molecular genetic or nucleic acid probe techniques 
to problems of HBV infection has markedly improved diagnostic medicine, and 
our knowledge of the biology of HBV, and of the interaction of HBV with its 
natural host cells. The hepatitis В virus contains DNA as well as a surface antigen 
(HBsAg), a core antigen (HBcAg), a viral DNA polymerase and a protein kinase. 
Besides HBcAg, the nucleocapsid contains a cryptic form of hepatitis 'e' antigen 
(HBeAg), and a peptide which is covalently bound to viral DNA (2). During the 
acute phase of hepatitis B, a high titer of HBsAg is usually found in serum. Per­
sistence of HBsAg for more than six months is often followed by development of 
chronic hepatitis (3). Both detectable HBeAg and HBV-DNA in serum were 
claimed to be reliable markers of active virus replication in the liver (4). Loss of 
HBeAg and HBV-DNA, seroconversion to anti-HBe, and loss of HBsAg with 
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seroconversion to anti-HBs indicate clearance of the disease and complete elimi­
nation of HBV. However, assessment of patients following HBV infection is 
complicated by viral genomes that can be present either as free virus in the cytop­
lasm of hepatocytes or as integrated into the cellular genome. Integration of 
HBV-DNA into the hepatocyte genome may lead to persistence of HBs antige-
nemia and is correlated with the development of hepatocellular carcinoma (5). 
Recently, it has been reported that HBV-DNA sequences may also be present in 
white blood cells of patients with HB V-associated chronic liver disease (6-9). 
The present study aimed to investigate the presence of HBV-DNA in peripheral 
blood lymphocytes obtained from patients with various serologic and histologic 
manifestations of hepatitis В virus infection, and to study the relationship 
between the presence and state of HBV-DNA in the liver and in lymphocytes. 
6.2 Patients and methods 
Peripheral blood lymphocytes obtained from 51 patients with chronic liver 
disease were analyzed for the presence of HBV-DNA sequences; samples were 
obtained from patients with HBV serologic markers (n=45), and from patients 
with chronic liver diseases without HBV serologic markers (n=6). 
The technique for isolation of lymphocytes, extraction of DNA, and Southern 
blot analysis are described in chapter 2. 
Contamination of the lymphocyte pellet by serum-associated HBV-DNA was 
excluded by the negative findings during spot hybridization of the last wash of 
lymphocytes isolated from the blood of patients (n=2) with HBV-DNA in 
serum. 
To determine the state of HBV-DNA in these cells, endonuclease digestion was 
performed with H I N D III restriction enzyme, and with EcoRl if necessary. 
In some cases, the HBV-DNA status in lymphocytes was compared with that in 
hepatocytes. 
6.3 Results 
The results of HBV-DNA detection in peripheral blood lymphocytes obtained 
from 51 patients, and the relation to HBV serologic markers are shown in table 
6.1. 
In patients positive for both HBsAg and HBeAg (group I), HBV-DNA could be 
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Table 6.1 Presence of hepatitis В virus DNA in peripheral blood lymphocytes 
and reUtion to HB V serologic markers and serum HB V-DNA 
Group 
I 
II 
III 
IV 
V 
HBV serologic 
markers (+) 
HBsAg 
HBeAg 
anti-HBc 
HBsAg 
anti-HBe 
anti-HBc 
anti-HBc 
(anti-HBe posi­
tive or negative) 
anti-HBc 
anti-HBs 
No HBV marker 
η 
11 
14 
8 
12 
6 
Lymphocyte (%) 
HBV-DNA (+) 
7 
7 
4 
7 
0 
(63.6) 
(50.0) 
(50.0) 
(58.3) 
( 0 ) 
serum 
HBV DNA 
8/10 
1/14 
0/8 
0/12 
0/6 
(%) 
(80.0) 
(7 .1) 
( 0 ) 
( 0 ) 
( 0 ) 
detected in 7/11 cases, while serum HBV-DNA was positive in eight of the ten 
patients including four patients with HBV-DNA in the lymphocytes. 
In patients positive for HBsAg and anti-HBe, anti-HBe, group II, seven out of 
14 samples tested were positive for HBV-DNA in lymphocytes, whereas serum 
HBV-DNA was positive in only one patient. In samples that had been obtained 
from patients with anti-HBc as the sole marker (group III, total eight patients), 
HBV-DNA was positive in four patients. None of these eight patients was posi­
tive for serum HBV-DNA. 
In patients positive for both anti-HBc and anti-HBs, group IV, viral DNA could 
be detected in lymphocytes of 7/12 cases. Serum HBV-DNA was negative in all 
cases. N o HBV-DNA sequences could be detected in lymphocytes obtained 
from any of the six patients without HBV serologic markers (group V). 
Table 6.2 shows the HBV-DNA status in peripheral blood lymphocytes of the 48 
patients studied by means of Southern blot analysis after H I N D III digestion. In 
all groups of patients with HBV serologic markers, HBV-DNA sequences in 
lymphocytes could be absent, could appear as high molecular weight forms or as 
3.2 kb and low molecular weight intermediate viral DNAs. After digestion with 
EcoRl restriction enzyme, high molecular weight banding patterns of viral 
DNAs were converted to a 3.2-kb band in all but one patient (table 6.3). In two 
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Table 6.2 H BV-DNA status in peripheral blood lymphocytes after HIND III 
digestion 
HBV markers η 
(+) 
HBV-DNA sequences in Southern blot analysis 
HMW 3.2kb/I HMW +3.2/1 HBV-DNA-
negative 
HBsAg 
HBeAg 
anti-HBc 
HBsAg 
anti-HBe 
anti-HBc 
anti-HBc 
(anti-HBe 
pos or neg) 
anti-HBc 
anti-HBs 
no HBV 
markers 
11 
14 
11 
0 
0 
0 
HMW : bands of high-molecular weight regions in the Southern blot. 
3.2/1 : 3.2 kb band and/or intermediate D N A sequences 
patients, low molecular weight viral DNA sequences were present in lympho­
cytes; these low molecular weight viral DNAs were seen after H I N D III as well 
after EcoRl digestion. Table 6.4 demonstrates a comparison of the HBV-DNA 
status in lymphocyte-derived DNA and DNA extracted from liver tissue in eight 
HBsAg-positive patients with chronic liver disease. 
6.4 Discussion 
In this study we demonstrated that HBV-DNA sequences are present in periphe­
ral blood lymphocytes of the majority of patients with hepatitis В virus-asso­
ciated liver disease. In lymphocytes from seven of the 12 patients positive for 
both anti-HBc and anti-HBs, HBV-DNA could be detected as well. Since HBV-
DNA sequences were absent from lymphocytes obtained from patients with 
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non-hepatitis В chronic liver disease, the aforementioned findings may be consi­
dered specific for patients with current or previous HBV infection. HBV con­
tains a circular DNA genome with a length of 3,200-3,300 nucleotide pairs (kb), 
and this genome has one cutting site for the restriction enzyme EcoRl. In hepa-
tocytes, HBV-DNA can be found either integrated into the cellular DNA or as 
Table 6.3 HBV-DNA status in peripheral blood lymphocytes after HIND III 
and EcoRl digestion 
HBV markers 
( + ) 
HBsAg 
HBeAg 
anti-HBc 
HBsAg 
anti-HBe 
anti-HBc 
anti-HBc 
(anti-HBe pos or neg) 
anti-HBc 
anti-HBs 
no HBV 
markers 
Type of digestion 
H I N D III 
3.2/1 
3.2 
HMW 
HMW/I 
neg 
neg 
HMW 
HMW 
HMW 
HMW/3.2 
HMW/3.2 
HMW/3.2 
neg 
neg 
neg 
САН 
СРН 
Gir 
РНС 
HMW 
3.2/1 
EcoRl 
3.2/1 
chronic active hepatitis 
chronic persistent hepatitis 
liver cirrhosis 
primary hepatocellular carcinoma 
high-molecular weight HBV-DNA sequences 
3.2-kb band and/or intermediate viral D N A sequences 
Histology 
P H C 
3.2 
3.2 
HMW/I 
neg 
neg 
3.2 
3.2 
3.2 
3.2 
3.2 
3.2 
neg 
neg 
neg 
Gir 
Gir 
Gir 
САН 
P H C 
Gir 
unknown 
САН 
СРН 
unknown 
unknown 
С А Н 
P H C 
normal 
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Table 6.4 Comparison of HBV-DNA status in lymphocyte-derived DNA and 
DNA extracted from liver tissue of eight HBsAg-positive patients with chronic 
liver disease 
N o 
1 
2 
3 
4 
5 
6 
7 
8 
Histology 
PHC (*) 
САН 
CPH 
САН 
Cir 
Cir 
Cir 
САН 
HBeAg 
+ 
+ 
+ 
+ 
-
-
-
-
Lymphocytes 
after H I N D III di 
21.8 kb 
20.0 kb 
5.2 kb 
neg 
neg 
3.2 kb 
5.2 kb 
21.8 
neg 
Liver 
igestion 
3.2 kb/I 
3.2 kb/I 
3.2 kb 
3.2 kb 
3.2 kb 
I 
nt 
3.2 kb 
PHC : primary hepatocellular carcinoma 
CPH : chronic persistent hepatitis 
САН : chronic active hepatitis 
Cir : liver cirrhosis 
I : intermediate viral D N A sequences 
nt : not tested 
(:: ) in the hepatocellular carcinoma tissue of this patient viral D N A was present in the integra­
ted form; bands were noted at positions 16, 11, 7.5 and 5.9 kb. 
free or episomal forms of viral DNA. Since HBV-DNA has no cutting site for 
the restriction enzyme H I N D III, digestion with this enzyme would result in 
appearance of integrated HBV-DNA during Southern blot analysis as discrete 
band(s) at positions exceeding 3.2 kb, while free HBV-DNA would show up as a 
3.2-kb band. After treatment with H I N D III, HBV-DNA sequences in lympho­
cytes of the majority of patients were found as discrete bands at positions higher 
than 3.2 kb (table 6.2). However, after digestion with EcoRl, HBV-DNA 
sequences were found at the 3.2-kb position (table 6.3), except in one patient. 
These findings indicate that HBV-DNA sequences in blood lymphocytes repre­
sent extrachromosomal viral DNA oligomers - relaxed circular head-to-tail oli­
gomers of the intact viral genome - rather than integrated viral DNA sequences. 
This viral DNA is distinct from integrated DNA in the liver and from episomal 
forms of HBV-DNA found in liver cells or in serum (table 6.4). These findings 
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H E H E H E H E 
А В С D 
Figure 6.1: Autoradiogram ofnP-labeled nick translation product of HBV-DNA probe hybridi­
zed to lymphocyte DNA and analyzed by the Southern blotting technique. Lymphocyte DNA 
was prepared from patients with HBV associated liver diseases. In each Une, 20 ßg of lymphocyte 
DNA was electrophoresed in 0.5% agarose gel and blotted onto nitrocellulose filter sheets as 
described in section 2.3.1, chapter 2. 
H: HIND Ill-digestion; E: EcoRI-digestion. 
Panel A: lymphocyte DNA prepared from an anti-HBc- and anti-HBs-positive patient with chro-
nic active hepatitis, B: from a patient with liver cirrhosis and anti-HBc as the sole HB V serologic 
marker, C: from a HBsAg-positive/anti-HBe-positive patient with liver cirrhosis, D: from a 
HBsAg-positive/HBeAg-posttive patient with primary hepatocellular carcinoma. 
The position of the 3.2 kb band (representing linear double- stranded HBV-DNA) is indicated. 
are in accordance with those reported by Yoffe et al. (10). Nevertheless, Bréchot 
and co-workers (7) considered the high-molecular weight patterns of HBV-
DNA in peripheral blood lymphocytes to be integrated forms of HBV-DNA 
sequences. Moreover, they reported that the integration patterns during Sou-
thern blot analysis of white blood cell DNA are similar to those obtained during 
DNA analysis from livers or tumors of the same patients (11). They have, there-
fore, suggested that a finding of high-molecular weight HBV-DNA sequences in 
white blood cell-DNA preparations reflects the presence of integrated HBV-
DNA in the liver (11). 
As the mechanism employed by HBV to gain entry into the hepatocyte is still not 
well understood, the mechanism to explain the existence of HBV-DNA se-
quences in blood lymphocytes also remains to be determined. Since the presence 
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of HBV-DNA in blood lymphocytes cannot be correlated with the presence of 
HBV-DNA in serum or with episomal forms of HBV-DNA in the liver, adsorp­
tion of HBV from serum or liver followed by penetration into the cytoplasm 
through membrane fusion of viral and cellular plasma membranes or endocytosis 
is unlikely. Although HBV-DNA sequences in peripheral blood lymphocytes 
were usually found as intact HBV genomes, showing up as a 3.2-kb band during 
Southern blot analysis of DNA after EcoRl digestion, a heterogeneous smear of 
2.0 to 3.2 kb representing intermediate viral DNAs could also be detected. 
However, as HBV-DNA sequences were frequently found in lymphocytes from 
patients with undetectable HBV-DNA in serum and in patients who had cleared 
HBV (anti-HBc/anti-HBs positive), we believe that the HBV-DNA in periphe­
ral blood lymphocytes does not represent viral particles or infectious agents. 
Nevertheless, further studies are needed to clarify the biologic and clinical signi­
ficance of the presence of HBV-DNA sequences in white blood cells. From the 
present study, we can, however, conclude that the presence of HBV-DNA 
sequences in peripheral blood lymphocytes is a frequent finding in patients with 
current or previous HBV infection. This viral DNA represents extrachromoso­
mal viral DNA oligomers as indicated by Lie-Injo et al. and Yof f e et al. (6,10). In 
addition, no correlation was found between the presence of HBV-DNA sequen­
ces in lymphocytes and histologic manifestations in the livers of these patients. 
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Summary 
In chapter 1 (General introduction), the structure and replication of hepatitis В 
virus (HBV) as well as the serologic and clinical manifestations of HBV infection 
are outlined. HBV (Dane particle) with a diameter of 42 nm contains the viral 
DNA, viral enzymes and antigens including the surface antigen (HBsAg). This 
latter antigen can also be found in serum as, non-infectious, spherical or tubular 
forms with an average diameter of 22 nm. The HBV genome consists of a par­
tially double-stranded DNA molecule, and the long (minus) strand contains four 
open reading frames (C, P, S and X) coding for viral proteins. HBV infection is 
transmitted by blood or blood products, but transmission via other body fluids 
or excretions is also possible. Various courses of liver disease may develop after 
HBV infection, probably due to cell-mediated immune mechanisms. Approxi­
mately 5-10% of adult patients develop a chronic HBsAg carrier state following 
infection with HBV which resulted in acute hepatitis. The rates of seroconver­
sion to anti-HBs and to anti-HBe in these chronic HBsAg carriers are up to 8% 
and 25%, respectively. Chronic HBsAg carriers have an increased risk of pri­
mary hepatocellular carcinoma. Extrahepatic manifestations of HBV infection 
are not uncommon. Specific therapy for HBV-related liver disease is not yet 
available, and treatment to eliminate infectious agents with such agents as interfe­
rons or combinations of steroids and anti-viral agents is still under investigation. 
In chapter 2, the principles of techniques for detection of HBV-DNA sequences 
in serum, tissues and cells are described. As D N A in the double-helix form can be 
separated into single strands by heat treatment, and because these single-stranded 
DNA molecules can be reassociated under appropriate conditions with a labeled, 
specific complementary DNA probe, it is possible to detect HBV-DNA sequen­
ces in various preparations. 
In chapter 3, the results of HBV-DNA detection in serum, obtained from 388 
patients with various HBV serologic markers and from 80 HBV-negative con­
trols, are presented (section 3.1). The findings show a strong correlation between 
the presence of HBV-DNA and of HBeAg in serum, irrespective of histologic or 
clinical manifestations of liver disease. However, disappearance of HBeAg from 
serum is not always associated with HBV-DNA clearance. In approximately 
15% of anti-HBe-positive chronic HBsAg carriers, viral DNA could still be 
detected in serum. In addition, HBV-DNA was detected in one patient with anti-
HBc as the sole serologic marker of infection. HBV-DNA is not detectable in 
serum of patients positive for both anti-HBc and anti-HBs. 
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In order to determine whether sera obtained from apparently healthy blood 
donors, negative for HBsAg, could harbor HBV-DNA, entailing a risk of trans­
mission of HBV, we analyzed blood samples drawn from 1,423 potential blood 
donors for the presence of viral DNA (section 3.2). None of these specimens was 
found positive for HBV-DNA and none of the donors developed clinically mani­
fest hepatitis. No posttransfusion hepatitis was noted in any of the patients recei­
ving blood from these donors. We conclude, therefore, that in a community with 
a low prevalence of HBV infection, routine testing for HBsAg of sera from appa­
rently healthy donors is effective in preventing posttransfusion hepatitis due to 
HBV. Routine screening with the much more sensitive, but time consuming, 
hybridization technique is, therefore, not justified. 
The results of HBV-DNA detection in serum and its relation to IgM anti-HBc 
are presented in section 3.3. IgM anti-HBc was detected in high titers in patients 
with acute type В hepatitis and was also present during the 'window period'. This 
marker was also found, though less frequently, when other markers of HBV 
infectivity, including HBV-DNA, were absent from chronic hepatitis В patients 
as well as from 'healthy carriers'. The assay for IgM anti-HBc is useful for estab­
lishing the diagnosis of recent type В hepatitis, especially in cases when HBsAg 
has been cleared from serum, or when reactivation of hepatitis in a chronic 
HBsAg carrier has to be differentiated from other causes of liver injury, such as 
other viral agents or alcohol. 
In section 3.4, the results of detection of serum pre-S proteins and its relation to 
serum HBV-DNA and HBV serologic markers are shown. Pre-S 1- and pre-S2-
proteins were more often found in HBV-DNA-positive than in HBV-DNA 
negative HBsAg carriers, regardless of liver histologic findings. In HBV-DNA-
negative HBsAg carriers, pre-S proteins were found irrespective of serum 
HBeAg/anti-HBe or serum aminotransferase status. We could not demonstrate a 
relation between the pre-S proteins and liver disease activity on a histologic basis. 
These findings suggest that, despite the strong correlation between pre-S pro­
teins, HBeAg and HBV-DNA in serum, the presence of pre-S proteins is not 
equivalent to HBV-DNA as a marker of viral replication and infectivity. The 
appearance of anti-pre-S2 antibodies seems to have no predictive value for clear­
ance of HBV and of liver disease. 
The value of HBV-DNA determination in a patient treated with immunosup­
pressive agents is illustrated by means of a case history (section 3.5). 
Results of a cross-sectional survey on the prevalence of HBV serologic markers 
and of HBV-DNA in sera of mentally retarded patients and part of the staff 
members of two institutions are presented in chapter 4. In one institution for 
male mentally retarded (section 4.1), 62.1% of 493 male residents had serologic 
evidence of HBV infection, while 16.7% of residents with markers of HBV infec-
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tion were HBsAg-positive. HBV-DNA was found in 24% of HBsAg carriers (all 
positive for HBeAg). Among residents who were under 15 years of age at entry, 
those with Down's syndrome were more often carriers of HBsAg than other 
mentally retarded residents. In addition, residents with Down's syndrome more 
often had serum HBV-DNA than residents with other forms of mental retarda­
tion. A young age at entry was recognized as an important factor with regard to 
the prevalence of HBV markers. From the longitudinal studies it appeared that 
loss of HBV-DNA from serum indicated imminent loss of HBeAg and normali­
zation of alanine aminotransferase values. 
In another institution (section 4.2), studies were performed in a population of 
667 mentally handicapped, both males and females, and in 676 staff members. A 
young age on admission was found to be one of the important factors in the 
development of the chronic HBsAg carrier state in females. The well-known 
higher prevalence of the HBsAg carrier state in subjects with Down's syndrome 
appeared to be restricted to males. Markers indicative of viral replication, HBeAg 
and HBV-DNA, were also more prevalent in male than in female residents with 
Down's syndrome or other mentally retarded residents. These findings indicate 
that the phase of active viral replication is prolonged in male HBsAg carriers with 
Down's syndrome. However, only 66.7% of HBV-DNA positive and 26.2% of 
HBsAg-positive residents had abnormal serum alanine aminotransferase values. 
These results indicate that male HBsAg-positive residents with Down's syn­
drome are the main source of HBV infection in institutions for the mentally 
retarded, and that determination of alanine aminotransferase values is not very 
useful in identifying those HBsAg carriers capable of transmission the infection. 
In chapter 5, section 5.1, the results of HBV detection in liver biopsy specimens 
by means of a hybridization technique and Southern blot analysis are presented. 
Episomal forms of HBV-DNA were detected in the majority of HBsAg/ 
HBeAg-positive patients and in approximately 50% of HBsAg/anti-HBe-posi-
tive patients. In liver tissues of HBsAg-negative patients, episomal forms of 
HBV-DNA were not detectable. In addition, serum HBV-DNA was negative in 
patients without episomal HBV-DNA in the liver. Determination of episomal 
forms of HBV-DNA in the liver therefore represents the most sensitive method 
to acquire knowledge about complete elimination of HB virus from the body, 
especially in anti-HBe positive HBsAg carriers. A strong correlation was observ­
ed between the presence of integrated HBV-DNA sequences in the liver and 
primary hepatocellular carcinoma. However, integrated HBV-DNA was also 
found in chronic HBsAg-positive carriers without this tumor, and even in 
HBsAg-negative subjects. The clinical significance of the presence and state of 
viral DNA in the liver is discussed. To examine the relationship of hepatitis В 
virus DNA sequences in the liver with histopathologic features and antigenic 
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markers, we have also determined the hepatocytic status of viral DNA by in situ 
cyto-hybridization in formaldehyde-fixed liver tissue sections with a biotinyla-
ted probe (section 5.2). The results were compared retrospectively with HBV 
serologic markers and histopathologic features, including the presence of 
ground-glass cells or Shikata staining positivity. The specificity of this in situ 
detection of HBV-DNA was proven to be excellent in a double-blind control 
study in patients in whom liver HBV-DNA was also determined by DNA 
extraction, gel electrophoresis and the Southern blot technique. From this study, 
it is concluded that in situ detection of HBV-DNA in formaldehyde-fixed liver 
sections has clinical value and is suitable for routine use. 
The results of HBV-DNA detection in peripheral blood lymphocytes of patients 
with or without HBV serologic markers are described in chapter 6. HBV-DNA 
sequences were present in peripheral blood lymphocytes of the majority of 
patients with HBV-associated liver disease, and in more than 50% of patients 
positive for anti-HBc and anti-HBs. Since HBV-DNA sequences were absent 
from lymphocytes obtained from patients with non-hepatitis В chronic liver dis­
ease, the afore-mentioned finding can be considered specific for patients with 
ongoing or previous HBV infection. These viral DNAs represent extrachromo­
somal viral DNA oligomers or intermediate viral DNAs and do not represent 
viral particles or infectious agents. However, the biologic and clinical significance 
as well as the mechanism accounting for the presence of HBV-DNA sequences in 
blood lymphocytes remain to be determined. 
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Samenvatting 
In hoofdstuk 1 (Inleiding) worden de structuur, wijze van vermenigvuldiging, 
alsmede de serologische en klinische uitingsvormen van infectie met het hepatitis 
В virus (HBV) beschreven. Het hepatitis В virus (Dane-partikel) heeft een dia­
meter van 42 nm en bevat het virus-DNA, virale enzymen en virale antigenen 
waaronder het oppervlakte-antigeen (HBsAg). Dit laatste antigeen kan ook in 
serum worden aangetroffen als niet-infectieuze, bol- of staafvormige particles 
met een gemiddelde diameter van 22 nm. Het genetisch materiaal van het HBV 
bestaat uit een gedeeltelijk dubbelstrengs DNA-molecuul, waarbij in de lange 
(negative) keten vier z.g. open reading frames (C,P,S en X), gebieden die de code 
voor de virale eiwitten bevatten, kunnen worden onderscheiden. Infectie met het 
HBV vindt doorgaans plaats door contact met bloed of bloedprodukten, hoewel 
besmetting door lichaamsvloeistoffen of excreta ook mogeijk is. Verschillende 
vormen van leverziekte kunnen optreden na infectie met het HBV, waarbij het 
beloop waarschijnlijk in belangrijke mate bepaald wordt door cellulaire afweer­
mechanismen. Circa 5-10% van de volwassen patiënten wordt na een acute hepa-
titis chronisch drager van het virus. Het percentage chronische dragers wat een 
seroconversie naar anti-HBs- en anti-HBe-antistoffen venoont, bedraagt naar 
schatting respectievelijk maximaal 8 en 25% per jaar. Chronische dragers van het 
virus hebben een aanzienlijk grotere kans op het ontstaan van een primair lever-
celcarcinoom. Extrahepatische afwijkingen als gevolg van een HBV infectie wor-
den niet zelden waargenomen. Tot nu toe is geen specifieke behandeling voor 
leverziekte ten gevolge van HBV-infectie mogelijk gebleken. Toch hebben de 
huidige pogingen om het infecteuze agens te elimineren met behulp van inter-
feronen al dan niet in combinatie met antivirale middelen bij een deel van de 
behandelde patiënten succes gehad. 
In hoofdstuk 2 worden de principes van de technieken om HBV-DNA sequen-
ties in serum, weefsels of cellen aan te tonen uiteengezet. Aangezien DNA, aan-
wezig in de dubbele helixvorm, door verhitting kan worden gesplitst in enkel-
voudige ketens, en deze enkelvoudige ketens onder bepaalde condities herenigd 
kunnen worden met een gelabelde complementaire DNA-probe, is het mogelijk 
DNA-sequenties in diverse weefsels op te sporen. 
In hoofdstuk 3 worden de resultaten van de bepaling van hepatitis В virus DNA 
in serummonsters van 388 patients met diverse HBV serummarkers en van 80 
controlepatienten besproken (3.1). Er blijkt sprake van een nauwe correlatie tus-
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sen de aanwezigheid van HBV-DNA en HBeAg in serum, dit ongeacht de histo-
logische of klinische kenmerken van leverziekte. Het verdwijnen van het HBeAg 
uit het serum blijkt evenwel niet in alle gevalllen gepaard te gaan met het verdwij-
nen van HBV-DNA: bij circa 15% van de anti-HBe positive chronische dragers 
van het HBsAg kan nog steeds viraal DNA in het serum worden aangetoond. 
Tevens konden wij bij herhaling HBV-DNA aantonen in serummonsters van een 
patient met anti-HBc als enige serologische marker. Daarentegen werd geen 
viraal DNA meer gevonden nadat anti-HBc- en anti-HBs-antistoffen waren 
verschenen. 
Om vast te stellen of in sera afkomstig van gezonde HBsAg-negatieve bloed-
donoren virus DNA aanwezig kon zijn, met kans op overdracht van de infectie, 
werden serummonsters verkregen van 1.423 potentiële donoren onderzocht op 
HBV-DNA (deel 3.2). In geen van deze monsters kon viraal DNA worden aan-
getoond en bij geen van de donoren is een hepatitis ontstaan. Evenmin is sprake 
geweest van een post-transfusie hepatitis bij patiënten die bloed afkomstig van 
deze donoren hebben ontvangen. Wij kunnen uit deze resultaten de conclusie 
trekken dat in een populatie met een lage prevalentie van HBV infectie, routine-
gewijs onderzoek van serum op de aanwezigheid van HBsAg effectief is om een 
post-transfusie hepatitis door HBV te voorkomen. Routinematig onderzoek met 
de gevoeligere, maar tijdrovende, hybridisatietechniek is dan ook niet geïndi-
ceerd. 
De resultaten van HBV-DNA bepaling in serum en de relatie met de aanwezig-
heid van IgM anti-HBc worden besproken in deel 3.3. Zowel bij patiënten met 
een acute hepatitis В infectie als tijdens de zogenaamde window-period zijn hoge 
titers IgM anti-HBc aantoonbaar. Deze antistoffen kunnen eveneens, zij het in 
veel lagere titer, worden gevonden bij patiënten met chronische hepatitis of bij 
'gezonde dragers' bij wie andere serum-merkstoffen wijzende op infectiositeit 
ontbreken. Bepaling van IgM anti-HBc is van belang voor het stellen van de diag-
nose acute hepatitis В infectie, en wel met name in de volgende situaties: a) wan­
neer tijdens een acute hepatitis het HBsAg niet meer aantoonbaar is; b) de moge­
lijkheid bestaat dat patient reeds drager was van het HBsAg en zich presenteert 
met een reactivatie van de infectie; c) onduidelijk is of een ander virus dan wel 
toxische stof oorzaak is van de leverbeschadiging. 
In deel 3.4 worden de resultaten van de bepaling van pre-S eiwitten in serum­
monsters en de relatie met de aanwezigheid van andere serum merkstoffen en 
HBV-DNA besproken. Ongeacht de histologische bevindigen bij leveronder-
zoek bleken zowel pre-Si als pre-S2 eiwitten vaker aanwezig te zijn bij HBV-
DNA positieve dan bij HBV-DNA negatieve dragers van het virus. Deze pre-S 
eiwitten bleken evenwel ook aantoonbaar bij de meeste HBV-DNA-negatieve 
patiënten, dit ongeacht de HBeAg/anti-HBe status of serum transaminasewaar-
den. Er bleek geen verband te bestaan tussen aanwezigheid van pre-S eiwitten en 
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activiteit van de leverontsteking. Deze bevindingen wijzen er op dat ondanks de 
nauwe correlatie tussen de aanwezigheid van pre-S eiwitten, HBeAg en HBV-
DNA in serum, aan de aanwezigheid van pre-S eiwitten niet dezelfde betekenis 
mag worden toegekend als aan die van HBV-DNA, welke laatste een betrouw-
bare merkstof is voor virus-vermenigvuldinging en infectiositeit. Het verschijnen 
van anti-pre S2-antisoffen lijkt geen voorspellende waarde te hebben voor ver-
dwijnen van het virus of van de leverziekte. 
In deel 3.5 wordt aan de hand van een ziektegeschiedenis het belang van de bepa-
ling van het HBV-DNA bij de patient die behandeld gaat worden met immuun-
suppressiva geïllustreerd. 
In hoofdstuk 4 worden de resultaten van een cross-sectional onderzoek naar de 
aanwezigheid van serologische merkstoffen van hepatitis В infectie en van HBV-
DNA in serummonsters van geestelijk gehandicapten besproken. In dit onder­
zoek participeerden twee instituten voor geestelijk gehandicapten. 
In het eerste instituut (deel 4.1), waarin uitsluitend mannelijke bewoners verble­
ven, bleek 62,1 % van de bewoners een of meerdere HBV-merkstoffen te hebben, 
en 16,7% van degenen met merkstoffen bleek HBsAg-positief te zijn. HBV-
DNA bleek aanwezig in 24% van de serummonsters afkomstig van deze dragers, 
en werd uitsluitend aangetroffen in HBeAg-positieve sera. In de groep bewoners 
die bij opname in het instituut jonger was dan 15 jaar, bleken bewoners met het 
Down-syndroom vaker HBsAg-positief dan overige bewoners. Ook werd in 
serum van bewoners met het Down-syndroom vaker HBV-DNA gevonden dan 
bij bewoners zonder Down-syndroom. Een jeugdige leeftijd bij opname bleek 
een belangrijke factor te zijn met betrekking tot de prevalentie van HBV merk­
stoffen. Uit het longitudinaal onderzoek kwam naar voren dat het verdwijnen 
van HBV-DNA uit het serum een belangrijke aanwijzing is dat binnen afzienbare 
tijd ook het HBeAg zal gaan verdwijnen en dat de serumtransaminasen tot nor­
male waarden zullen terugkeren. 
In het tweede instituut (deel 4.2) werden 667 geestelijk gehandicapte mannelijke 
en vrouwelijke bewoners en 676 stafleden onderzocht. Een jeugdige leeftijd bij 
opname bleek een belangrijke factor voor het ontstaan van chronisch HBsAg-
dragerschap, doch dit bleek uitsluitend het geval voor vrouwelijke bewoners. De 
reeds langer bekende hogere prevalentie van HBsAg-positiviteit onder patiënten 
met het Down-syndroom werd in deze groep uitsluitend onder mannelijke 
bewoners vastgesteld. Merkstoffen wijzende op infectiositeit, HBeAg en HBV-
DNA, werden frekwenter aangetroffen onder mannelijke bewoners met het 
Down-syndroom dan onder vrouwelijke Down-syndroom patiënten of bewo-
ners met andere vormen van retardatie. Deze bevindigen wijzen er op dat de 
periode waarin sprake is van actieve virusvermenigvuldiging bij mannelijke 
patiënten met het Down-syndroom verlengd is. Slechts 66,7% van de HBV-
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DNA-positieve en 26,6% van de HBsAg-positieve bewoners bleek verhoogde 
serum transaminasewaarden te hebben. Uit deze bevindingen kan de conclusie 
worden getrokken dat binnen instituten voor geestelijk gehandicapten, manne-
lijke HBsAg-positive bewoners met het Down-syndroom de belangrijkste bron 
van HB V-infectie vormen en dat bepaling van serum transaminasen, met het oog-
merk infectieuze HBsAg-dragers op te sporen, van weinig nut is. 
In hoofdstuk 5, deel 5.1, worden de resultaten van de HB V-bepaling met behulp 
van een hybridisatietechniek en analyse met de methode volgens Southern 
besproken. Bij de meeste HBsAg/HBeAg-positieve-, en bij ca. 50% van de 
HBsAg/anti-HBe-positieve patiënten werden extrachromosomale (=episomale) 
vormen van HBV-DNA aangetroffen. Bij patiënten zonder deze episomale 
HBV-DNA-vormen in de lever was geen virus DNA in serum aantoonbaar. 
Deze resultaten wijzen er op dat onderzoek naar de aanwezigheid van extrachro-
mosomale virus-DNA-vormen in de lever de meest gevoelige methode is om 
geïnformeerd te worden over de vraag of het virus uit het lichaam is verdwenen. 
Deze vraag zal zich met name voordoen bij de follow-up van de anti-HBe-posi-
tieve drager van het HBsAg. Er bleek een nauwe relatie te bestaan tussen de aan-
wezigheid van geïntegreerde HBV-DNA-sequenties in de lever en het primair 
levercelcarcinoom. Geïntegreerd HBV-DNA bleek evenwel ook aanwezig te 
kunnen zijn in leverweefsel van chronische HBsAg-dragers zonder deze tumor, 
alsook in de lever van HBsAg-negatieve personen. De klinische betekenis van de 
aanwezigheid van virus DNA en van de vorm waarin dit in de lever kan worden 
gevonden, wordt besproken. 
Het verband tussen de aanwezigheid van virus DNA sequenties in de lever, sero-
logische merkstoffen en histologische afwijkingen werd voorts bestudeerd met 
een in situ cytohybridisatie techniek (deel 5.2). Bij deze techniek wordt gebruik 
gemaakt van een aan biotine gelabelde HBV-DNA-probe, en kunnen virale 
DNA sequenties worden aangetoond in weefsel wat in formaline is gefixeerd. De 
bevindingen werden retrospectief vergeleken met de serologische gegevens als-
mede met gegevens verkregen uit histologisch onderzoek van de lever. Laatst-
genoemde onderzoek bestond onder meer uit onderzoek naar de aanwezigheid 
van z.g. ground-glass cellen en de kleuring op HBsAg-bevattende cellen volgens 
Shikata. Uit een dubbel-blind onderzoek, waarin met zowel de in situ hybridisa-
tie-techniek als met de Southern blot-methode lever-DNA werd onderzocht, is 
naar voren gekomen dat de in situ hybridisatie-methode voldoende specifiek is. 
De resultaten uit dit onderzoek laten zien dat de detectie van HBV-DNA in 
weefsel wat in formaline is gefixeerd met behulp van de in situ hybridisatietech-
niek van klinisch belang is en op routine-basis kan worden uitgevoerd. 
In hoofdstuk 6 zijn de resultaten beschreven van de detectie van HBV-DNA in 
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perifere lymphocyten verkregen uit bloedmonsters van patiënten die al dan niet 
HBV-serologische merkstoffen bezaten. HBV-DNA sequenties bleken aanwe-
zig bij de meeste patiënten met chronische leverziekte ten gevolge van HBV-
infectie, doch ook bij ca. 50% van de patiënten met anti-HBc- en anti-HBs-anti-
stoffen konden virus-DNA-sequenties in de lymphocyten worden aangetoond. 
Aangezien deze DNA-sequenties ontbraken in lymphocyten van HBV-nega-
tieve patiënten met chronische leveraandoeningen, is sprake van een fenomeen 
wat specifiek genoemd kan worden voor patiënten met een actieve dan wel met 
een doorgemaakte HB V-infectie. Het virale DNA bleek aanwezig in de vorm van 
extrachromosomale virus-DNA oligomeren, die evenwel niet identiek kunnen 
worden gesteld met virus partikels of andere infectieuze agentia. De biologische 
en klinische betekenis van de aanwezigheid van HBV-DNA sequenties in lym-
phocyten is nog onduidelijk. 
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Woorden van dank 
Velen hebben bijgedragen aan het tot stand komen van dit proefschrift en allen 
betuig ik langs deze weg mijn dank. Enkele personen wil ik met name noemen: 
dr. Jos Rijntjes en Gera Backx hebben mij wegwijs gemaakt in de moleculair-
biologische technieken en in belangrijke mate geholpen bij de vele bepalingen. 
Na hun vertrek hebben ook William Leenders, Wieke de Bruin, en dr. Han 
Moshage waar nodig de helpende hand geboden. Professor dr. U.J.G.M. van 
Haelst (afdeling Pathologische Anatomie) beoordeelde de Shikatakleuringen van 
de levercoupes, die vervaardigd werden door Koos Diepenbroek. Verscheidene 
collegae uit het land boden leverweefsel of sera voor analyse aan. Met name van 
de collegae S.H. Tan (afdeling Inwendige Ziekten, Canisius-Wilhelminazieken-
huis, Nijmegen), dr. KH. Brandt, afdeling Inwendige Ziekten, ziekenhuis De 
Malberg, Arnhem, en dr. A.R. Janssens (afdeling Gastroenterologie, Academisch 
Ziekenhuis, Leiden) mocht ik regelmatig materiaal ontvangen. De samenwerking 
met Leo Kuijpers en Ludo Matthyssen (Organon, Oss), Reint Huizenga (afde-
ling Hepatologie, Rijksuniversiteit Groningen, hoofd: Professor dr. C.H. Gips), 
en dr. R.A. Heijtink (afdeling Virologie, Erasmusuniversiteit, Rotterdam) verliep 
immer prettig en heeft tot vruchtbare discussies geleid. De heer F. Bruijnis en 
mw. M.J. Koens (Organon, Oss) wisten binnen korte tijd de bepalingen van res-
pectievelijk IgM anti-HBc en pre-S eiwitten te verrichten. Anti-pre-S2-antistof-
fen werden bepaald door J. Kruining (afdeling Virologie, Erasmusuniversiteit, 
Rotterdam). Mevrouw W.C.A.M. Buys en dr. A.J. Hoitsma ben ik erkentelijk 
voor hun hulp bij de statistische analyses en mevrouw C.B.M. Reintjes voor 
secretariële hulp bij publikaties. Bij het opsporen van medische dossiers werd 
nimmer tevergeefs een beroep gedaan op mw. W. van Deursen van het Medisch 
Archief; dr. M.H.L. Salden (laboratorium Hematologie) bleek in geval van 
onverhoopt ontbrekende chemicaliën nagenoeg altijd tot hulp in staat. De 
figuren werden vervaardigd door de heren A.T. van Uden en C.P. Nicolasen van 
de afdeling Medische Illustratie en gefotografeerd door medewerkers van de 
afdeling Medische Fotografie. Mijn collega's hebben waar nodig bijgesprongen 
indien klinische activiteiten en onderzoeksactiviteiten op gespannen voet dreig-
den te geraken. Veel dank ben ik verschuldigd aan Frederick J.A. Mostert uit 
Haarlem, die met groot enthousiasme en zeer nauwgezet het manuscript van 
grammaticale misstappen wist te zuiveren, en aan Merck Sharp & Dohme, die 
uitgave van dit proefschrift mogelijk maakte. Ten slotte gaat mijn dank uit naar 
mijn ouders, Irene en Thomas, en niet het minst naar haar aan wie dit proefschrift 
is opgedragen. 
191 
Curriculum vitae 
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Mei 1979 werd het artsexamen behaald. Aansluitend begon hij de opleiding tot 
internist in het ziekenhuis 'De Weezenlanden' te Zwolle (opleider: dr. J.A. ten 
Bokkel Huinink). De opleiding werd in 1981 voortgezet in het Canisius-Wilhel-
minaziekenhuis te Nijmegen (opleider destijds: dr. J.H.J. Enneking), en per 
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als internist (mei 1984), werkte hij middels subsidies van het Praeventiefonds en 
uit de Universitaire Onderzoekspool aan dit onderzoek. Juli 1985 werd begon-
nen met de opleiding tot gastroenteroloog binnen de afdeling Maag-, darm-, en 
leverziekten van het St. Radboudziekenhuis (hoofd: dr. J.H.M, van Tongeren), 
welke opleiding per 1.1.1988 werd afgerond. Sindsdien is hij werkzaam geweest 
binnen laatstgenoemde afdeling. Hij is gehuwd met Mariette Roding, zij hebben 
twee kinderen. 
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Stellingen 
1. Bij chronische dragers van het HBsAg gaat het verdwijnen van het 
HBV-DNA uit het serum geruime tijd vooraf aan het verdwijnen van 
hetHBeAg. 
- dit proefschrift -
2. Bij personen met het syndroom van Down die chronisch drager van 
het HBsAg zijn is de periode van het dragerschap waarin sprake is van 
actieve virusvermenigvuldiging langer dan bij dragers zonder dit syn-
droom. 
- dit proefschrift -
3. Hoewel episomale virale DNA-sequenties aanwezig kunnen zijn in 
perifere lymphocyten, is virale replicatie binnen deze cellen alsmede 
overdracht van de infectie door deze cellen onwaarschijnlijk. 
- dit proefschrift -
4. Het verwijderen van ascites middels paracentèse bij een patient die 
hiervan mechanische bezwaren ondervindt is een veilige ingreep, mits 
gelijktijdig albumine intraveneus wordt toegediend. 
(V. Arroyo et al. J Hepatol 1986; 2: 504-12) 
5. Behandeling van „bruine tumoren" welke zijn ontstaan in het kader 
van een secundaire hyperparathyreoidie vereist een totale extirpatie 
van bijschildklierweefsel wil recidief-cystevorming worden voorko-
men. 
(ThJM van Ditzhuijsen, IH Go. Neth J Med 1983; 26:48-53) 
6. Bij verdenking op een pseudo-xanthoma elasticum kunnen biopten uit 
littekens tot de diagnose leiden in geval de typische huidafwijkingen 
ontbreken. 
(M. Lebwohl et al. N Engl J Med 1987; 317: 347-50) 
7. De reactie van het lichaam op een sepsis wordt in belangrijke mate 
gemedieerd door de tumor necrosis factor. 
(HR Michie et al. N Engl J Med 1988; 318:1481-6) 
8. Indien een myocardinfarct wordt gecompliceerd door pompfunctie-
stoornissen, dan is behandeling met een angiotensine-converting 
enzyme-remmer geïndiceerd. 
(MA Pfeffer et al. N Engl J Med 1988; 319: 80-6) 
9. Bij de beoordeling van de congenitale heupdysplasie vóór de leeftijd 
van 1 jaar is evaluatie van de ontwikkeling van het acetabulum middels 
echografie te verkiezen boven conventionele röntgendiagnostiek. 
10. Ten onrechte wordt nogal eens afgezien van het verrichten van een 
leverbiopsie bij de patiënt met gestoorde leverparameters. Het argu-
ment dat deze geen therapeutische consequenties zou hebben moge 
voor een deel juist zijn, inzicht in de histologische veranderingen zal 
niet alleen in vele gevallen alsnog aanwijzingen opleveren voor de etio-
logie van leverlijden, maar ook de follow-up meer inhoud geven. 
11. Parlementaire enquêtes zoals die de laatste jaren in zwang zijn geko-
men, kunnen gekenschetst worden als tijdrovende, kostbare procedu-
res waarvan tot nu toe alleen de publicitaire waarde vast staat. 
12. In ons dichtbevolkte land lijkt de tijd rijp dat behalve de hond ook het 
gedrag van honden aan banden worden gelegd. 
Nijmegen, 16 september 1988 Th.J.M. van Ditzhuijsen 


